Protocol: I8F -MC-GPGV 
 
 
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with an Open- Label Extension 
Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in  
Pediatric and Adolescent Participants with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin, or Basal Insulin, or Both (SURPASS- PEDS)  
 
 [STUDY_ID_REMOVED] 
 
 Approval Date: 14- Dec-2021 
 
CONFIDENTIAL Protocol I8F-MC-GPGV
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the pro perty of Eli Lilly and 
Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of  tirzepatide 
(LY3298176) unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. 
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt 
from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In  the United 
States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise dissem inated 
without the written approval of Eli Lilly and Company or its subsidiaries.
Protocol Title: A Randomized, D ouble-Blind, Placeb o-Controlled, Phase 3 Study with an Open-Label 
Extension Assessing the Efficacy, Safety, and Phar macokinetics/Pharmacodynamics of Tirzepatide in 
Pediatric and Adolescent Participants with Type 2 Diabetes Mellitus Inadequately Controlled with 
Metformin, or Basal Insulin, or Both (SURPASS-PEDS)
Protocol Number: I8F-MC-GPGV
Amendment Number: Initial protocol
Compound: LY3298176
Brief Title: A Study to Evaluate Tirzepatide Compared to Placebo in Pediatric and Adolescent 
Participants with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin, or Basal Insulin, or 
Both
Study Phase: 3
Acronym : SURPASS-PEDS
Sponsor Name: Eli Lilly and Company
Legal Registered Address: Indianapolis, Indiana, USA 46285
Regulatory Agency Identifier Number
IND: 128801
Approval Date: Protocol Electronically Signed and A pproved by Lilly on date provided below.
Approval Date: 14-Dec-2021 GMT
CONFIDENTIAL Protocol  I8F-MC-GPGV
2Medical Monitor Name and Contact Information will be provided separately .
CONFIDENTIAL Protocol  I8F-MC-GPGV
3Table of Contents
1. Protocol Summary ...................................................................................................... 6
1.1. Synopsis ....................................................................................................................... 6
1.2. Schema ....................................................................................................................... 10
1.3. Schedule of Act ivities (SoA) ...................................................................................... 11
1.3.1. Screening and Double -Blind Peri od SoA .................................................................... 11
1.3.2. Open -Label  and Foll ow-up Peri od SoA ...................................................................... 18
2. Introduction .............................................................................................................. 23
2.1. Study  Rati onale .......................................................................................................... 24
2.2. Backgro und................................................................................................................ 24
2.3. Benefit/Risk Assessment ............................................................................................ 25
2.3.1. Risk Assessment ......................................................................................................... 25
2.3.2. Benefit Assessment ..................................................................................................... 26
2.3.3. O verall Benefit Risk Conclusio n................................................................................. 26
3. Objectives, Endpoints and Estimands ..................................................................... 27
4. Study Design ............................................................................................................. 31
4.1. Overall Desig n............................................................................................................ 31
4.1.1. Overview of Study  Visi ts............................................................................................ 31
4.2. Scientific Rationale for Study  Design ......................................................................... 35
4.3. Justification for Dose .................................................................................................. 36
4.4. End of Study  Definit ion.............................................................................................. 36
5. Study Population ...................................................................................................... 37
5.1. Inclusio n Cri teria........................................................................................................ 37
5.2. Exclu sion Criteria....................................................................................................... 38
5.3. Lifest yle Considerat ions............................................................................................. 40
5.4. Screen Failures ........................................................................................................... 40
5.5. Criteria for Tem porarily  Delaying Enrollment of a Participant .................................... 41
6. Study Intervention(s) and Concomitant Therapy ................................................... 42
6.1. Study  Intervent ion(s) Administered ............................................................................ 42
6.1.1. Timing of Doses and Dosing Site ................................................................................ 42
6.1.2. Medical Devices ......................................................................................................... 43
6.2. Preparati on, Handling, Storage, and Accountabilit y.................................................... 43
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 43
6.4. Study  Intervent ion Compliance ................................................................................... 44
6.5. Dose Modificat ion...................................................................................................... 45
6.5.1. Tirzepati de Dose Escal ation........................................................................................ 45
6.5.2. Management of Increased Hypoglycemia Risk ........................................................... 45
6.5.3. Tirzepati de Dose Modifications .................................................................................. 46
6.5.4. Management of Gastrointestinal Symptoms ................................................................ 47
6.6. Continued Access to Study  Intervent ion after the End of the Study ............................. 47
6.7. Treatment of Overdose ............................................................................................... 47
6.8. Concomitant Therapy ................................................................................................
.48
6.8.1. Rescue Therapy .......................................................................................................... 48
6.8.2. Allow ed Acute Di abetes Therapies ............................................................................. 49
CONFIDENTIAL Protocol  I8F-MC-GPGV
46.8.3. Allowed Chronic Diabetes Therapies .......................................................................... 49
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 50
7.1. Discontinuati on of  the Study  Intervent ion................................................................... 50
7.1.1. Liver Chemistry  Stopping Cri teria.............................................................................. 50
7.1.2. Temporary  Discont inuat ion........................................................................................ 51
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. 52
7.3. Lost to Follow -up....................................................................................................... 52
8. Study Assessments and Procedures ......................................................................... 53
8.1. Efficacy Assessments .................................................................................................53
8.1.1. P atient Reported Outcomes Assessments .................................................................... 53
8.2. Safety Assessments .................................................................................................... 55
8.2.1. Physical Examinat ions................................................................................................ 55
8.2.2. Body  Weight, Body  Mass Index, Hei ght, and Waist Ci rcumference ............................ 55
8.2.3. Assessment of Pubertal Progression –Tanner Staging ................................................ 55
8.2.4. Pregnancy Testing ...................................................................................................... 55
8.2.5. Vital Signs.................................................................................................................. 56
8.2.6. Electrocardiograms ..................................................................................................... 56
8.2.7. Clinical Safety  Laboratory  Tests ................................................................................. 56
8.2.8. Hepati c Moni toring..................................................................................................... 57
8.3. Adverse Events, Seri ous Adverse Events, and Product Complaints ............................. 59
8.3.1. Timing and Mechanism for Collect ing Events ............................................................ 60
8.3.2. Pregnancy ................................................................................................................... 61
8.3.3. Adverse Events of Special Interest .............................................................................. 62
8.4. Pharmacokinet ics........................................................................................................ 67
8.5. Pharmacodynamics ..................................................................................................... 68
8.6. Genet ics..................................................................................................................... 68
8.7. Biomarkers ................................................................................................................. 68
8.8. Immunogenicit y Assessments ..................................................................................... 69
8.9. Medical Resource Utilizat ion and Healt h Economics .................................................. 69
9. Statistical Considerations ......................................................................................... 70
9.1. Statistical Hypotheses .................................................................................................70
9.2. Analyses Sets ............................................................................................................. 70
9.3. Statistical Analyses ..................................................................................................... 70
9.3.1. General Considerations ............................................................................................... 70
9.3.2. Treatment Arm Comparabilit y.................................................................................... 72
9.3.3. Efficacy Analyses ....................................................................................................... 72
9.3.4. Safety Analyses .......................................................................................................... 74
9.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 75
9.3.6. Evaluat ion of Immunogenicit y.................................................................................... 75
9.3.7. Other Analyse(s) ......................................................................................................... 75
9.4. Interim Analyses ......................................................................................................... 76
9.5. Sample Si ze Determinat ion......................................................................................... 76
10. Supporting Documentation and Operational Considerations ................................ 77
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight Consi derat ions....................... 77
CONFIDENTIAL Protocol  I8F-MC-GPGV
510.1.1. Regulatory  and Ethi calConsiderat ions........................................................................ 77
10.1.2. Financial Disclo sure................................................................................................... 77
10.1.3. Inform ed Consent Process .......................................................................................... 78
10.1.4. Data Protection ........................................................................................................... 78
10.1.5. Committee Structure ................................................................................................... 79
10.1.6. Disseminat ion of Clinical Study  Data ......................................................................... 79
10.1.7. Data Qualit y Assurance .............................................................................................. 79
10.1.8. Source Documents ...................................................................................................... 81
10.1.9. Study  and Si te Start a nd Closure ................................................................................. 81
10.1.10. Publicat ion Policy ....................................................................................................... 82
10.1.11. Invest igator Informat ion............................................................................................. 82
10.1.12. Sample Retent ion........................................................................................................ 82
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 83
10.3. Appendix 3: Adverse Events and Serious Adverse Events: Definit ions 
and Procedures for Re cording, Evaluat ing, Fo llow
-up, and Reporting ......................... 87
10.3.1. Definit ion of AE......................................................................................................... 87
10.3.2. Definit ion of SAE ....................................................................................................... 88
10.3.3. Definit ion of Product Complaint s............................................................................... 89
10.3.4. Recording and Fo llow-Up of AE and/or SAE and Product Complaint s....................... 90
10.3.5. Reporting of SAEs ...................................................................................................... 91
10.3.6. Regulatory  Reporting Requirements ........................................................................... 92
10.4. Appendix 4: Contraceptive and Barrier Guidance ....................................................... 93
10.4.1. Definit ions.................................................................................................................. 93
10.4.2. Contraception Guidance .............................................................................................. 94
10.5. Appendix 5: Geneti cs.................................................................................................97
10.6. Appendix 6: Liver Safet y: Suggested Actions and Follow -up 
Assessments ............................................................................................................... 98
10.7. Appendix 7: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies: Definit ion and Procedures for Rec ording, Evaluating, 
Follow-up, and Reporting ......................................................................................... 100
10.8. Appendix 8: Criteria for the Diagnosis of Diabetes ................................................... 101
10.9. Appendix 9: Tanner Staging ..................................................................................... 102
10.10. Appendix 1 0: Laboratory  Sam ples to be Obtained at the Time of a 
Systemic Hypersensit ivity Event ............................................................................... 103
10.11. Appendix 11: Standardized Protocols for the Measurement of Height, 
Weight, Waist Circumference, Vital Signs ................................................................ 104
10.12. Appendix 12: Provisio ns for Changes in Study  Conduct During 
Except ional Circumstances ....................................................................................... 106
10.13. Appendix 13: Abbreviat ions and Definit ions............................................................ 110
11. References ............................................................................................................... 116
CONFIDENTIAL Protocol  I8F-MC-GPGV
61. Protocol Summary
1.1. Synopsis
Protocol Title: A Rando mized, Double -Blind, Pl acebo -Controlled, Phase 3 Study  with an Open -Label 
Extensio n Assessing the Efficacy, Safet y, and P harmacokinet ics/Pharm acodynamics of Tirzepat ide in 
Pediatric and Ado lescent Participants with Type 2 Di abetes Mellitus Inadequatel y Controlled with 
Metformin,or Basal Insulin , or Both (SURPASS -PEDS)
Brief Title: A Study to Eval uate Ti rzepat ide Compared to Placebo in Pediatric and Adolescent
Participants with Type 2 Di abetes Mellitus Inadequately Controlled wit h Met formin,or Basal Insulin , or 
Both
Rationale :
Type 2 di abetes m ellitus (T2DM) is a disease that is primarily diagnosed in adults, and the risk of the 
disease increases with age (CDC 2020 [WWW]). There has been a significant increase of T2DM in the 
pediatric and adolescent popul ationin recent y ears, al though the absol ute number of y outh wi th T2DM 
remains l ow and T1DM accounts for approximately  90% of  all diabetes in the pediatri c population
(Dabelea et al. 2014).
There i s an important need for addit ional safe and effect ive a gents approved to treat the pediatric and 
adolescent population with T2DM. Unlike adults, thepediatric and ado lescent populationwith the 
disease have few erglucose -lowering treatment optio ns that are regul atory approved. Metformin, most
insulins, liraglut ide,and recent lyexenat ide2 mg once weekly ( QW)are the only agents approved in the 
United States (US)and/orEuropean Union ( EU)for treatment (Tamborlane and Klingensmit h 2013 ; 
Tamborl ane et al . 2019 ; Victoza® summary of product characterist ics[SmPC]and prescribing 
inform ation[PI]; BYDUREON BCISE® PI 2021 ).
Tirzepati de is adual glucose -
dependent insulinotropic polypeptide ( GIP)and a glucagon -like peptide -1 
(GLP -1)receptor agonist . Tirzepat ideis administered QW subcutaneous ly(SC) and is being 
investigated for its potential use in the treatment of T2DM .
CONFIDENTIAL Protocol  I8F-MC-GPGV
7Objectives , Endpoint s, and Estimands
Objectives Endpoints
Primary
Efficacy
To demonstrate that pooled 5 mg and 10 mg
tirzepatide QW is superior to placebo at 30 weeksChange in hemoglobin A1c (HbA1c) from baseline
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate that 5 mg and 10 mg tirzepatide QW, 
analy zed as pooled and se parate treatment arms ,is 
superior to placebo at 30 weeksIncidence of HbA1c ≤6.5%
Change in body mass index (BMI )standard deviation 
score (age-and sex -matched) from baseline
Change in fasting serum glucose (FSG) from baseline
To demonstrate that 5 mg and 10 mg tirzepatide QW, 
analy zed as separate treatment arms, is superior to 
placebo at 30 weeksChange in HbA1c from baseline
Additional Secondary
(not controlled for type 1 error)
To demonstrate that 5 mg and 10 mg tirzepatide QW, 
analyzed as pooled and separate treatment arms , is 
superior to placebo at 30 weeksIncidence of HbA1c <7.0%
Incidence of HbA1c <5.7%
Change in daily average 6 -point self -monitored blood 
glucose profiles from baseline
To assess the effect of 5 mg and 10 mg tirzepatide 
QW, analy zed as pooled and separate treatment arms, 
at 52 weeksChang e in HbA1c from baseline
Incidence of HbA1c <7.0%
Incidence of HbA1c ≤6.5%
Incidence of HbA1c <5.7%
Change in BMI standard deviation score (age -and sex -
matched) from baseline
Change in FSG from baseline
To compare 5 mg, and 10 mg tirzepatide QW, 
analy zedas pooled and separate treatment arms, to 
placebo at 30 weeks ; and to assess the effect of 5 mg ,
and 10 mg tirzepatide QW, analyzed as pooled and 
separate treatment arms at 52 weeksChange f rom baseline for serum lipid levels
Incidence of new or worsening of dyslipidemia
CONFIDENTIAL Protocol  I8F-MC-GPGV
8To assess safety of 5 mg and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment arms, at 30 
weeks and at the end of the safety follow -up periodTreatment -emergent adverse events (TEAEs)
Discontinuation of study intervention due to adverse 
events (AEs )
Adjudicated pancreati c AEs
Serum calcitonin
Incidence of allergic ,hypersensitivity reactions , and 
injection site reactions
Incidence of treatment -emergent anti -drug antibodies to 
tirzepatide
Change in sy stolic and diastolic blood pressure and 
heart rate from baseline
Incidence of new or worsening of hypertension
Incidence of new or worsening of albuminuria
Occurrence of hypoglycemic events
Incidence of initiation of rescue therapy for severe -
persistent hyperglycemia
Inciden ce of new or worsening of diabetic neuropathy
To compare 5 mg, and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment arms, to 
placebo at 30 weeks ; and to assess the effect of 5 mg,
and 10 mg tirzepatide QW, analyzed as pooled and 
separate treatment arms at 52 weeks Change from baseline for physical and developmental 
measures
oHeight and weight
oHeight SDS and weight SDS
oWaist circumference, and
oTanner Staging
To assess the safety of 5mg and 10 mg tirzepatide 
QW,analy zed as separate and pooled arms ,at 52 
weeks for diabetic retinopathyIncidence of new or worsening of diabetic retinopathy 
or diabetic maculopathy in either eye
Characterize the pharmacokinetics and 
pharmacodynamic re lationships of tirzepatideRelationship between tirzepatide exposure and key 
safety and efficacy measures
To assess the effect of 5 mg, and 10 mg tirzepatide 
QW, analy zed as pooled and separate treatment arms,
on patient reported outcomes at 30 and 52 weeksChange f rom baseline for
oPedsQL Generic Core Scales
oPedsQL (3.2) Diabetic Module from baseline
Abbreviations: AEs = adverse events ;BMI = body mass index; FSG = fasting serum glucose; HbA1c = hemoglobin A1 c; 
PedsQL = Pediatric Quality of Life Inventory ;QW = once weekly; TEA Es = Treatment -emergent adverse events .
The clinical quest ion of interest for the “treatment -regimen est imand” is the treatment difference 
between ti rzepat ide and placebo after 30 weeks of intervent ion in pediatric and ado lescent participants 
with T2DM, regardl ess of intervention discont inuation for any reason (excluding inadvertent ly enro lled 
participants who have discontinued study  interventi on for that reason) and regardless of init iation of 
rescue ant ihyperglycemic intervent ion.
The clinical quest ion of interest for the “efficacy estimand” is the treatment difference between 
tirzepat ide and placebo after 30 weeks of interventio n in pediatric and ado lescent participants with 
T2DM, prior tointervention discont inuat ion for any  reason and prior to the init iation of rescue 
antihyperglycemic intervent ion.
CONFIDENTIAL Protocol  I8F-MC-GPGV
9Overall Design :
This is a r ando mized, doubl e-blind, parallel arm, placebo -controlled study with an open -label extension, 
to assess the efficacy , safety, and pharma cokinet ics/pharm acodynamics ( PK/PD )of tirzepat ide in male 
and female participants 10 to <18 years of age with T2DM and inadequate glycemic control on diet and 
exercise withmetformin ,orbasal insulin , or both .
Study  GPGV will evaluate 5 -mg and 10 -mg doses of tirzepat ide starting at 2.5 m g and using a dose 
escalat ion of 2.5 mg increments every 4 weeks to achieve the assigned maintenance dos e.
Brief Summary:
The purpose of this study  is to eval uate the safet y and efficacy of tirzepat ide 5 mg and tirzepat ide 10 mg 
QW, wi th metformin, or basal insulin, or both, compared to placebo for glycemic control in the pediatric 
and ado lescent populat ion with T2DM over a 30 -week period, followed by a 22- week open -label 
extensio n.
Numbe r of Participant s:
At least 90 participants will be randomiz edin a 1:1:1 ratio to each study arm unt il an expected accrual of 
90 evaluable participants is achieved . Eval uable parti cipants are those who have been rando mized and 
exposed to at least one dose of study  treatm ent wi th HbA1c m easurements at baseline and at the Week 
30 visit.
Intervention Groups and Duration :
The overall study  durati on is approximately 60 weeks over 4 required study  periods. This table describes 
the study  periods.
Study Period Duration Intervention
Screening/lead -in Approximately 4 weeks -----
Double -blind ,placebo -controlled 30 weeks 5 mg tirzepatide
10 mg tirzepatide , or
placebo
Open-label extension on active 
treatment period 22 weeks 5 mg tirzepatide ,or
10 mg tirzepatide
Post-treatment safety follow -up 30 days -----
In the 22-week open-label period, parti cipants in 5 mgand 10 m g armswill cont inue withcurrent 
treatm ent while participants randomized to placebo will initiate treatment at 2.5 mg QW and after 4 
weeks, will receive 5 mg tirzepat idefor the remainder of the period .
Data Monitoring Committee:
An external data monitoring co mmit tee (DMC) will have the responsibilit y to review unblinded interim 
analyses resul ts tomonitor the safet y of the participant s in the study  until  the last participant completes 
the Week 52visit. More details will be included in the DMC charter.
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 0 1. 2. Sc he m a 
       A b bre viati o n s: P K = p har mac o ki netics; Q W = o nce wee kl y ; V = visit .
aP h o ne visit .
C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 1 1. 3. Sc he d ule of Acti vities ( S o A) 
1. 3. 1. Scree ni n g a n d D o u ble -Bli n d P eri o d S o A 
Perf or m pr oce d ure sas i n dicate d. 
St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
Pr oce d ures 
I n f or me d c o nse nt a n d 
asse nt X Pare nt/le gal g uar dia n si g ns i nf or me d c o nse nt f or m a n d 
pa rtici pa nt si g ns asse nt f or m bef ore a n y tests or 
pr o ce d ures are perf or me d .
E val uati o n of i ncl usi o n 
a n d e xcl usi o n criteria X  X  X 
Me dical hist or y /
pre e xisti n g c o n diti o ns X I n vesti gat ors s h o ul d re vie w t he vacci nati o n stat us of t heir 
partici pa nts. 
De m o gra p hics X I n cl u des et h nicit y ( U nite d States o nl y), f ull date of birt h, 
ge n der, race. 
A d verse e ve nts ( A E) X  X  X X  X X  X  X X X X
C o nc o mita nt 
me dicati o ns X  X  X X  X X  X  X X X X
P h ysic al E v al u ati o ns 
P h ysical E xa m 
X X X
Ta n ner Sta gi n g 
X X XPartici pa nts w h o ha ve reac he d Ta n ner sta ge 5 will n ot be 
e val uate d a gai n. 
Ta n ner sta gi n g details i n A p pe n di x 9, Secti o n 1 0. 9 .C CI 
C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 2 St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
S y m pt o m -directe d 
p h ysical e xa m b y 
p h ysicia n X X  X See Secti o n 8. 2. 1 .
Vital si g ns 
X X X X  X  X XVital si g n meas ure me nts s h o ul d be ta ke n bef ore 
c ollecti o n of bl o o d sa m ples f or la b orat or y testi n g, at 
visits w here re q uire d. F or i nstr ucti o ns see A p pe n di x 1 1, 
Secti o n 1 0. 1 1 .
Hei g ht (c m) X X X X  X  X XTri plicate m eas ure me nts m ust be i n ce nti meters. F or 
i nstr ucti o ns see A p pe n di x 1 1 , Secti o n 1 0. 1 1 .
Wei g ht ( k g) X X X X  X  X XMeas ure me nts m ust be i n kil o gra ms. F or i nstr ucti o ns see 
A p pe n di x 1 1 , Secti o n 1 0. 1 1 .
Calc ulati o n of B MI X
Waist circ u mfere nce 
(c m) X X X  X  X XMeas ure me nts m ust be i n ce nti meters. F or i nstr ucti o ns 
see A p pe n di x 1 1 , Secti o n 1 0. 1 1 .
Vis ual ac uit y c hec ks 
a n d dilate d fu n d osc o pic 
e xa mi nati o n X Vis ual ac uit y c hec ks a n d dilate d f u n d osc o pic 
e xa mi nati o n will be sc he d ule d bet wee n Visit 2 a n d Visit 
3 o nl y after re vie w of la b orat or y res ults fr o m Visit 1 
(e xce pt f or G A D 6 5 , Isl et cell A b res ults if  se nt a n d 
pe n di n g at Visit 2 )a n d partici pa nt q ualif yi n g i n all ot her 
criteria . T he e xa m will be perf or me d b y a n e ye care 
pr ofessi o nal ( o p ht hal m ol o gist or o pt o metrist) f or all 
partici pa nts .A pre vi o us e xa m ≤ 9 0 da ys of scree ni n g 
meeti n g st u d y re q uire me nts is acce pta ble t o c o nfir m 
eli gi bilit y .A d diti o nal vis ual ac uit y c hec ks a n d dilate d 
f u n d osc o pic e xa mi nati o ns s h o ul d be perf or me d w he n 
cli nicall y i n dicate d b y a n y s us pici o n of w orse ni n g 
reti n o pat h y .See Secti o n 8. 3. 3. 6 .C CI 
C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 3 St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
E C G X XVital Si g ns s h o ul d be ta ke n bef ore E C G, see 
Secti o n 8. 2. 6 .
Esta blis h baseli ne basal 
i ns uli n d ose (if 
a p plica ble) 
XVisit 1 H b A 1c will be use d t o esta blis h t he baseli ne d ose 
f or basal i ns uli n. O nce t his d ose is esta blis he d, it s h o ul d 
re mai n sta ble ( ±1 5 % )d uri n g t he st u d y, alt h o u g h it ma y 
be decrease d at a n y ti me if t he partici pa nt e x perie nces 
h y p o gl yce mia .
Visit 3: All partici pa nts wit h a H b A 1c < 8 % at Visit 1 will 
re d uce t heir dail y d ose of basal i ns uli n b y 2 0 % t o re d uce 
t he p ote ntial ris k of h y p o gl yce mia. (see Ma na ge me nt of 
I n crease d Ris k of H y p o gl yce mia, Secti o n 6. 5. 2 .f or 
f urt her details.). 
Re vie w me nstr ual c ycle 
hist or y X X X X  X  X X X XAll a p plica ble fe male partici pa nts .
P artici p a nt E d uc ati o n 
Disc ussi o n of effecti ve 
c o ntrace pti o n X X X  X X  X  X X X XF or males w h o ha ve reac he d p u bert y a n d are se x uall y 
acti ve ,a n d f or fe males of c hil d beari n g p ote ntial .F or 
c o ntrace pti ve g ui da nce see A p pe n di x 4, Secti o n 1 0. 4 
Re vie w h y p o gl yce mic 
e ve nts X  X X  X X  X  X X X XI n cl u des S M B G res ults, h y p o gl yce mic e ve nts, date, a n d 
e xact ti me of e ver y st u d y i nter ve nti o n i njecti o n. 
B G meter/ S M B G 
trai ni n g XPartici pa nt or pare nt or g uar dia n will be trai ne d at 
ra n d o mizati o n. A d diti o nal trai ni n g ma y occ ur as nee de d. 
Dis pe nse B G 
meter/s u p plies as 
nee de d X X X  X  X XC CI 
C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 4 St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
Re mi n d patie nts a b o ut 
6- p oi nt S M B G 
X XPatie nt is re q uire d t o c ollect t w o 6 -p oi nt S M B Gs o n 2 
n o nc o nsec uti ve da ys pri or t o t he ne xt visit. A 6 -p oi nt 
S M B G c o nsists of meas ure me nt bef ore a n d 2 h o urs after 
eac h of 3 mai n meals wit hi n t he sa me da y. T hese S M B G 
pr ofiles will be c ollecte d b y t he patie nt wit hi n 2 wee ks 
pri or t o t he assi g ne d visits. 
Re vie w 6 -p oi nt S M B G 
val ues c ollecte d i n t he 
diaries X X
Lifest yle ma na ge me nt 
i nstr ucti o n (ie, diet a n d 
e xercise) X X X  X  X XSee Secti o n 5. 3 .
P artici p a nt di ar y (electr o nic) 
Dis pe nse e -diar y t o 
partici pa nt a n d trai n o n 
use X
L a b or at or y Testi n g 
Islet cell A b (I A 2) X
G A D 6 5 X
He mat ol o g y X X X X XSee A p pe n di x 2. Secti o n 1 0. 2 
Cl i nical c he mistr y X X X X XSee A p pe n di x 2. Secti o n 1 0. 2 
Li pi d Pa nel X X X X
Ser u m gl uc ose X X X X  X  X X
H b A 1c X X X X  X  X X
Pa ncreatic a m ylase X X XC CI 
C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 5 St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
Li pase X X X
T h yr oi d -sti m ulati n g 
h or m o ne ( T S H) X X
T h yr o xi ne ( T 4, free) X X
Calcit o ni n X X X
e G F R ( C K D -E PI) X X X X X
Uri nar y 
al b u mi n/creati ni ne rati o X X
Ser u m pre g na nc y test X XF or fe male sof c hil d beari n g p ote ntial a ser u m pre g na nc y 
test will be perf or me d at Visit s 1 a n d 9 a n d a d diti o nal 
ti mes if nee de d base d o n t he cli nical j u d g me nt of t he 
i n vesti gat or .
Uri ne pre g na nc y test X XbX X  X  X XbXbXFe males of c hil d beari n g p ote ntial: M ust c o m plete a l ocal 
uri ne pre g na nc y test at Visit 3wit h t he res ult a vaila ble 
pri or t o ra n d o mizati o n a n d pri or t o recei vi n g st u d y 
i nter ve nti o n at all s u bse q u e nt visits . If re q uire d per l ocal 
re g ulati o ns a n d/ or i nstit uti o nal g ui deli nes, pre g na nc y 
testi n g ca n als o occ ur at ot her ti mes d uri n g t he st u d y 
treat me nt peri o d. 
bIf pre g na nc y is s us pecte d, t he partici pa nt s h o ul d c o me 
t o t he cli nic f or a uri ne a n d ser u m test . If a l ocal uri ne 
pre g na nc y test is perf or me d at t he cli nic ,c ollect ser u m 
pre g na nc y test at t he sa me ti me a n d se n d t o ce ntral 
la b orat or y. 
I ns uli n X X X X
Pr oi ns uli n , i ntact X X X XC CI 
C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 6 St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
C- pe pti de X X X X
Gl uca g o n X X X X
A di p o necti n, t otal X X X X
 
 
 
 
I m m u n o ge nicit y X X X XI n t he e ve nt of s yste mic dr u g h y perse nsiti vit y reacti o ns 
(i m me diate or n o ni m me diate), a d diti o nal bl o o d sa m ples 
will be c ollecte d i ncl u di n g A D A,   a n d e x pl orat or y 
i m m u ne safet y sa m ple s. I m m u n o ge nicit y sa m ples m ust 
be ta ke n pri or t o i nter ve nti o n a d mi nistrati o n (see 
A p pe n di x 2, Secti o n 1 0. 2 ). 
 
St ore d S a m ples 
Ge netics X
E x pl orat or y bi o mar ker sX X X XC CI 
C CI 
C CI 
C CI C CI 
C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
1 7 St u d y I 8 F -M C -G P G V Scree n i n g D o u ble -Bli n d Peri o d N otes 
Cli nic Cli nic Cli nic P h o ne Cli nic Cli nic 
 Cli nic Cli nic Cli nic P h o ne P h o ne Cli nic 
 Cli nic T y pe of visit. 
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 1 0 V 1 1V 1 2V 1 3
Wee k - 4 - 2 0 1 4 7a8 1 2 1 6 2 0 24 2 9 a3 0  
All o we d Visit 
I nter v als ( D) 7_ _ _ 3 7         7 7 7 7
F asti n g Visit X X X XPartici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fast i n g visit 
m a y  be te m p oraril y a dj uste d u p o n cli nical j u d g me nt of 
t he i n vesti gat or .
Patie nt R ate d O utc o mes ( P R O) (electr o nic) N ot e: C o m plete q uesti o n n aires bef ore a n y ot her st u d y pr oce d ures 
E Q - 5 D- Y X X
Pe ds Q L Ge neric C ore 
Scales X XA ge a p pr o priate Pe ds Q L s h o ul d be use d at baseli ne a n d 
t he sa me versi o n use d f or t he e ntire st u d y. 
Pe ds Q L ( 3. 2) Dia betes 
M o d ule X XA ge a p pr o priate Pe ds Q L s h o ul d be use d at baseli ne a n d 
t he sa me versi o n use d f or t he e ntire st u d y. 
R a n d o miz ati o n a n d D osi n g 
Ra n d o mizati o n X
St u d y  i nter ve nti o n 
i njecti o n trai ni n g XUs ede m o nstrati o n pe n w hic h d oes n ot ha ve a nee dle a n d 
is fille d wit h air. Trai ni n g at Visit 3 is re q uire d. 
A d diti o nal trai ni n g ma y occ ur as nee de d. 
Distri b ute st u d y 
i nter ve nti o n X X X  X  X X
Partici pa nt ret ur ns 
st u d y  i nter ve nti o ns a n d 
i njecti o n s u p plies X X  X  X X
Assess st u d y 
i nter ve nti o n 
c o m plia nce X X  X  X X X X
A b bre viati o ns: A b = a nti b o dies; A D A = a nti -dr u g a nti b o dies; A E = a d verse e ve nt; B G = bl o o d gl uc ose; B MI = b o d y mass i n de x; C K D -E PI = C hr o ni c  Ki d ne y 
Disease E pi de mi ol o g y C olla b orati o n ; D = da ys; E C G = electr ocar di o gra m; e- diar y  = electr o nic diar y; e G F R = esti mate d gl o mer ular filtrati o n rate ; G A D 6 5 = 
gl uta mic aci d decar b o x ylase 6 5 a ut oa nti b o dies; H b A 1c = h e m o gl o bi n A 1c; I A 2 = t yr osi ne p h os p hatase -li ke i ns uli n o ma a nti ge n 2 a ut oa nti b o dies; IW R S = 
I nteracti ve We b -Res p o nse S yste m; Pe ds Q L = Pe diatric Q ualit y of Life I n ve nt or y;  P R O = Patie nt R e p orte d O utc o mes ;S M B G = self -
m o nit ore d bl o o d gl uc ose; V = visit. C CI 
C CI 
C CI C CI 
CONFIDENTIAL Protocol  I8F-MC-GPGV
181.3.2. Open -Label and Follow -up Period SoA
Perform procedure sas indicated.
FhStudy I8F -MC-
GPGVOpen -Label Period Follow -up 
PeriodNotes
Phone Clinic Phone Clinic Phone Clinic Clinic Clinic Type of visit .
Any phone visit may be converted to a clinic visit if 
deemed medically necessary by study personnel.
Visit V14 V15 V16 V17 V18 V19 ET V801
Week 31 34 38 42 46 52 56
Allowed Visit 
Intervals (D)3 7  7 7 7  7
Fasting Visit X X Participants should fast at least 8 hours without eating, 
drinking (except water), or performing any significant 
physical activity. The dose of insulin on a fasting visit may 
be adjusted upon clinical judg ment of the investigator.
Procedures
Adverse events X X X X X X X X
Concomitant 
medicationsX X X X X X X X
Physical Evaluations
Physical Exam X X X
Tanner Staging X X Participants who have reached Tanner stage 5 will not be 
evaluated again.
Tanner staging details in Appendix 9, Section 10.9
Symptom -directed 
physical exam by 
physicianX
See Section 8.2.1 .
Vital signs X X X X Vital sign measurements should be taken before collection 
of blood samples for laboratory testing, at visits where 
required. See Appendix 1 1, Section 10.11
Height (cm) X X X X Measurements must be in centimeter. For instructions see 
Appendix 11Section 10.11
Weight (kg) X X X X Measurements must be in kilogram. For instructions see 
Appendix 11, Section 10.11
Waist circumference 
(cm)X X X X Measurements must be in centimeter. For instructions see 
Appendix 11Section 10.11
Visual acuity checks 
and dilated 
fundoscopic 
examinationX X V19 allowable window of ± 21days. ET allowable window 
of +21 days. If the ET visit is scheduled within 6 months of 
the previous visual acuity checks and dilated fundoscopic 
examination, follow -up exam is not needed.
CONFIDENTIAL Protocol  I8F-MC-GPGV
19FhStudy I8F -MC-
GPGVOpen -Label Period Follow -up 
PeriodNotes
Phone Clinic Phone Clinic Phone Clinic Clinic Clinic Type of visit .
Any phone visit may be converted to a clinic visit if 
deemed medically necessary by study personnel.
Visit V14 V15 V16 V17 V18 V19 ET V801
Week 31 34 38 42 46 52 56
Allowed Visit 
Intervals (D)3 7  7 7 7  7
Fasting Visit X X Participants should fast at least 8 hours without eating, 
drinking (except water), or performing any significant 
physical activity. The dose of insulin on a fasting visit may 
be adjusted upon clinical judg ment of the investigator.
ECG X X
Vital Signs must be taken before ECG , see Section 8.2.6
Review menstrual 
cycle historyX X X X X X X X All applicable female participants.
Participant Education
Discussion of 
effective 
contraceptionX X X X X X X Formales who have reached puberty and are sexually 
active, and forfemales of childbearing potential . For 
contraceptive guidance see Appendix 4, Section 10.4.
Review hypoglycemic 
events c ollect edX X X X X X X X Includes SMBG results, hypoglycemic events, date, and 
exact time of every study intervention injection .
Dispense BG 
meter/supplies as 
neededX XParticipant or parent or guardian will be trained as needed.
Lifestyle management 
instruction (ie, diet 
and exercise)X X XSee Section 5.3.
Partic ipant Diary (electronic)
e-Diary  return X X
Laboratory Testing
HematologyX X X XSeeAppendix 2. Section 10.2
Clinical chemistr y X X X X SeeAppendix 2. Section 10.2
Lipid PanelX X X X
Serum glucoseX X X X
HbA1cX X X X
Pancreatic amylaseX X X X
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
2 0 F h St u d y I 8 F -M C -
G P G V O pe n -L a bel Peri o d F oll o w -u p 
Peri o d N otes 
P h o ne Cli nic P h o ne Cli nic P h o ne Cli nic Cli nic Cli nic T y pe of visit .
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 4 V 1 5 V 1 6 V 1 7 V 1 8 V 1 9 E T V 8 0 1 
Wee k 3 1 3 4 38 4 2 4 6 5 2 5 6 
All o we d Visit 
I nter v als ( D) 3 7     7 7 7  7
F asti n g Visit X X Partici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fasti n g visit ma y 
be a dj uste d u p o n cli nical j u d g me nt of t he i n vesti gat or. 
Li pase X X X  X 
T h yr oi d -sti m ulati n g 
h or m o ne ( T S H) X
T h yr o xi ne ( T 4, free) X
Calcit o ni n X X X  X 
e G F R ( C K D -E PI) X X X  X 
Uri nar y 
al b u mi n/creati ni ne 
rati o X X  X 
Ser u m pre g na nc y 
test X XI n fe males of c hil d beari n g p ote ntial o nl y. 
Uri ne pre g na nc y 
test XaX X * aX XaX X If re q uire d per l ocal re g ulati o ns a n d/ or i nstit uti o nal 
g ui deli nes, pre g na nc y testi n g ca n als o occ ur at ot her 
ti mes d uri n g t he st u d y treat me nt peri o d. 
aIf pre g na nc y is s us pecte d , t he partici pa nt s h o ul d c o me 
t o t he cli nic f or t his test . I f a l ocal uri ne pre g na nc y test is 
perf or m e d, c ollect ser u m pre g na nc y test at t he sa me ti me 
a n d se n d t o ce ntral la b orat or y. 
I ns uli n X X
Pr oi ns uli n , i ntact X X
C- pe pti de X X
Gl uca g o n X X
A di p o necti n, t otal X X
C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
2 1 F h St u d y I 8 F -M C -
G P G V O pe n -L a bel Peri o d F oll o w -u p 
Peri o d N otes 
P h o ne Cli nic P h o ne Cli nic P h o ne Cli nic Cli nic Cli nic T y pe of visit .
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 4 V 1 5 V 1 6 V 1 7 V 1 8 V 1 9 E T V 8 0 1 
Wee k 3 1 3 4 38 4 2 4 6 5 2 5 6 
All o we d Visit 
I nter v als ( D) 3 7     7 7 7  7
F asti n g Visit X X Partici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fasti n g visit ma y 
be a dj uste d u p o n cli nical j u d g me nt of t he i n vesti gat or. 
I m m u n o ge nicit y X X X  X I n t he e ve nt of s yste mic i nter ve nti o n h y perse nsiti vit y 
reacti o ns (i m me diate or n o ni m me diate), a d diti o nal bl o o d 
sa m ples will be c ollecte d i ncl u di n g A D A,   a n d 
e x pl orat or y i m m u ne safet y sa m ple s. I m m u n o ge nicit y 
sa m ples m ust be ta ke n pri or t o i nter ve nt i o n 
a d mi nistrati o n (see A p pe n di x 2, Secti o n 1 0. 2 ). 
 
.
St ore d S a m ples 
E x pl orat or y 
bi o mar ker sa m ples X X X  X C CI C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
2 2 F h St u d y I 8 F -M C -
G P G V O pe n -L a bel Peri o d F oll o w -u p 
Peri o d N otes 
P h o ne Cli nic P h o ne Cli nic P h o ne Cli nic Cli nic Cli nic T y pe of visit .
A n y p h o ne visit ma y be c o n verte d t o a cli nic visit if 
dee me d me dicall y necessar y b y st u d y pers o n nel. 
Visit V 1 4 V 1 5 V 1 6 V 1 7 V 1 8 V 1 9 E T V 8 0 1 
Wee k 3 1 3 4 38 4 2 4 6 5 2 5 6 
All o we d Visit 
I nter v als ( D) 3 7     7 7 7  7
F asti n g Visit X X Partici pa nts s h o ul d fast at least 8 h o urs wit h o ut eati n g, 
dri n ki n g (e xce pt water), or perf or mi n g a n y si g nifica nt 
p h ysical acti vit y. T he d ose of i ns uli n o n a fasti n g visit ma y 
be a dj uste d u p o n cli nical j u d g me nt of t he i n vesti gat or. 
P atie nt R e p orte d O utc o mes ( P R O) N ote: C o m plete q uesti o n n aires bef ore a n y ot her st u d y pr oce d ures 
E Q - 5 D- Y X X
Pe ds Q L Ge neric C ore 
Scales X X
Pe ds Q L ( 3. 2) Dia betes 
M o d ule X X
D osi n g 
Dis tri b ute st u d y 
i nter ve nti o n X X
Partici pa nt ret ur ns 
st u d y  i nter ve nti o n s
a n d i njecti o n s u p plies X X X X  X 
Assess st u d y 
i nter ve nti o n 
c o m plia nce X X  X X XX
A b bre viati o ns: A D A = a nti -dr u g a nti b o dies; A E = a d verse e ve nt; B G = bl o o d gl uc ose; C K D -E PI = C hr o nic Ki d ne y Disease E pi de mi ol o g y C olla b orati o n ; D = 
da y s; E C G = electr ocar di o gra m; e G F R = esti mate d gl o mer ular filtrati o n rate ; E T = earl y ter mi nati o n; H b A 1c = he m o gl o bi n A 1c; Pe ds Q L = Pe diatric Q ualit y 
of Life I n ve nt or y;  P R O = Patie nt R e p orte d O utc o mes ; S M B G = self -m o nit ore d bl o o d gl uc ose; V = visit. C CI 
CONFIDENTIAL Protocol  I8F-MC-GPGV
232. Introduction
The state of T2DM in youth today
Type 2 di abetes m ellitus is a disease that is primarily  diagnosed in adults, and the risk of the disease increases 
with age (CDC 20 20[WWW]). However, there has been a significant relat ive increase of T2DM in the 
pediatric and adolescent popul ationin recent y ears, al though the absol ute number of y outh wi th T2DM rem ains 
a low porti on of all diabetes in thispopul ation(Dabelea et al. 2014 ;Lawrence et al. 2021 ).
Pathophysiology of T2DM in youth
In adults and youthwith T2DM, the pathophysio logy of the disease i s characteri zed by  insulin resistance in the 
peripheral  tissues and the liver anddecreased insulin secret ion by pancreat ic β cells (D’Adamo and Capri o 
2011). However, T2DM in youth is a more aggressive disease than in adults with higher insulin resistance, 
more rapi d decline in β
-cell function and higher ri sk of microvascular and macrovascular complicat ions at a 
younger age than study  participants with T1DM, and after a shorter interval than adults with T2DM ( ADA 
2021 a;Constant ino et al. 2013 ;RISE Consorti um 2018 ;TODAY Study  Group 2021 ).
Treatment options for youth with T2DM
Youth with T2DM have fewer approved glucose -lowering treatment options compared to adults with T2DM 
(ADA 2021a; ADA 2021 b). Metformin, insulin and GLP -1 receptor agonist (RA) are the only agents approved 
in the US and EU for the treatment of children and adolescents with T2DM (Tamborlane et al .2019). 
Metformin mo notherapy  is often inadequate for achieving and maintaining glycemic control in youth with 
T2DM (TODAY Study  Group 2012 ;Badaru et al .2014). The subsequent options to metformin are limited to 
insulin and GLP -1 RA s(liraglutideandexenat ide2mg QW recent ly approved in the US )for youth wi th 
T2DM. Insulin is associated with weight gain while GLP -1 RA sare not (Tamborl ane et al . 2019, 2021). 
Therefore, there is an important clinical need for addit ional approved agents to treat children and adolescents 
with T2DM that are safe and effect ive in this populat ion with potent glycemic and weight loss effects.
Tirzepatide
Tirzepati de is a dual  GIP and GLP -1 receptor agonist thatis currently being invest igated for its potential use in 
the treatment of T2DM as a QW SC inject ion. Tirzepati de is a single m olecule based on the GIP sequence and 
it includes a C20 fatty  diacid m oiety. 
It has a half- lifeof approximately 5 days enabling once weekly 
administr ation.
This study  isdesigned to investigate the efficacy, safet y, and PK/PD of t irzepat ide (5 mg and 10 mg) in the 
pediatric and adolescent popul ationaged 10 years to under 18 y ears wi th T2DM who have inadequate 
glycemic control, despite diet and exercise, with metformin or basal insulin, or both. The double -blind period
of the clinical trial will last for 30 weeks and will test placebo against tirzepat ide 5 an d10 m g SC injecti on
QW. This will be followed by  the 22 -week open -label period of  the clinical trial where all pa rticipants will 
receive eit her ti rzepat ide 5 mg/week or 10 mg/week, which will be fo llowed by  a 30 -day safety  follow-up 
period.
CONFIDENTIAL Protocol  I8F-MC-GPGV
242.1. Study Rationale
This study  aims to eval uate the eff icacy and safet y of tirzepat ide in the pediatric populat ion.The data fro m this 
study  will inform the clinical development of tirzepatide.
2.2. Background
Because of the pathophy siological similari ties between T2DM in adults and y outh, i t is hypothesized that 
tirzepat ide will have efficacy in the pediatric and adolescent populat ion witha similar safety  profile as in the 
adult populati on.The background therapies o f diet and exercise, with met formin or basal insulin, or both , are 
considered appropriate, as these are approved treatments for pediatric and adolescent participants with T2DM 
in the US, EU, and many countries around the world.
Infour Phase 3 studies in adult s with T2DM, once weekly t irzepat ide was associated with clinically relevant 
improvement in glycemia and body  weight ,withlow risk of hypoglycemia, and a safet y profile similar to 
approved agents fro m the GLP -1 RA class ( Rosenstock et al . 2021 ;Fríaset al. 2021; Ludvik et al. 2021; Dahl  
et al.
2021 a bstract ).Of the Phase 3 studies, the two placebo -controlled studies ,SURPASS -1 (Study  I8F-MC-
GPGK) and SURPASS-5 ( Study  I8F-MC-GPGI) provide the benefit/risk informat ionfor tirzepat ide.
SURPASS -1 (monotherapy)
This 40 -week Phase 3study  assessed the efficacy , tolerabilit y, and safety  of QW administrati on of  3doses 
(5mg,10 m g,and 15 m g) of  tirzepati de versus pl acebo in 478 adult participant s with T2DM wi th inadequate 
glycemic control on diet and exercise .Baseline characterist ics of the parti cipants included a mean age of 54.1 
years , 
diabetes duration o f 4.7 y ears, HbA1c of 7.9% and BMI of 31.9 kg/m2 (Rosenstock et al . 2021).
Tirzepati de 5 m g, 10 m g, and 15 m g doses si gnificant ly reduced HbA1c by 1.87%, 1.89% and 2.07% 
respectively  compared to placebo (+0.04%) and 81% to 86 %of those patients receiving tirzepat ide achieved 
HbA1c goal ≤6.5% and 31% to 52 %achieved normoglycemia (HbA1c <5.7%) . In addit ion, tirzepatide 
treatm ent led to a reduction in body  weightof7 to 9.5 kgwit
h 31% to 47 %of the patients achieving ≥ 10% 
weight loss goal .Similar to the GLP -
1 receptor agonist class, most of the tirzepat ideadverse events ( AEs)
were gastro intestinal ( GI)-related, consist ing mainly o f nausea, vo miting, and diarrhea and mild to moderate in 
severit y. Serious adverse event s (SAEs) were balanced across the treatment groups and no participant from the 
study reported severe hypoglycemia.
SURPASS -5 (add -on to basal insulin)
This40-week Phase 3 study  assessed the efficacy , tolerabilit y, and safety  of QW administrati on of  3 doses 
(5mg,10 mg, and 15 mg) of tirzepat ide, as com pared wi thplacebo in 4 75adult parti cipants wi th T2DM as an 
add-on to ti trated basal insulin glargine wit h or without met formin. Baseline characteristics of the participants 
included a mean age of 60.6 years, diabetes duration of 13.3 years, HbA1c o f 8.31% and BMI of 33.4 kg/m2
(Dahl et al.
2021 abstract).
Tirzepati de 5 mg, 10 m g, and 15 m g doses si gnificant ly reduced HbA1c by 2.23%, 2.59% and 2.59% 
respectively  com pared to pl acebo ( -0.93%) and 8 0% to 95 %of those receiving tirzepat ide achieved HbA1c 
goal≤6.5% and 26% to 62 %achieved normoglycemia (HbA1c>5.7%). In addition, tirzepat ide treatment led to 
a reducti on in body  weight of 6.2to 10.9 kgwit
h 23% to 51 %achieving ≥ 10% wei ght loss goal . Similar to the 
GLP -1 receptor agonist class, most of the tirzepat ideAEs were GI -related, consist ing mainly o f nausea, 
vomiting, and diarrhea and mild to moderate in severit y. Serious adverse events were similar across the 
CONFIDENTIAL Protocol  I8F-MC-GPGV
25treatm ent groups and the relative rate of clinically significant hypoglycemia events (BG <54 mg/dL) was 
similar across all groups .
These data support development of tirzepat ideas a therapy  for T2DM in the pediatric and adolescent
popul ation.
2.3. Benefit/Risk Assessment
More informat ion about the known and expected benefits ,risks, reasonably expected AEs oftirzepatide may
be found in the Invest igator’s Brochure ( IB).
2.3.1. Risk Assessment
Because tirzepat ideis adual GIP and GLP -1 receptor agonist , the potential risks associated with tirzepati deare 
expected to be similar to risks associ ated wi th current ly available GLP -1 receptor agonist s.
Risks associated with tirzepat ideare detailed in Section 6.1 of the IB .
Adverse events of special interest (AESI) , whi ch include the r isks associated with tirzepatide aredescribed in 
Secti on8.3.3 .Each of the AESI will be m onitored as described in Section 1.3and Section 8.3.3 .
Study design
To protect the safet y of the parti cipants enrolled in both the placebo and treatment arms of this study, the 
doubl e-blind period is relat ively short . There are also clear rescue criteria for participants with severe, 
persistent hy perglycemia (see Sect ion 8.3.3.2 ),in addit ion to conti nuing the baseline ant ihyperglycemic 
medicat ions such as met formin and/or basal insulin.
Gastrointestinal symptom management
Thedose escalat ion scheme (Section 6.5) used in this study willhelp mitigate the GI symptoms associated wi th 
tirzepat ide.
Addit ional guidance on t he management of GI symptom s such as small meals, symptom atic m edicatio ns and 
skipping a dose of the study  intervent ion is described in Section 6.5.4 .
Hypoglycemia
Parti cipants wi th baseline HbA1c<8% and on basal insulin will be instructed to reduce the dose of basal 
insulin by  20% upon randomization to reduce the risk of hypoglycemia. If a hypoglycemic event occurs, 
insulin therapy  and metformin doses may  be further reduced or stopped as detailed in Sect ion 6.5.2 .
For com plete details regarding t he management of hypoglycemia risk,seeSecti on 6.5.2 .
Deve
lopmental and reproductive safety
Developmental risks in the pediatric and ado lescent populat ion will be mo nitored by  regul ar height and wei ght 
measurements and Tanner staging (Secti on 1.3).
To mit igate possible reproductive risks, p regnant or l actating females are excluded from the study .
Effect ive contraception usewill be discussed regularly  with males who have reached pubert y and are sexually  
active, and withfemales of childbearing potential (Secti on10.4.2 ).
Menstrual  cycle reviews and regular pregnancy testing (Section 8.2.4 ) will also occur for females of 
childbearing potential. For females who entered the study  at prepubertal sta te, physical exams wit h Tanner 
CONFIDENTIAL Protocol  I8F-MC-GPGV
26Staging, time of menarche and menstrual cycle reviews throughout the study  period will help monitor for 
transi tion to childbearing potenti al sta te (A ppendix 9, Secti on10.9) .
2.3.2. Benefit Assessment
Clinical safety and efficacy
In fourPhase 3 studies in adult s with T2DM, QW tirzepat ide was associ ated wi th clinically relevant 
improvement in glycemia and body  weight wi th low risk of hypoglycemia, and a safet y profile similar to 
approved agents fro m the GLP -1 receptor agonist class (Rosenstock et al . 2021; Fríaset al. 2021; Ludvik et al.
2021; Dahl  et al .2021 abstract ).Because of the pathophy siological similari ties between T2DM in adul ts and 
youth, i t is hypothesized that tirzepatide will also have efficacy  in the pediatri c and adolescent popul ation wi th 
a similar safety  profile.
Unmet therapeutic need
Youth with T2DM have fewer approved glucose -lowering treatment options compared to adults with T2DM ,
and T2DM in y outh is a more aggressive disease than in adults with higher insulin resistance, more rapid 
decline in β
-cell funct ion,and higher risk of microvascular and macrovascular complications at a y ounger age
(ADA 2021 a;ADA 202 1b;Constant ino et al. 2013 ;RISE Consorti um 2018 ; TODAY Study  Group 2021 ).
There fore, there is an important clinical need for addit ional optionsto treat children and adolescents with 
T2DM that are effect ive wit h an acceptable safet y profile with potent glycemic and weight loss effects.
This study will provide the parti cipants wi th another treatment option for T2DM . The 1:1:1 randomization ratio 
of tirzepatide 5 mg QW:tirzepatide 10 mg QW:placebo QW provides participants with a better chance of 
receiving act ive intervent ion rather than pl acebo , and all participants will receive act ive intervent ion during the 
open -label period.
2.3.3. Overall Benefit Risk Conclusion
The overall benefit -risk assessment for this study  is considered favorable. Current efficacy data provides the 
rationale to eval uate tirzepat ide as atherapeuti c opti on for parti cipants in thi s age group wi th T2DM . The 
current safety profile of tirzepat ide appears similar to the GLP -1 RA class ,andmeasures will be taken to 
minimize the identified risksto parti cipants in this study .
CONFIDENTIAL Protocol  I8F-MC-GPGV
273. Objectives ,Endpoints and Estimands
Objectives Endpoints
Primary
Efficacy
To demonstrate that pooled 5 mg and 10 mg
tirzepatide QW is superior to placebo at 30 
weeksChange in HbA1c from baseline
Key Secondary (controlled for type 1 error)
Efficacy
To demonstrate that 5 mg and 10 mg 
tirzepatide QW , analy zed as pooled and 
separate treatment arms ,is superior to placebo 
at 30 weeksIncidence of HbA1c ≤6.5%
Change in BMI standard deviation score (age-and sex -matched) from 
baseline
Change in fasting serum glucose (FSG) from baseline
To demonstrate that 5 mg and 10 mg 
tirzepatide QW, analy zed as separate treatment 
arms, is superior to placebo at 30 weeksChange in HbA1c from baseline
Additional Secondary 
(not controlled for type 1 error)
To demonst rate that 5 mg and 10 mg 
tirzepatide QW,analy zed as pooled and 
separate treatment arms , is superior to placebo 
at 30 weeksIncidence of HbA1c <7.0%
Incidence of HbA1c <5.7%
Change in daily average 6 -point self -monitored blood glucose profiles 
from baseline
To assess the effect of 5 mg and 10 mg 
tirzepatide QW, analy zed as pooled and 
separate treatment arms, at 52 weeks Change in HbA1c from baseline
Incidence of HbA1c <7.0%
Incidence of HbA1c ≤6.5%
Incidence of HbA1c <5.7%
Change in BMI standard deviation score (age-and sex -matched) from 
baseline
Change in FSG from baseline
To compare 5 mg, and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment 
arms, to placebo at 30 weeks; and to assess the 
effect of 5 mg, and 10 mg tirzepatide QW , 
analy zed as pooled and separate treatment 
arms at52 weeksChange f rom baseline for serum lipid levels
Incidence of new or worsening of dyslipidemia
CONFIDENTIAL Protocol  I8F-MC-GPGV
28To assess safety of 5 mg and 10 mg tirzepatide 
QW, analy zed as pooled and separate 
treatment arms, at 30weeks and at the end of 
the safety follow -up periodTreatment -emergent adverse events (TEAEs)
Discontinuation of study intervention due to adverse events (AEs)
Adjudicated pancreatic AEs
Serum calcitonin
Incidence of allergic, hypersensitivity reactions, and injection site 
reactions
Incidence of treatment -emergent anti -drug antibodies to tirzepatide
Change in systolic and diastolic blood pressure and heart rate from 
baseline
Incidence of new or worsening of hypertension
Incidence of new or worsening of albuminuria
Occurrence of hypoglycemic events
Incidence of initiation of rescue therapy for severe -persistent 
hyperglycemia
Incidence of new or worsening of diabetic neuropathy
To compare 5 mg, and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment 
arms, to placebo at 30 weeks; and to assess the 
effect of 5 mg, and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment 
arms at52 weeksChange from baseline for physical and developmental measures
oHeight and weight
oHeight SDS and wei ght SDS
oWaist circumference, and
oTanner Staging
To assess the safety of 5mg and 10 mg 
tirzepatide QW ,analy zed as separate and 
pooled arms ,at 52 weeks for diabetic 
retinopathyIncidence of new or worsening of diabetic retinopathy or diabetic 
maculopathy in either eye
Characterize the pharmacokinetics and 
pharmacodynamic relatio nships of tirzepatideRelationship between tirzepatide exposure and key safety and efficacy 
measures
To assess the effect of 5 mg, and 10 mg 
tirzepatide QW, analy zed as pooled and 
separate treatment arms, on patient reported 
outcomes at 30 and 52 weeksChange f rom baseline for
oPedsQL Generic Core Scales
oPedsQL (3.2) Diabetic Module from baseline
Tertiary/Exploratory
To compare 5 mg, and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment 
arms, to placebo at 30 weeks; and to assess the 
effect of 5 mg, and 10 mg tirzepatide QW, 
analy zed as pooled and separate treatment 
arms at52 weeksIncidence of HbA1c ≤6.5% without severe or documented symptomatic 
(<70 mg/dL) hypoglycemia
Incidence of HbA1c <7.0% without severe or documented symptomatic 
(<70 mg/dL) hypoglycemia
To assess the effect of 5 mg, and 10 mg 
tirzepatide QW, analy zed as pooled and 
separate treatment arms, on patient reported 
outcomes at 30 and 52 weeksChange f rom baseline for EQ -5D-Y
To assess the effect of 5 mg, and 10 mg 
tirzepatide QW, separately and pooled, at Measures of insulin resistance, alpha cell and beta cell function, and 
serum adiponectin 
CONFIDENTIAL Protocol  I8F-MC-GPGV
29Weeks 8, 16 and 30 on additional metabolic
measures
Abbreviations: AEs = adverse events; BMI = body mass index; FSG = fasting serum gluc ose; HbA1c = hemoglobin A1c; PedsQL = 
Pediatric Quality of Life Inventory; QW = once weekly; SDS = standard deviation score .
Treatment -Regimen Estimand
The clinical quest ion of interest for the “treatm ent-regimen est imand ”is the treatm ent difference betwee n 
tirzepat ide and placebo after 30 weeks of interventio n in pediatric and ado lescent participants with T2DM ,
regardl ess of intervent ion discont inuat ion for any  reason (excluding inadvertently enrolled participants who 
have discont inued study  intervent ion for that reason) and regardless o f initiation of rescue antihyperglycemic
intervent ion.
Treatment -regimen estimand attributes
Population: pediatric and adolescent participants with T2DM who meet the inclusio n and exclusio n 
criteria. Further details on participants populat ion and inclusio n/exclusion criteria can be found in 
Secti on5.
Treatment condition :the randomized treatment with or without rescue antihyperglycemic medicat ion.
Further details on study  intervent ions and co ncomitant, including rescue, intervent ions can be found in 
Secti on6.
Endpoints: the primary and key second aryendpo intswill be studi e
d. Further details on theendpo ints 
can be found in the Object ives and Endpo intstable.
Population level summary :the difference in mean change from baseline to 30 weeks will be used for 
continuous endpo ints and the difference in proporti on (absol ute or rel ative, as appropriate) will be used 
for dichotom ous endpo ints. The pop
ulation level summary  will be conducted using Full Analysis Set 
(FAS) .Further details on statist ical analyses and analysis sets can be found in Sect ion 9.
Intercurrent events: the 2 intercurrent events “intervent ion discont inuat ion for any  reason” and 
“initiation of rescue intervent ion” are both addressed by  the treatm ent condi tion of  interest attribute. 
There are no remaining intercurrent events.
Rationale: the “treatment -regimen estimand” estimates treatment effect ,including the effect of 
intervent ion discontinuati on and rescue medicat ion to reflect clinical practice .
Efficacy Estimand
The clinical quest ion of interest for the “efficacy estimand” is the treatm ent difference b
etween t irzepati de and 
placebo after 30 weeks of intervent ion in pediatric and ado lescent participants with T2DM, prior to
intervent ion discontinuati on for any  reason and prior to the init iation o f rescue ant ihyperglycemic int ervent ion.
Efficacy estimand attributes
The populat ion and endpo ints attributes for the “efficacy est imand” are the same as the “treatment -regimen 
estimand”. This describes addit ional attri butes for the efficacy  estimand .
Treatment condition: the randomized treatment without rescue an tihyperglycemic medicat ion
.
Population level summary: the difference in mean change from baseline to 30 weeks will be used for 
continuous endpo ints and the difference in proporti on (absol ute or rel ative, as appropriate) will be used 
for dichotom ous endpo ints. The popul ation level summary  will be conducted using Efficacy Analysis 
Set (EAS).
CONFIDENTIAL Protocol  I8F-MC-GPGV
30Intercurrent events: the 2 intercurrent events “intervent ion discont inuat ion for any  reason” and 
“initiation of rescue intervent ion” are both addressed by  the treatm ent condi tion of  interest attribute. 
There are no remaining intercurrent events.
Rationale: The “efficacy estimand”provi des an on-treatment assessment without confoun ding the 
treatm ent effect fromoff-treatm entor rescue antihyperglycemic therapy data.
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
3 1 4. St u d y Desi g n 
4. 1. O ver all Desi g n 
St u d y  G P G V is a P hase 3, ra n d o mi ze d ,d o u bl e- bli n d ,pl ace b o -c o ntr olle d st u d y i n pe diatric a n d a d o le sce nt 
parti ci pa nts wi t h  T 2 D M i na de q uatel y c o ntr olle d wit h met f o r mi n or basal i ns uli n, or b ot h, t o as sess t he 
efficac y , s af et y, a n d P K/ P D of  ti rze pat i de at 3 0 a n d at 5 2 wee ks f o ll o wi n g a 2 2- wee k o pe n -la bel e xte nsi o n
p eri o d after Wee k 3 0. 
T he st u d y  will  c o nsist of 4 peri o ds 
an a p pr o xi mate 4- wee k scree ni n g peri o d ,
a 3 0- wee k d o u ble -bli n d pl ace b o -c o n tr olle d p eri o d ,
a 2 2 -wee k o pe n -la bel e xte nsi o n peri o d o n acti ve treat me nt ,a n d 
a 3 0 -d a y  p ost -tr e a tme nt  safet y f o ll o w-u p peri o d. 
4. 1. 1. O ver vie w of St u d y Visits 
St u d y  pr oce d ures a n d t heir ti mi n g are s u m marize d i n t he S o A, Secti o n 1. 3 .
A pare nt or le gal g uar dia n m ust acc o m pa n y  t he pa rti ci pa nt at eac h visit. 
F or cli nic visits n ote d i n t he S o A , t h e partici pa nt will arri ve at t he cli nic i n a faste d state ,at l east 8 h o urs 
wi t h o ut e ati n g a n d dri n ki n g e xce pt f or water. 
T hr o u g h o ut t he st u d y , p arti ci pa nt or pare nt or g uar dia n s h o ul d perf or m  a self - m o ni t or e d bl o o d gl uc ose 
(S M B G )i n t he faste d state 3 ti mes per wee k, t w o 6 -p oi nt S M B Gs o n n o n c o n sec ut i ve da ys pri or t o Visit 3 a n d 
Vi si t 1 3 as well as at a n y  ti me t he parti ci pa nt ha ss y m pt o m s s u g gesti ve of h y p o gl yce mia ( See Secti o n 8. 3. 3 . 1 ). 
T his ta ble descri bes t he visit t y pes. 
Visit Nu m ber Visit T y pe 
1-3, 5-9, 1 2, 1 3, 1 5, 17, a n d 1 9 Cli nic 
4, 1 0 , 1 1, 1 4, 1 6, a n d 1 8 Tele p h o ne visits 
6 a n d 1 2  
Earl y  ter mi nati o n (if a p plica ble) a n d 8 0 1 f oll o w - u p Cli nic 
A b bre viati o n: P K = p har mac o ki netic .
A n y tel e p h o ne visit ma y be c o n verte d t o a cli nic visit if dee me d me dicall y necessar y b y st u d y pers o n nel. 
Scree ni n g 
Visit 1 Cli nic Visit 
T h e pare nt or l e gal  g u ar di a n (s) will si g n t he i nf or me d c o nse nt f or m (I C F) a n d t he parti ci pa nt will si g n t he 
asse nt f or m. If t he parti ci pa nt has reac he d t he a ge of maj orit y p er l o c al  c o u ntr y  r e g ul at i o ns, a se parate asse nt 
d oc u m e nt m a y  n ot be re q ui re d, as t he partici pa nt will be eli gi ble t o si g n t he I C F .T he I C F a n d asse nt m ust be 
si g ne d bef ore a n y st u d y  pr oce d ures are perf or me d. C CI 
CONFIDENTIAL Protocol  I8F-MC-GPGV
32The purpose of screening procedures at Visit 1 and Visit 2 is to establish eligibilit y.
Doses of m etformin and basal insulin must bestable (±15% for basal insulin) for at least 90 days prior to the 
screening visit.
Visit 2 Clinic Visit
Available laboratory  resul ts are r eviewed ,and applicable inclusio n/exclusio n criteria evaluated .
Concomitant medicat ion isdocum ented ,and AEs reviewed .
The parti cipant and parent or legal guardian will receive
study  e-diaries and instructions on how to com plete them
a glucometer, supplies, and training
instructi on on measuring two 6-point SMBG son nonconsecut ive days within two week sprior to 
Visit 3, and
diet and exercise instruction for their T2DM
If a participant qualifies for the study  based on inclusion and exclusio n criteriathus far , avisual acuit y check 
and dilated fundoscopic examinat ion will be performed by  an eye care professio nal (ophthalmo logist or 
optom etrist) between Visit 2 and Visit 3
. A previo us exam ≤90 days of screening meet ing study  requirements 
by an ophthalm ologist or optom etrist i s acceptable.
Visit 3 Randomiz ation
The baseline dose for basal insulin will be established based on Visit 1 HbA1c . 
Once thi s dose i s established, it 
must remain stable during the study ( ±15%) , although i t may be further decreased at any  time if the participant
experiences hypoglycemia. All part icipants witha Visit 1 HbA1c <8%, will reduce their daily  dose of basal 
insulin by  20% at randomizat ion to reduce the potent ial risk of hypoglycemia (see Management of Increased 
Hypoglycemia Risk,Secti on 6.5.2 ).The 6 -point SMBG data will be reviewed at this visit.
The participant and parent or legal guardian will receive study  interventi on inject ion training and study 
intervent ion supply.
Prior to the concl usion of this visi t, the participant , parent or guardian , or study  personnel (whichever is 
deem ed m ost appropri ate by  study  personnel) will inject the participant with the first dose of study  
intervent ion, noting the date and time of inject ion in the study  e-diary . This day isthe participant ’s first day of 
study  interventi onadministrati on.
Visits 4-13 Double -blind Period
Visits 4, 10 and 11 Telephone Visit s
These topics will  be reviewed for the previous week (s)
AE informat ion
any new conco mitant m edicat ions or change in metformin or insulin dose
discussio n of effect ive contraception for males who have reached pubert y and are sexually 
active and for females of childbearing potential
study  e-diary  entries
CONFIDENTIAL Protocol  I8F-MC-GPGV
33oSMBG resul ts
obasal insulin dose, if applicable
ohypoglycemia events
ostudy  interventi on com pliance including date and time of inject ions (V10 and V11) , and
olast m enstrual  cycle for applicable females (V10 and V11) . 
If pregnancy is suspected, 
refer to Section 8.2.4 for pregnancy testing information .
The study  staff will confirm that the participant tolerated the previous weeks of study  intervent ion.
Visits 5-9 and 12 Clinic Visits
These topi cs will  be reviewed for the previous week(s)
AE informat ion
any new conco mitant m edicat ions or change in metform in or insulin dose
discussio n of effect ive contraception for males who have reached pubert y and are sexually 
active and for females of childbearing potential
study  
e-diary  entries
oSMBG resul ts
obasal insulin dose, if applicable
ohypoglycemia events
ostudy  interventi on com pliance including date and time of inject ions, and
olast m enstrual  cycle for applicable females. If pregnancy is suspected, refer to Section 
8.2.4 for pregnancy testing informat ion
.
The study  staff will confirm that the participant tolerated the previous weeks of study  intervent ion.
The participant and parent or legal guardi anwill receiv e
glucometer supplies ,
diet and exercise instruction for their T2DM , and
study interventi onsupply .
Reminder to obtain two 6 -point SMBG son nonconsecut ive days within two week sprior to Vi sit 
13
Visit 13 Clinic Visit
Clinic visit procedures are similar to Visits 5 -9 and 12 .Addit ionally, 6-point SMBG data will be reviewed at 
this visi t. At 
the end of the double -blind period, the dose of background diabetes medicat ion may be re-
adjusted as needed (see table in Sect ion8.3.3.2 ). After the site processes the visit in the interactive web-
response system (IWRS ), parti cipants will be dispensed the appropriate open -label study  intervent ion.
Those who received placebo and basal insulin during the dou ble-blind period may be asked, per clinical 
judgment of the investi gator, to reduce the dose of basal insulin upon tirzepat ide treatment during the open -
label period.
CONFIDENTIAL Protocol  I8F-MC-GPGV
34Open -label Period
Visits 14Telephone Visit
These topi cs will  be reviewed for the previous week
AE informat ion
any new conco mitant m edicat ions or change in metformin or insulin dose
discussio n of effect ive contraception for males who have reached pubert y and are sexually 
active and for females of childbearing potential
study  
e-diary  entries
oSMBG resul ts
obasal insulin dose, if applicable , and
ohypoglycemia events.
The study  staff will confirm that the participant tolerated the previous week of study  interventi on.
Visit 15 Clinic V isit
Clinic visit procedures are likethose in the double -blind period EXCEPT fasting is not required at this visit .
Visits 1 6and 18 Telephone Visit
Telephone visit procedures are likethose in the double
-blind period .
Visit 17 Clinic Visit
Clinic visit procedures are like those in the doubl e
-blind period EXCEPT fasting is not required at this visit .
Visit 19 (end of open -label)
Upon com pletion of this visi t, participant swill stop taking t irzepat ideandthe participant’s background 
diabetes m edicati on shoul dbe adjusted.
Only met formin or insulin canbe restarted or increased in dose as needed between Visit 1
9and Visit 801.
A follow-up visual acuit y check and dilated fundoscopic examinat ion will be performed by an eye care 
professio nal (ophthalmo logist or optom etrist) within ±21 day s of this visi t.
Early Termination and Safety Follow -up Visit
The parti cipant will arrive at the clinic in a fasted state for Early Terminat ion Visit .Safety Follow-up Vi sit is a 
non-fasted visit.
Parti cipant and parent or legal guardian must return study  equi pment and device s (e- diary and gl ucometer) to 
the invest igative site.
Parti cipants discont inuing the study early should have the follow-up visit approximately 30 days after the early 
termination visit and shoul d have a fo llow-up visual  acui ty check and dilated fundoscopi c examinat ion 
perform ed by  an eye care professio nal (ophthalmo logist or optom etrist) wi thin +21 days of the early  
termination visit. If the early terminat ionvisit is scheduled wit hin 6 months of the previous visual acui ty check 
and dilated fundoscopic examinat ion, a follow-up visual acuit y check and dilated fundoscopic exam inationare
not needed.
Participants who discontinue the study  before randomizat ion do not need to complete this visit.
CONFIDENTIAL Protocol  I8F-MC-GPGV
354.2. Scientific Rationale for Study Design
This is a superiority  study , the m ain objective of which is to compare the effects of tirzepat ide5mg and 
tirzepat ide10mgQW (pool ed), withmetformin or basal insulin, or both to those on placebo for glycemic 
control  (defined as change from baseline in HbA1c) in pediatric and adolescent populat ionwith T2DM over a 
30-week period , followed by a 22 -week open -label extensio n .
The efficacy measure, HbA1c, was chosen as the primary  object ive because it is an accepted endpoint in 
glycemic studiesin pediatric and adolescent participant s with T2DM.
The use of placebo for 30weeks during the double -blind portion of the study is considered appropriate, as 
Phase 3 studi eswith tirzepat idehave not been conducted to date in the pediatric and adolescent populat ion. 
Thus, a pl acebo com parator i s necessary  to understand tirzepati de’s true safet y and efficacy . To protect the 
safet y of the pa rticipant s enro lled across all arms of this study , the doubl e-blind period is relatively  short, there 
are cl ear rescue criteria for participant s with severe, persistent hy perglycemia (see Sect ion8.3.3.2 ) and 
participant s are allowed to decrease basal insulin and/ or metformin as needed if hypoglycemia occurs (for the 
definit ion of hypoglycemia, see Sect ion 8.3.3.1 ).
The doses of tirzepat idefor this study were based on efficacy, safet y and PK /PD data from  two pl acebo -
controlled studies in adults with T2D M,SURPASS -1 (GPGK ), monotherapy  study  versus placebo and 
SURPASS -5 (GPGI ), add -on to basal insulin vs placebo.
To mit igate the occurrence of GI AEs and permit time for the development of tolerance to GI effects, a dose 
escalat ion scheme will beused that start sat a low dose of 2.5 mg QW for 4 weeks and then escalates 2.5 mg 
increments every  4 weeks (Secti on 6.5.1 ). Therefore, it will take 4 weeks of dosing to reach a maintenance 
dose of 5 m g and 12 weeks to reach a maintenance dose of 10 mg.
The background therapies of diet and exercise, with metformin or basal insulin or both , are considered 
appropriate, as these are approved treatments for pediatric and adolescent participant s with T2DM in the US, 
EU, and many countries around the world.
In adults, tirzepati dehas been shown to be effect ive in lowering HbA1c with consistent safet y in the 
monotherapy  setting (di et and exercise only) and when added to met formin and other oral ant i-diabetes agents 
and/or basal insulin. The decisio n not to m aximize the doses of met formin and basal insulin was considered 
appropriate, as metformin at a dose of ≥1000 mg/day  is considered an effect ive dose in pediatric partici pants. 
For participant s using basal insulin, up -titration of  insulin during the double -blind period would reduce the 
study ’s abilit y to perceive a difference between the placebo and tirzepat idetreatm ent arm s and therefore is not 
allowed beyo nd ±15% of the ba seline dose (see Section 6.8.1 ). Tem porary  increases in insulin dose are 
allowed during the study and appropriate rescue methods exist in the protoco l to ensure that participant s do not 
continue in the double -blind porti on of  the study with poor glycemic control. Participant s may decrease doses 
of background di abetes m edicat ions at any  time if hypoglycemia is noted.
According to the visit schedule, par ticipants will be seen by physicians in the clinic during tirzepati de dose 
escalat ion approximately every  monthuntil maintenance dose is achieved , and with telephone visits
approximately  every  monthin between the clinic visit s. Thi s is considered appropriate, as pedi atricand 
adolescent participant s with T2DM are usually seen in the clinic every 3 months.
CONFIDENTIAL Protocol  I8F-MC-GPGV
36To optimize statist ical power to detect a meaningful treatment difference, there will be treatm ent group 
comparisons at the 30-week primary endpo int based on the pooled tirzepat idearms com pared to pl acebo.
4.3. Justification for Dose
The dose levels proposed for Study  GPGV are m aintenance dose levels of 5 mg and 10 mg.
Data from the Phase 3 studies SURP ASS-
1 and SURPASS -5in adult patients with T2DM, was used along 
with exist ing Phase 1 and Phase 2 data to j ustify the dose and escalation scheme proposed for Study GPGV.
Following com pletion of Phase 3 studies SURPASS -1and SURPASS -5, the PK m odel was updated to 
incorporate up -to-date tirzepat ide PK informat ion. This m odel was used to simulate exposures in the pediatric 
popul ation account ing forbody weight effects on PK parameters . The m edian body  weight in adult patients 
with T2DM was about 88 kg .
Simulations showed that ti rzepat ide average steady -state exposure (Css,avg) increased 1.5% per kg decrease in 
body  weight.
Theexposures fro m SURPASS -
1and SURPASS-5 werestratified by baseline body weight into 3 categories :
[1]< 75 kg [2] 75 -100 kg, and[3] > 100 kg . Model predi cted ti rzepat ide exposure following the 10-mg dose in 
the weight range of <75kg was comparable to exposure following the 15-mg dose in the weight range of 75 -
100kg. T hese exposures correspond to a near maximum HbA1c lowering effect (EC90 -EC95).
Study  GPGV plansto enroll ado lescent and pediatric pat ients with at least 50 kg i n body  weight and meet inga 
body  mass index ( BMI )thresho ldof >85thpercent ileat Visi t 1. Based on the PK/PD data, benefit/risk 
assessment fro m the Phase 3 stu dies in adult s with T2DM, tirzepat ide doses of 5 and 10 m g QW are expected 
to be efficacious with an acceptable tolerabilit y and safet y profile in an adolescent and pediatri cpopulat ionfor 
T2DM treatment .
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if he/she has co mpleted all requi red phases of the study  
including the last visit or the last scheduled procedure shown in the SoA (Section 1.3)
.
The end o f the study  is defined as the date of the last st udy visit or last scheduled procedure shown in the SoA
(Secti on1.3)for the last participant in the study globally .
CONFIDENTIAL Protocol  I8F-MC-GPGV
375. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as protocol 
waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criter ia apply:
Age
1.Parti cipant m ust be 10to<18years of age, at the time of signing the informed consent /assent .
Type of Participant and Disease Characteristics
For T2DM diagnosis criteria see Appendix 8, Section 10.8.
2.Parti cipants have T2DM treated at the time o f randomizat ion with lifest yle measures (standardized diet 
and exercise program), and
a.Metformin, or
b.Basal insulin, or
c.Metformin and b asal insulin
.
If metformin is used, the dose must be ≥1000 m g/day  and not m ore than the l ocally approved dose
a.Doses of m etformin and basal insulin must have been stable (±15% for basal insulin) f or at l east 
90 day sprior to Visit 1 and until Visit 3
3.Have HbA1c >6.5% to ≤11% at screening visit (determined by central  laboratory )
4.Body  weight ≥50kg and BMI of >85thpercent ileof the general  age and gender -matched populat ion for 
that country  orregion
Sex
5.Male or female
Contraceptive use by men or women o f childbearing potential should be consistent with local regulatio ns 
regarding the methods of contraception for those participat ing in clinical studies . See Appendix 4, 
Secti on 10.4 for guidance.
a.Male parti cipants who have reach edpubert y are requi red to use contraception ,
ifsexually act ive, in 
compliance wi th specific l ocal government study  requi rements (see Appendix 4, Secti on 10.4 for 
contraceptive requirements )
b.Female participants:
Are not of childbearing potential, defined as not having reached pubert y (see Appendix 4, 
Secti on10.4)
OR
Areof childbearing potential (see Appendix 4, Secti on10.4):
Are not breastfeeding .
CONFIDENTIAL Protocol  I8F-MC-GPGV
38Must test negative for pregnancy prior to init iation of treatment as indicated by  a 
negat ive serum pregnancy test at Visit 1 , followed by  a negative urine pregnancy 
test within 24 hours prior to study  intervent ionexposure.
If sexually act ive, there must be agreement to use two effect ive contraceptive 
methods that include one highly effect ive method (less than 1% failure rate) for 
the ent irety of the study plus 30 day s.
Informed Consent
6.Capable of giving signed informed consent or assent as described in Appendix 1 Secti on 10.1, whi ch 
includes compliance with the requi rements and restrictions listed in the ICF and in this protocol .
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
7.Have T1DM .
8. A FTER the diagnosis of T2DM , have a history  of diabetic ketoaci dosis or hy perosm olar syndro me.
9.Have diabetes -associ ated autoantibodies (GAD65 and /orIA2), historically or at Visit 1.
10.Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness withinthe 
last 6 months .
11.Have history  of:
proliferat ive diabet ic retinopathy, or
diabetic macular edema, or
nonpro liferat ive diabet ic retinopathy that requires acute treatment.
Note : A dilated fundoscopic examinat ion,evaluated by  an eye care professio nal (ophthalmo logist or 
optom etrist) or a previous exam ≤90 days of Visit 1meet ing study requirements is acceptable to 
confirm eligibilit y
.
12.Have blood pressure above the 99th percentile for age and gender OR systolic blood pressure 
≥160 mmHg or di astolic blood pressure ≥100 mmHg at screening .
13.Have family or personal history  of medullary thy roid carcino ma(MTC) or mult iple endocrine neoplasia 
syndro me type 2 (MEN2) .
14.Had chronic or acute pancrea titisany t ime prior to study entry (Visit 1) .
15.Are chronically taking drugs that direct ly affect GI mot ility, or have a known clinically significant gastric 
emptying abnormalit y, such as severe di abetic gastroparesi s or gastri c outl et obstructi on, or have 
undergone or plan to undergo weight loss procedure during the study , such as
1)a gastri c bypass (bariatri c) surgery
2)sleeve gastrectomy , or
3)restri ctive bariatric surgery, such as Lap- Band® gastri c banding.
CONFIDENTIAL Protocol  I8F-MC-GPGV
3916.Have evidence of a significant, uncontrolled endocrine abnormalit y, in the opinion o f the invest igator.
Examples : thyrotoxi cosis or adrenal crises
17.Known or suspected hy persensi tivity to study intervent ionor related products.
18.Have evidence of a significant, active autoimmune abnormalit y that, i n the opinio n of the invest igator, is 
likely  to requi re concurrent treatm ent wi th systemic gl ucocorti coids in the next 1 5months.
Examples : lupus or rheumatoid arthrit is
19.Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ 
transpl ant.
20.Have an act ive or previously treated m alignancy .
21.Have a history  of any other condit ionthat, in the opinio n of the investigator, may preclude the participant 
from following and com pleting the protocol.
Examples : known drug oralcoho l abuse, eating disorder or psy chiatri c disorder
22.Female participants who are pregnant or breast feeding or intending to become pregnant .
Prior/Concomitant Therapy
23.Treatment with any glucose -lowering agent other than stated in the inclusio n criteria 2 in a peri od of  90 
days pri or to Visit 1 and use of any  other gl ucose -lowering medication except basal insulin and 
metformin ( ≥1000 m g/day), between Visit 1and rando mizat ion (Visit 3).
Note: Participant s must not have received bo lus insulin wit hin 45 days of Visit 1, except as rescue 
treatm ent for management of acute medical condit ions for a maximum of 14 days .
24.Have been treated with prescription drugs or over -the-counter medications that prom ote wei ght loss 
within 90 days prior to Visit 1 and/or between study  entry (Visi t 1) and randomizat ion (Vi sit 3).
Examples :Saxenda®[liraglut ide 3.0 mg], Xenical®[orlistat ],and phentermine .
25.
Are receiving chronic (great erthan 2 weeks or 14 days consecut ively ) systemic gl ucocorti coid therapy 
(excluding topical, intraocular, intranasal, or inhaled preparations) or have received such therapy wit hin 1 
month prior to Visit 1 or between Visit 1 and Visit 3.
Prior/Concurrent Clinical Study Experience
26.Are current ly enrolled in any other clinical study  involving an intervent ionor any  other ty pe of medical  
research judged not to be scient ifically or medically co mpat ible with this study.
27.Have part icipated, within the last 30 days in a clinical study  involving an intervent ion. If the previ ous 
intervent ionhas a l ong half -life, 5 h alf-lives or 30 days (whichever is longer) must have passed.
28.Have previously co mpleted or discont inued fro m this study  or any  other study  invest igating tirzepat ide.
Diagnostic 
assessments
29.Have acute or chronic hepat itis, signs and symptoms of any other liver disease other than Nonalcoholic 
fatty liver disease (NAFLD ), or ALT or AST level > 5.0 times the upper limit of the age-adjusted 
reference range, or Total 
bilirubin ≥1.5times the upper limit of the age -adjusted reference range (except 
CONFIDENTIAL Protocol  I8F-MC-GPGV
40in the case of Gilbert’s syndro me) as determined by  the central  laboratory  at study  entry; parti cipants 
with NAFLD are eligible for participat ion in this study only if their ALT and AST levelsare ≤ 5 .0 times 
the ULN for the reference range and T otal bilirubin level is< 1.5 times the ULN at screening .
30.Have an est imated glomerular filtration rate < 45 mL/min/1.73 m2, calculated by  Chronic Kidney  
Disease -Epidemio logy as determined by central la boratory  at Visi t 1.
31.Have a serum calcitonin level ≥35 ng/L, as determined by  central  laboratory  at Visi t 1.
32.Have had a blood transfusio n or severe blood loss with in90 days pri or to Visit 1 or have known
hematol ogical condi tions that m ay interfere with H bA1c measurement.
Examples : hem olytic anemias, sickle cell disease
Other Exclusions
33.Are invest igator site personnel directly affiliated wit h this study  and/or thei r immediate families. 
Immediate family is defined as a spouse, parent, child, or sibling, whether bio logical or legally adopted.
34.Parent or legal guardians a re Lilly  empl oyees.
35.Are unwilling or unable to comply wit h all aspects of the pro tocol including the use of an e- diary to 
directly record data from the participant.
5.3. Lifestyle Considerations
Per SoA, Section 1.3, qualified medical staff will provide diabetes management counseling, which will include 
instructi ons on di et and exercise and educat ion about the signs, symptoms, and treatment of hypoglycem ia, 
shoul d it occur.
Parti cipants shoul d continue their usual exercise habits and generally  follow a healt hy meal  plan, wi th 
consistent meal size and t ime of day, throughout th e course of the study . Dietary  counseling m ay be reviewed 
throughout the study , as needed.
5.4. Screen Failures
A screen failure occurs when a participant who consents to participate in the clinical study is not subsequent ly 
rando mly assigned to study intervent ion or entered in the study . A minimal set of screen failure informat ion is 
required to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries fro m regulatory  authori ties. 
Minimal informat ion includes demography, scr een failure details, eligibilit y criteria, and any SAE.
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be re -screened one
time. The interval between re- screening must be at least 8 weeks. If re-screening is pe rformed, the parent or 
legal guardian must sign a new ICF and the participant a new assent. They  will be assigned a new ident ification 
number.
In addit ion,participants wi thnonpro liferat ive diabetic retinopathy requiring acute treatment may be eligible for 
one-time re-screening after treatment and meet requirement sin the opinio n of the invest igator .The study  
site/invest igator must receive p rior sponsor approval prior to re -screening .
CONFIDENTIAL Protocol  I8F-MC-GPGV
415.5. Criteria for Temporarily Delaying Enrollment of a Participant
This sect ion is not applicable for this study . All entry  criteria m ust be met wi thin the specified visit intervals in 
the SoA.
CONFIDENTIAL Protocol  I8F-MC-GPGV
426. Study Intervention (s) and Concomitant Therapy
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), placebo ,or medical 
device(s) intended to be administered to /used by a study  participant according to the study  protocol .
6.1. Study Intervention(s) Administered
Study  interven tion will be self- administered by  the parti cipant or administered to the participant by  the 
parent/caregiver.
This table describes the intervent ions administered in this study .
Intervention Name Tirzepati de (LY3298176) Placebo
Type Intervention Intervention
Dose Formulation Single dose pen (SDP) SDP
Unit Dose Strength(s) 2.5 m g, 5 m g, 7.5 m g, 10 m g Not applicable
Dosage Level(s) 5mg, 10mg Not applicable
Dose Volume 0.5 m L 0.5 m L
Route of Administration SCinject ion SCinject ion
Use Experimental Placebo
IMP and NIMP IMP IMP
Sourcing Provi ded centrally  by the Sponsor and dispensed by  IWRS
Packaging and Labeling Study  intervent ion will be provided in single dose pens and packaged in 
cartons to be dispensed.
Clinical study  materials will be l abeled according to country  regulatory  
requi rements.
Abbreviations: IMP = investigational medicinal product ; IWRS = interactive web -response sy stem ;NIMP = non -investigat ional 
medicinal product; SC=subcutaneous ; SDP = single dose pen .
6.1.1. Timing of Doses and Dosing Site
There are no restrict ions on the time of day  each weekly dose of study  interventi onis given, but it is advisable 
to administer the SC inject ions on the same day  and sam e time each week, wi th or wi thout m eals.
The actual  date and tim e of all dose administrati ons will  be recorded by  the parti cipant or parent or guardi an. If 
a dose of study  interventi onis missed, the participant must take i t as soon as possible unless it is within 72 
hours of the next dose, in which case, that dose must be skipped and the next dose must be taken at the 
CONFIDENTIAL Protocol  I8F-MC-GPGV
43appropriate time. The day  of weekly administration can be changed if necessary , as long as the l ast dose was 
administered 72 or more hours before.
All participants will inject study  interventi onsubcut aneously in the abdo men or thi gh using the SDPs provided; 
a caregiver may administer the inject ion in the participant’s upper arm. A new SDP will be used for each 
inject ion. If study  intervent ionis to always be injected in the same body  region, parti cipan ts shoul d be advised 
to use a different inject ion site each week.
6.1.2. Medical Devices
The combinat ion products provided for use in the study  is the ti rzepat ideSDP and placebo SDP.
All Product Complaints ( PCs; including malfunct ion, use error and inadequate la beling) shall be docum ented 
and reported by  the invest igator throughout the clinical invest igation and appropriately  managed by the sponsor
(see Section 10.3.3 ).
6.2. Preparation , Handling , Storage , and Accountability
The invest igator or designee must confirm appropriate storage conditions have been maintained during transit 
for all study  intervent ionreceived and any  discrepancies are reported and resolved before use of the study  
intervent ion.
Only participants enro lled in the study  may receive study  intervent ion. Only  authori zed study  personnel may 
supply , prepare , or dispense study  interventi on. All study  intervent ionmust be stored in a secure, 
environmentally  controlled, and m onitored (m anual  or autom ated) area i n accordance with the labeled storage 
condi tions wi th access limited to the invest igator and authorized study  personnel .
The invest igator or authori zed study  personnel are responsible for study interventi onaccountabilit y, 
reconciliat ion, and record maintenance (i .
e., recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  interventi onsare provided in the 
study training docum ents.
6.3. Measures to Minimize Bias: Randomization and Blinding
All participants will be centrally assigned to randomized study  intervent ion using an IWRS. Parti cipants will 
be randomized in a 1:1:1 r atio to tirzepat ide 5 mg QW :tirzepat ide 10 mg QW :placebo QW .
Parti cipant stratificat ion factors are:
age ( ≤ 14 y ears of age, >14 y ears of age), and
baseline ant ihyperglycemic medicat ion use of
ometformin only, or
obasal insulin only , or
ometformin and basal insulin.
CONFIDENTIAL Protocol  I8F-MC-GPGV
44Double -blind period
Invest igators, site staff, clinical monitors, and participan ts will remain blinded to the treatment assignments 
until the double -blind period of the study  is com plete.
Emergency  unblinding for AEs m ay be perform ed through the IWRS, which may supplement or take the place 
of emergency codes generated by  a com puter drug -labeling system. This option may be used ONLY if the 
participant’s well -being requires knowledge of the pa rticipan t’s treatm ent assignment. All act ions result ing in 
an unblinding event are recorded and reported by  the IWRS.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding of a 
participants’ treatmentassignment is warranted for medical management of the event . Part icipant safety  must 
always be the first considerat ion in making such a determinat ion. If the investigator decides that unblinding is 
warranted, it is the responsibilit y of the invest igator to prompt ly document the decisio n and rati onale and notify 
Lilly as soon as possible.
If an invest igator, site personnel performing assessments, or participant is unblinded during the double -blind 
period, the participant must be discont inued fro m the study . In cases where there are ethical reasons to have the
participant rem ain in the study , the invest igator must obtain specific approval fro m a sponsor medical monitor
for the participant to continue in the study .
Open -label period
During this part, study intervent ion will be assigned using an IWRS.
6.4. Study Interv ention Compliance
Study  intervent ionadministration data will be recorded by  the parti cipant or parent or guardian throughout the 
study .
The invest igator will assess study intervent ion compliance at each visi tby reviewing
participant’s recorded administration data
adherence to the visit schedule
completion of study  diaries , 
and
any other parameters the invest igator considers necessary.
The parti cipant and parent or guardian will be instructed to return any  unused study  intervent ion and/or empt y 
cartons at the next visit to the study  site for the purpose of performing drug accountabilit y.
Parti cipants consi dered poorly com pliant wi th their m edicat ion and/or the study  procedures will receive 
additional training and instructi on, as requi red, and will be reminded of the importance of complying with the 
protocol .
CONFIDENTIAL Protocol  I8F-MC-GPGV
456.5. Dose Modification
6.5.1. Tirzepatide Dose Escalation
The dose escalat ion scheme consists of a starting dose of 2.5 mg QW acco mpanied by a dose escalat ion of 2.5 
mg increments every  4 weeks until thedesired dose l evel is reached and maintained for the duration of the 
study .
This figure illustrates the tirzepatide dose escalat ion regimen.
6.5.2. Management of Increased Hypoglycemia Risk
What the participant should do if they experience a hypoglycemic event
Study  parti cipant and parent or guardian will be instructed on recognizing symptoms of hypoglycemia and how 
to treat i t. If a hypoglycemic event requires treatment assistance , then the participant or parent or guardian
shoul dcall the investi gative si te as soon as it is safe to do so .
If safe to do so during the symptoms of hypoglycemia , the participant or parent or guardian must record in the 
study  e-diary
the blood glucose (BG) level measured pri or to administration of treatment, if taken
associ ated symptom s, and
treatm ent administered .

CONFIDENTIAL Protocol  I8F-MC-GPGV
46What the investigator should do if the participant experiences a hypoglycemic event
If a participant experiences a hypoglycemic event the invest igator should
use definit ions and criteria provided in Sect ion 8.3.3.1 to diagnose hypoglycemia ,
properly categorize the suspected or confirmed event ,
assess the effect and timing of the intervent ion(s),
evaluate the frequency of the event(s) ,
establish the role of dietary  changes in the development of the event,
establish the role of physical exercise, or any  other contribut ing factor, in the development of the event, 
and
provi de parti cipant addi tional educat ion, if deemed appropriate.
Invest igators should pay clo se attention as to whether the basal insulin dose needs to be reduced in participants 
on basal insulin, especially  those who are in good glycemic control (HbA1c <7.0%).
Invest igators are responsible for their parti cipant’s management and well -being. Therefore, it is their 
responsibilit y to implement these generally  recommended measures, or to modify  them, taking into account 
clinical and other relevant criteria.
Management of antihyperglycemic medication s to reduce the risk of hypoglycemia
For participants using basal insulin who experienced hypoglycemia without anobvious cause, such as dietary  
or physical activit y changes ,the daily dose of basal insulin should be adjusted first per the clinical judg mentof 
the invest igator .
This table shows a suggested scheme for adjusting basal insulin in response to hy poglycemia and/or to reduce 
the risk of hypoglycemia .
If, within one week, a participant has 2 FBG
results of…Then …
50 mg/dL (<2.8 mmol/L) Decrease the basal insulin by 8 units 
>51-70 mg/dL (>2.8 -3.9 mmol/L) Decrease the basal insulin by 6 units 
>70-80 mg/dL (>3.9 -4.4 mmol/L) Decrease the basal insulin by 4units
>80 mg/dL (>4.4 mmol/L) No adjustment needed
Abbreviation: FPG = fasting plasma glucose
In case of repeated hypoglycemic events with a low basal insulin dose, that is, less than 10 unit s/day , and 
despite basal insulin dose decreases per the titration algorithm, administration of daily basal insulin may be 
temporarily or perm anently discont inued.
If the hypoglycemia persists despite discon tinuingbasal insulin and the parti cipant takes metformin , the 
metformin dose may be reduced or discont inued.
6.5.3. Tirzepatide Dose Modifications
Dose m odificat ion for tirzepat ide is not permitted.
CONFIDENTIAL Protocol  I8F-MC-GPGV
476.5.4. Management of Gastrointestinal Symptoms
During the double -blind dose escalat ion peri od, every  effort must be made by the investigator to maintain 
participants on the dose assigned by  IWRS.
This table describes steps the invest igator should follow t o mitigate GI symptom s and m anage part icipants wi th 
intolerable GI AEs during the escalat ion peri od.
STEP 1 Advise participants to eat smaller meals, for example, splitting 3 daily meals into 4 or more smaller meals, and to 
stop eating when they feel full.
STEP 2 Continue STEP 1 +
Prescribe symptomatic medication, for example, anti -emetic or anti -diarrheal medication, per local country 
availability  and individual participant needs. Use of symptomatic medication should be captured as concomitant 
medication in the eCRF.
STEP 3 Continue STEP 1 + STEP 2 +
Temporarily interrupt tirzepatide; omit 1 dose, the participant will take 3 of 4 doses at that dose level. After the 
interruption, the investigator should restart the dose or escalate the dose as required ,with the participant taking 
medication to alleviate their GI symptoms. The data related to temporary interruption of study treatment should 
be documented in source documents .
STEP 4 If intolerable GI symptoms or events persist despite the above measures, the inves tigator may decide to 
discontinue study interventio npermanently.
Participants who stop study intervention permanently will intensify insulin treatment and/or receive another 
glucose -lowering intervention (Section 7.1) and will continue participating in the study according to the protocol 
to collect all planned efficacy and safety measurements. The new glucose -lowering intervention will be recorded 
on the  eCRF for collecting anti -hyperglycemic medications.
Note: De-escalation of study intervention will not be allowed.
Abbreviations: eCRF = electronic case report form; GI = gastrointestinal.
6.6. Continued Access to Study Intervention after the End of th e Study
Study  intervent ion, tirzepat ide,will not be made available to participants after the conclusio n of the study . 
Parti cipants may  cont inue treatment with met formin available locally and/or basal insulin at invest igator 
discreti on.
6.7. Treatment of Overdo se
During this study , any dose of ti rzepat ide/placebo greater than the assigned dose within 72 h will be considered 
an overdose.
In the event of an overdose, the invest igator must :
1.Contact the medical mo nitor immediately
2.Evaluate the participant to determine, in consultat ion with the medical mo nitor, whether study  
intervent ion should be interrupted
3.Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities
4.Ensure approp riate supporti ve treatm ent is initiated according to the parti cipant ’scondi tion and 
symptoms
CONFIDENTIAL Protocol  I8F-MC-GPGV
48Decisio ns regarding dose interruptions or modifications will be made by the invest igator in consultat ion with 
the medical mo nitor based on the clinical evaluation of the participant.
In the event of overdose, refer to the IB f or tirzepatide.
6.8. Concomitant Therapy
Any medicat ion,including over-the-counter drugs, such as paracetamo l or aspi rin,or vaccine that the 
participant is receiving at the time of enro llment or receives during the study  must be documented in the 
concomitant medicat ions CRF. All non -diabetes concomitant therapies that are part of routine medical care that 
the participant requires are allowed and can be used during the study, except prescript ion and over -the-counter
weight loss medicat ions.
High dose inhaled or oral steroids should be used only  as medically  necessary .
Psychiatri c medicat ion shoul d rem ain stable.
Parti cipant or parent or guardian must consult with the investigator or a designated site staff member when 
they are prescribed any  new m edicati ons during the study . This m ay not be possible when init iated for 
treatm ent of m edical  emergencies, in which case, the participant or parent or guardian will inform the 
investigator or a designated site staff member as soon as possible.
Among participants screened but not randomized , non -study  medicat ionswill not be reported to Lilly unless an 
SAE or AE occurs that the invest igator believes may have been caused by a study procedure.
6.8.1. Rescue Therapy
In any situat ion that, in the invest igator’s opinio n, may require an intervent ion that i s not consistent with the 
requi rements provi ded in this section, he or she must also consult the Lilly medical monitorbefore such 
intervent ion is implemented, except w hen an immediate adjust ment of the treatment regimen is medically  
requi red.
Insulin therapy and metformin can be used as rescue therapy .
Rescue treatment with GLP -1 RAs or DPP -4 inhibitors are not allowed.
Definition of rescue therapy
These definit ions assume that a participant has not previously received rescue therapy .
Rescue therapy  is defined as any  of the f ollowing changes in glucose
-lowering regimen in response to 
persistent hy perglycemia:
A participant treated with metformin + study  intervent ion at baseline receives an increase d dose
of≥500 mg metformin and/or insulin at any dose for more than 2 weeks
A participant treated with metformin + basal insulin + study  intervent ionat baseline receives an 
increase d dose of ≥500 m g metformin and/or any  increased dose of >15% basal insulin and/or 
adding another ty pe of insulin at any dose for more than 2 weeks, or
A participant treated with basal insulin + study  intervent ionat baseline receives treatment with 
any increased dose of >15% basal insulin and/ or adding another ty pe of insulin at any  dose f or 
more than 2 weeks.
CONFIDENTIAL Protocol  I8F-MC-GPGV
49If a participant is experiencing severe, persistent hyperglycemia as outlined in sect ion 8.3.3.2 , the participant 
shoul d be considered for rescue. If they  are rescued, they  will cont inue in the study  and will  cont inue to take 
study  interventi onunless the invest igator determines that they  shoul d not.
6.8.2. Allowed Acute Diabetes Therapies
Antihyperglycemic medicat ions other than study  intervent ionsare ONLY allowed during these circumstances
for participants who require permanent discont inuation of study  intervent ionbut remain in the study
forrescue therapy  after randomizat ion due to sev ere, persistent hy perglycemia ,or
during the safet y follow-up peri od.
Short -term insulin use for up to 14 days is allowed for certain clinical situat ions (for example, elect ive surgery , 
during hospitalization, hyperosmolar states) and must be different iated from insulin use as rescue therapy  when 
reported in the electroni c case report form ( eCRF ).
6.8.3. Allowed Chronic Diabetes Therapies
The only allowed conco mitant chroni c diabetes therapi es are m etformin and basal insulin.
Use of metformin
After rando mizat ion, discont inuat ion of metformin or change in dosage and formulat ion is not permitted except 
in the sesituations:
In the event of a hypoglycemic episode(s) (clinical symptoms of hypoglycemia and/or fasting blood 
glucose [FBG]-confirmed symptomatic hypoglycemia of glucose concentrati on <3.0 mmo l/L [54
mg/dL]) , participant s shoul d first reduce or discontinue basal insulin (if applicable) and then may 
reduce or discont inue the dose of metformin only after discont inuing basal insulin (if applicable) .
In certain sit uations that require short -term discontinuat ion in line with the product(s) labeling for each 
respective country ,for example, forsevere dehydration, elective surgery, or need for radio logic 
examinat ion involving intravenous ( IV)iodinated contrast dy e.Once the situat ion that l ed to tem porary  
discontinuat ion is reso lved, treatment shoul d be restarted at invest igator discret ion.
If a participant develops contraindicat ions to met formin such that the use of the drug is contraindicated 
according to the countr y
-specific label.
If aparticipant meets the criteria for severe, persistent hyperglycemia (Sect ion 8.3.3.2 ) ordiscontinues 
study  interventi on, then the metformin dose may be increased according to country -specific label.
A participant will be considered nonco mpliant with the protocol (protocol de viation) if he or she changes the 
dose or discont inues metformin for reasons other than those described here. Dose reduction/discont inuation of 
metformin during the study must be properly documented and recorded on the appropriate eCRF.
Use of basal insulin
The ty pe of basal  insulin must remain the same throughout the study, if possible.
In case of hypog lycemic episode(s), please refer to Section 6.5.2 .
If the participant experiences acute illness with hyperglycemia, unlimited insulin therapy may be used for up to 
2 weeks. After that time, the participant ’s basal insulin dose should be at the baseline dose ( including up to 
±15% of baseline dose ) and other insulins (if used) should be stopped. This does not constitute rescue.
CONFIDENTIAL Protocol  I8F-MC-GPGV
507. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendix 1 , Secti on 10.1 .
7.1. Discontinuation of the Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue study  intervent ion. If study  
intervent ionis permanent lydiscont inued, the participant willremain in the study  and com plete all study  visits 
and procedures as outlined in the SoA (Secti on 1.3).
This lis t describes circumstances in which participants will be discontinued from the intervent ion:
If participants develop confirmed pancreatit is (if not confirmed, study  intervent ionmay be 
restarted )(see Section 8.3.3.3 )
If a participant is diagnosed with MTC or C -cell hyperplasia after rando mizat ion or has 
calcitonin value ≥35 ng/L thathas increased at least 50% over baseline after randomizat ion
If a participant i s diagnosed wi th an act ive malignancy or if a previously  treated m alignancy  becom es 
known after randomization
If a participant beco mes pregnant
If a participant is diagnosed with T1DM
Any significant study  intervent ion-related hypersensit ivityreacti on
Any other treatm ent-emergent adverse events ( TEAE ), SAE, or clinically  significant l aboratory  value 
for which the investigator believes that permanent study  interventi ondiscont inuat ion is the appropriate 
measure to be taken , or
If a participant requests to discont inue intervent ion.
Parti cipants who stop the study  intervent ionperm anent ly will receive another glucose
-lowering medication , if 
needed per clinical judg ment of invest igator, and will cont inue part icipating in the study according to the 
protocol  to collect all planned efficacy and safet y measurements per Section 1.3(SoA), Section 8.3(Adverse 
Events), and Section 8.2(Safet yAssessments ) of this protocol. The new gluco se-lowering medication will be 
recorded on the eCRF for antihyperglycemic medications.
7.1.1. Liver Chemistry Stopping Criteria
Discontinuation due to a hepatic event or liver test abnormality
Parti cipants who are di scont inued fro m intervent iondue to a hepatic event or liver test abnormalit y shoul d 
have addit ional hepatic safety  data collected via eCRF.
CONFIDENTIAL Protocol  I8F-MC-GPGV
51The study  intervent ionshoul d be interrupted or di scontinued if one or more of these condit ions occur .
Participants with Normal or Near Normal 
Baseline ALT and AST ( <1.5x ULN) at Visit 1Participants with Elevated Baseline ALT and 
AST ( ≥1.5x ULN) at Visit 1
ALT or AST > 5x ULN ALT or AST > 3x baseline at Visit 1
ALT or AST >3x ULN and either TBL >2x ULN or 
INR >1.5 
(Except for participants with Gilbert’s s yndrome)aALT or AST > 2x baseline at Visit 1 and either TBL 
>2x ULN or INR >1.5 
(Except for participants with Gilbert’s s yndrome)a
ALT or AST >3x ULN with the appearance of 
fatigue, nausea, vomiting, right upper quadrant pain 
or tenderness, fever, rash, and/or eosinophilia (>5%)ALT or AST > 2x baseline at Visit 1 with the 
appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or 
eosinophilia (>5%)
All participants
ALP >3x ULN (when the source of increased ALP is the liver )
ALP >2.5x ULN and TBL > 2x ULN 
(Except for participants with Gilbert’s syndrome)a
ALP >2.5x ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, 
fever, rash, and/or eosinophilia (>5%)
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July 2009 
and other consensus guidelines, with minor modifications
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate
aminotransferase; TBL = total bilirubin; ULN = upper limit of normal.
aIn participants with Gilbert’s syndrome, doubling of direct bilirubin should be used for drug interruption or 
discontinuation decisions rather than TB L>2x ULN.
Resumpt ion of the study  intervent ion can be considered only in consultat ion with the Lilly -designated medical  
monitor and only if the liver test results return to baseline and if a self -limited non -drug etio logy is identified.
See Secti on 8.2.8 (Hepati c Moni toring ) and Appendix 6, Secti on 10.6 ( Liver Safet y: Suggested Action and 
Follow-Up Assessments )for further gui dance on Hepatic mo nitoring .
7.1.2. Temporary Discontinuation
In certain situat ions, the invest igator may need to temporarily interrupt study  intervent ion. Every  effo rt should 
be made by the invest igator to maintain participants on study  intervent ionand to restart after any  temporary  
interrupti on, as soon as i t is safe to do so.
The data related to temporary  interrupti on of  study intervent ionwill be docum ented in source documents.
This table shows how to m anage treatment if there are missed study  treatm entdoses.
If the number of missed 
study treatment doses is...Then...
2 or less the study  treatment can be restarted at the last administered dose, if itwas well tolerated prior 
to interruption.
3 or mo re the IWRS will dispense 5 mg tirzepatide irrespective of the dose the participant was 
receiving before the interr uption and subsequently escalate as required by the protocol .
Abbreviations: IWRS = interactive web -response sy stem.
CONFIDENTIAL Protocol  I8F-MC-GPGV
52If the study  treatm entinterrupti on is due to intol erable persistent GI AE, such as nausea, vo miting, or diarrhea, 
the participant should be treated as suggested in Section 6.5.4 .
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study :
●at any  time at his/her own request
●at the request of his/her designee (for example, parents or legal guardian)
●at the discretion of the invest igator f or safet y, behavi oral, com pliance, or administrative reasons
if enro llment in any other clinical study invo lving an intervent ionor enrollment in any  other 
type of medical research judged not to be scient ifically or medically  com patible wit h this study , 
or
●if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent that has been 
demonstrated to be effect ive for treatm ent of the study  indicati on, discont inuat ion from the 
study  occurs pri or to introducti on of  the new agent .
If aparticipant i s found to be pregnant or breastfeeding during the study ,they will be discont inued from the 
study .
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early terminat ionvisit shoul d be conducted, as 
shown in the SoA. See SoA (Secti on 1.3)for data to be collected at the time of study discont inuat ion and 
follow-up and for any  further evaluat ions that need to be completed.
If the participant withdraws consent for disclosure of future informat ion, the sponsor may
 retain and continue 
to use any  data collected before such a withdrawal of consent. If a participant withdraws from the s tudy, they
may request destruction of any samples taken and not tested, and the invest igator must document this in the site 
study  records.
During the E Tvisit, the participant will not ini tiate any  new glucose -lowering therapy . Between ET visit and 
Visit 801, only metformin or insulin can be restarted or increased in dose as needed .
Visit 801 (safet y follow-up visi t) shoul d be performed approximately 4 weeks after the E Tvisit as the final 
study  visit.
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for scheduled visit s and 
is unable to be contacted by  the study  site. Si te personnel or designee are expected to make diligent attempts to 
contact parti cipants who fail to return for a scheduled visit or were otherwise unable to be fo llowed up by  the 
site.
CONFIDENTIAL Protocol  I8F-MC-GPGV
538. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA , Secti on 1.3.
Immediate safet y concerns mustbe discussed wit h the s ponsor immediately  upon occurrence or 
awareness to determine if the participant should cont inue or discont inue study  intervent ion.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial and 
requi red for study conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that potenti al participant s meet 
all eligibilit y criteria.The investigator will maintain a screening log to record details o f all partici pants 
screened and to confirm eligibilit y or record reasons for sc reening failure, as applicable.
8.1. Efficacy Assessments
HbA1c, fasting serum glucose and BMI standard deviat ion score ( SDS)will be used to charac terize the 
efficacy  of tirzepati de.
8.1.1. Patient Reported Outcomes Assessments
The self -reported questi onnai res will be translated into the nat ive language of the region and linguist ically 
validated .
The quest ionnaires should be completed before the participant has discussed their medical condit ion or 
progress in the study  with the invest igator and/or site staff.
The quest ionnaires should be completed before any other study  procedures.
8.1.1.1. EQ-5D-Y (Youth)
The youth-friendly  EQ-
5D-Y versio n consists of 2 pages ,the EQ-5D- Y descript ive system and the EQ visual 
analogue scale ( VAS) (EuroQol Research Foundatio n, 2020 ).
Each participant will co mplete this versio n of the EQ -5D.
The EQ-5D- Y descriptive system
The descriptive system comprises the same 5 dimensio ns as the EQ -5D 3 level (EQ -5D- 3L) but using a youth-
friendly wording. The 5 dimensio ns are
mobility,
looking after myself ,
doing usual act ivities,
having pain or disco mfort,and
feeling worried, sad or unhappy.
Each dimensio n has 3 levels: no problems, so me problems, or a lot of problems.
The EQ-5D- Y descript ive system will be converted into a single index value by applying a formula that 
attaches value (also called weights) to each of the levels in each dimensio n. The index value is a majo r feature 
of the EQ -5D instrument, facilitat ing the calculat ion of qualit y-adjusted life years that are used to inform 
economic evaluat ions of healthcare intervent ions.
CONFIDENTIAL Protocol  I8F-MC-GPGV
54The EQ -5D- Y VAS
The EQ VAS records the respondent’s self-rated heal th on a vertical scale , from , “The best healt h you can 
imagine,” to, “The worst health you can imagine.” This VAS informat ion can be used as a quant itative m easure 
of heal th outcom e as j udged by the individual.
Scoring
Details about scoring are available in the EQ -5D- Y User Guide at EuroQol Research Foundat ion, EQ-5D- Y 
User Gui de, 2020, available fro m: https://euroqol.org/publications/user -guides .
8.1.1.2. Pediatric Quality of Life Health Inventory (PedsQL)
The P edsQL is a health -related quali ty-of-life instrument that can be used in healt hy children and adolescents 
and those with acute and chronic healt h condit ions (Varni et al. 2019).
Different versio ns of the P edsQL (3.2) Diabetes Module and the PedsQL Generic Core Scales are a vailable for 
children of different ages.
The PedsQL Scoring Manual provides instructions to appropriately score all the dimensio ns, subscales, and 
total scores.
Peds QL (3.2) Diabetes Module
The P edsQL (3.2) Di abetes Modul e comprises33 item s for ages 13 years and older , and 32items (1 less i tem 
for the Worry  Scale) for ages 2 to 12 y ears.
This table describes the 5 dimensio ns of the PedsQL (3.2) Diabetes Modulefor both age groups .
Dimension Items perdimension
diabetes symptoms 15
treatment barriers 5
treatment adherence 6
worry  2 (3 for teens and adults )
communication 4
Scores are calculated for each dimensio n and a total score is available. Higher scores indicate l essprobl ems.
Peds QL Generic Core Scales
The 23- item PedsQL Generic Core Scales were designed to measure the core dimensio ns of healt h as 
delineated by  the Worl d Heal th Organizat ion, as well as role (school) funct ioning.
CONFIDENTIAL Protocol  I8F-MC-GPGV
55This table describes the scales in the generic scale and the summary scores .
Multidimensional Scale Items per Scale
Physical Functioning 8
Emotio nal Functioning 5
Social Functioning 5
School Functioning 5
Summary Scores Items per Summary Score
Psychosocial 15
Physical Health 8
Total 23
Higher scores indicate better health related qualit y of life.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA, Section 1.3.
8.2.1. Physical Examinations
Height, wei ght, and wai st circumference will be measured and recorded, per Appendix 11, Secti on10.11 .
Physical exams during in-clinic visit s willbe performedby a physician .
A co mplete physical examinat ion at Vi sits 3, 13,
19, V801 (andE Tif applicable) will include, at a minimum, 
assessments of
skin
cardi ovascular ( CV)
respi ratory
GI
neuro logical systems
thyroid exam , and
foot exam  including evaluat ionfordiabetic neuropathy .
8.2.2. Body Weight, Body Mass Index, Height, and Waist Circumference
Body  weight, hei ght, and wai st circumference will be measured at prespecified time points. Each participant’s 
weight, hei ght, and wai st circumference must be measured according to standardized guidelines (Appendix 11, 
Secti on10.11 ). Body  mass index will be computed from the participant’s weight and height.
8.2.3. Assessment of Pubertal Progression –
Tanner Staging
Parti cipants’ pubertal  progressi on will be assessed throughout the study . Tanner staging will be performed at 
baseline, Week 16, Week 30 and Week 52. Parti cipants who have reached Tanner stage 5 will not be evaluated 
again. (see Appendix 9, Secti on 10.9 for Tanner Stages).
8.2.4. Pregnancy Testing
Pregnancy testing will occur for females of childbearing potential according to the SoA (Section 1.3)
.
A local urine pregnancy  test m ust be performed at Visit 3 with the result available prior to randomization and 
first inject ion of study  intervent ion.
CONFIDENTIAL Protocol  I8F-MC-GPGV
56If pregnancy is suspected at any  time i n females of childbearing potential, a local urine pregnancy  test will be 
perform ed and a serum  pregnancy  test will be sent to the central laboratory . If requi red per l ocal regulati ons 
and/or institutional guidelines, pregnancy testing can also occur at ot her times during the study treatment 
period. If the parti cipant is pregnant, she must be permanent ly discont inued fro m study  interventi on and the 
study .
8.2.5. Vital Signs
Vital sign m easurements shoul d be taken before collect ion of blood samples for laboratory  testing, at visit s 
where required. For study-specific reco mmendat ions,see Appendix 1 1, Secti on10.11 .
Any clinically  significant findings from vital signs measurement that result in a diagnosis and that occur after 
the participant receives the first dose of study  intervent ion mustbe reported to Lilly or its designee as an AE 
via eCRF.
8.2.6. Electrocardiograms
For each participant, a single 12 -lead digital electrocardi ogram  (ECG )will be co llected according to the SoA.
The ECGs should be performed after vital signs are collected and prior to the collect ion of blood samples for 
laboratory  testing if the parti cipant is not adversely affected by  the fast ing con dition.
Parti cipants shoul d be supine for approximately  5 to 10 minutes before ECG collect ion and remain supine, but 
awake, during ECG collection .
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or qualified desi gnee) 
at the site as soon after the time of ECG collect ion as possible, and ideally while the participant is st ill present, 
for immediate participant management, should any clinically  relevant findings be identified. Any clinically 
significant findings fro m ECGs that result in a diagnosis and that occur after the participant receives the first 
dose of the intervention must be reported to Lilly or its designee as an AE via the eCRF.
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  Lilly .
A cardio logist at the central ECG laboratory  will then conduct a full overread on the ECG. A report based on 
data from  this overread will be issued to the invest igative site.
All data from the overreads will be placed in the Lilly  database for analy tical and study  report purposes.
If there are differences in ECG interpretation between the invest igator (or qualified designee) and the 
cardi ologist at the central  ECG l aboratory , the investi gator’s (or qualified designee’s) interpretati on will  be 
used for study  entry  and immediate subject management. Interpretations from the cardiologist at the central 
ECG laboratory  will be used for data analysis and report writing purposes.
The invest igator (or qualified designee) must document his/her review of ECG printed at the time of collect ion, 
the final overread ECG report issued by the central ECG laboratory , and any alert reports.
8.2.7. Clinical Safety Laboratory Tests
See Appendix 2, Secti on 10.2 for the list of clinical laboratory  tests to be performed and the SoA (Section 1.3) 
for the timing and frequency .
Due to blood volume considerations, frequency  of blood draws and bl ood vol umes have been limited.
CONFIDENTIAL Protocol  I8F-MC-GPGV
57One of the fo llowing m easures will  be offered to reduce pain associated with venipuncture: anesthet ic creams, 
anesthet ic patches , or hi gh pressure anesthet ic delivery system immediately before venipuncture.
The invest igator must review the laboratory results, document this review, and report any clinically relevant 
changes occurring during the study  as an AE. The laboratory  resul tsmust be retained wit h source documents 
unless a Source Document Agreement or comparable document cites an electronic locat ion that accommodates 
the expected retention duration. Clinically  significant abnorm al laboratory  findings are those which are not 
associated wi th the underlying disease, unless judged by  the invest igator to be more severe than expected for 
the participant's condit ion.
All laboratory  tests wi th values considered clinically  significantly abnorm al during parti cipat ion in the study  
shoul d be repeated until the values return to normal or baseline or are no longer considered clinically 
significant by  the invest igator or medical mo nitor.
If such values do not return to normal/baseline wit hin a peri od of  time judged reasonable by  the investi gator, 
the etiology  shoul d be i dentified and the sponsor notified.
All protocol -requi red laboratory  assessments, as defined in Appendix 2, Section 10.2 must be conducted in 
accordance with the SoA (Section 1.3), standard collect ion requirements, and laboratory  manual.
If laboratory  values fro m non-protocol  specified l aboratory  assessments perform ed at an invest igator -
designated local laboratory  requi re a change in parti cipant management or are considered clinically significant 
by the investigator (e.g., SAE or AE or dose modificat ion), then repo rt the informat ion as an AE.
8.2.8. Hepatic Monitoring
Close hepatic monitoring
Laboratory  tests ( Appendix 6, Secti on 10.6), including alanine amino transferase ( ALT ), aspartate 
amino transferase ( AST ),alkaline phosphatase (ALP ),total bilirubin (TBL ), direct bilirubin ( D. Bil ),gamma-
glutamyl  transferase ( GGT ), and creatine kinase ( CK), shoul d be repeated wi thin 48 to 72 hours to confirm the 
abnorm ality and to determine if it is increasing or decreasing, if one or more of these condit ions occur:
If a participant with baseline Visit 
1 results of ... develops the following elevations:
ALT or AST <1.5 XULN ALT or AST ≥3XULN
ALP <1.5X ULN ALP ≥2XULN
TBL <1.5XULN TBL ≥2XULN (except for participants with Gilbert’s syndrome)
ALT or AST ≥1.5XULN ALT or AST ≥2Xbaseline at Visit 1
ALP ≥1.5XULN ALP ≥2Xbaseline at Visit 1
* All ULN values should be age adjusted (AAULN)
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBL = total 
bilirubin; ULN = upper limit of normal.
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for possible causes o f 
abnorm al liver tests should be init iated by  the investi gator in consultat ion with the Lilly -designated medical 
monitor. At a minimum, this evaluat ion shoul d include physical examinat ion and a thorough medical history , 
including symptoms, recent illnesses (for examp le, heart failure, sy stemic infection, hypotensio n, or seizures), 
recent travel, history  of concomi tant medicat ions (including over -the-counter), herbal and dietary  suppl ements, 
history  of alcohol  drinking and other substance abuse.
CONFIDENTIAL Protocol  I8F-MC-GPGV
58Initially, m onitoring o f symptoms and hepat ic biochemical tests should be done at a frequency o f 1 to 3 times 
weekly, based on the participant’s clinical condit ion and hepatic biochemical tests. Subsequent ly, the 
frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the participant’s clinical condit ion and 
lab results stabilize. Monitoring of ALT, AST, ALP, and TBL should continue unt il levels norm alize or return 
to approximate baseline levels. Special care should be taken to minimize the vo lume of blood taken dur ing 
hepat ic monitoring.
Compr ehensive hepatic evaluation *
A comprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if one or m ore of 
these condit ions occur:
If a participant with baseline 
Visit 1 results of... develops the following elevations:
ALT or AST <1.5 XULN ALT or AST ≥3XULN with hepatic signs/symptoms **, or
ALT or AST ≥5XULN
ALP <1.5X ULN ALP ≥3XULN
TBL <1.5X ULN TBL ≥2XULN (except for participants with Gilbert’s syndrome)
ALT or AST ≥1.5XULN ALT or AST ≥2Xbaseline at Visit 1 with hepatic signs/symptoms **, or
ALT or AST ≥3Xbaseline at Visit 1
ALP ≥1.5XULN ALP ≥2Xbaseline at Visit 1
* All ULN values should be age and gender adjusted (AAULN)
**Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or eosinophilia 
>5%.
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBL = total 
bilirubin; ULN = upper limit of normal.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical history , as outlined 
above, as well as tests for PT -INR and direct bilirubin, if total bilirubin was elevated.
Based on the participant’s age, medical history  and ini tial results, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for viral hepat itis A, B, C, E; 
autoimmune hepat itis; or an abdo minal imaging study (for example, ultrasound, magnetic resonance imaging
[MRI ], or computerized tomography [ CT]scan). Consider addit ional tests, based on the medical history  and 
clinical picture, including tests for hepatit is D virus (HDV), cy tomegalovirus (CMV), Epstein -Barr virus 
(EBV), acetaminophen levels, acetaminophen p rotein adducts, urine toxico logy screen, Wilso n’s disease, blood 
alcoho l levels, urinary ethyl glucuronide, and blood phosphat idylethano l.
Speci al care shoul d be taken to pri oritize m ore pertinent bl ood tests and minimize the volume of blood taken 
during h epatic evaluat ion. Based on the circumstances and the invest igator’s assessment of the participant’s 
clinical condit ion, the investigator should consider referring the participant for a pediatric hepatologist or 
gastroenterologist consultation, magnet ic resonance cho langiopancreatography  (MRCP), endoscopic retrograde 
cholangiopancreatography  (ERCP), cardi ac echocardi ogram , or a liver biopsy  as deemed appropri ate for the 
clinical condit ion and participant’s age.
Additional hepatic data collection (hepatic safety CRF) in study participants who have abnormal liver 
tests during the study
CONFIDENTIAL Protocol  I8F-MC-GPGV
59Addit ional hepatic safet y data collect ion in hepat ic safet y case report forms (CRFs ) shoul d be performed in 
study  participants who m eet 1 or m ore of  the fo llowing 5 condit ions:
1.Elevat ion of serum AL T to ≥5Xupper limit of normal ( ULN )on 2 or more consecutive blood tests (if 
baseline Visit 1ALT <1.5x ULN)
In parti cipants wi th baseline Visit 1ALT ≥1.5X ULN, the thresho ld is ALT ≥3Xbaseline on 2 
or more consecutive tests
2.Elevated TBL  to ≥ 2XULN (except for cases of known Gilbert ’s syndro me)
3.Elevat ion of serum ALP to ≥2XULN on 2 or more consecutive blood tests (if baseline at Visit 1 ALP 
<1.5XULN)
In parti cipants wi th baseline Visit 1ALP ≥1.5X ULN, the thresho ld is ALP ≥2X baseline on 2 or 
more consecut ive blood tests
4.Hepati c event consi dered to be a SAE
5.Discontinuati on of  study  interventi ondue to a hepati c event
Note: the interval between the two consecut ive blo od tests should be at least 2 days.
All ULN values should be age and gender adjusted (AAULN) as applicable .
8.3. Adverse Events ,Serious Adverse Events , and Product Complaints
The definit ions of the fo llowing events can be found in Section 10.3, Appendix 3:
AEs
SAEs
PCs
These events will be reported by  the parti cipant (or, when appropriate, by
 a caregiver, surrogate, or the 
participant's legally  authori zed representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and recording events 
that meet these definit ions and remain responsible for fo llowing up events that are serious, considered related 
to the study  interventi onor study procedures, or that caused the participant to discont inue the study  
intervent ionand/or study  (see Section 7).
Care will be taken not to introduce bias when detecting events. Open -ended and non -leading verbal questioning 
of the participant is the preferred method to inquire about event occurrences.
After the init ial report, the invest igator is required to proactively fo llow each participant at subsequent 
visits/contacts. All SAEs and AESIs(as defined in Section 8.3.3 )will be followed unt il reso lution, 
stabilization, the event is otherwise explained, or the participant is lost to follow -
up (as defined in Section 7.3). 
For PCs, the investigator is responsible for ensuring that follow -up includes any  supplemental  invest igations as 
indicated to elucidate the nature and/or causalit y. Further inform ation on follow -up procedures is provided in 
Appendix 3, Secti on10.3.
CONFIDENTIAL Protocol  I8F-MC-GPGV
608.3.1. Timing and Mechanism for Collecting Events
This table describes the timing, deadlines ,and m echanism for collect ing events.
Event Collection 
StartCollection Stop Timing for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Adverse Event
AE signing of 
the informed 
consent form 
(ICF)participation in 
study has endedas soon as possible 
upon site awarenessAE eCRF N/A
Serious Adverse Event
SAE and SAE 
updates –prior to 
start of study  
interventio nand 
deemed reasonably 
possibly related 
with study 
proceduressigning of 
the informed 
consent form 
(ICF)start of 
interventio nwithin 24 hours of site 
awarenessSAE eCRF SAE paper 
form
SAE and SAE 
updates –after start 
of study 
interventio nstart of 
interventio nparticipation in 
study has endedwithin 24 hours of site 
awarenessSAE eCRF SAE paper 
form
SAE* –after 
participant’s study 
participation has 
ended and the 
investigator 
becomes awareafter 
participant’s 
study 
participation 
has endedN/A promptly SAE paper form N/A
Pregnancy
Pregnancy in female 
participants and 
female p artners of 
male participantsafter the start 
of study 
interventio nfour months after 
the last injection 
for female partners 
of male 
participants and 2 
months after the 
last injection for 
female participantswithin 24 hours pregnancy paper
formpregnancy 
paper form
Product Complaints (PC)
PCassociated with 
an SAE or might 
have led to an SAEstart of study  
interventio nend of study 
interventio nwithin 24 hours of site 
awarenessProduct Complaint 
formN/A
PC not associated 
with an SAEstart of study  
interventio nend of study 
interventio nwithin 1 business day 
of site awarenessProduct Complaint 
formN/A
CONFIDENTIAL Protocol  I8F-MC-GPGV
61Event Collection 
StartCollection Stop Timing for Reporting 
to Sponsor or 
DesigneeMechanism for 
ReportingBack -up 
Method of 
Reporting
Updated PC 
information— — as soon as possible 
upon site awarenessoriginally  
completed Product 
Complaint form 
with all changes 
signed and dated by 
the investigatorN/A
PC (if investigator 
becomes aware)participation 
in study has 
endedN/A promptly Product Complaint 
formN/A
8.3.2. Pregnancy
Female participants who become pregnant
For a female participant who becomes pregnant, this informat ion will be shared with the study  parti cipant’s 
legally acceptable representative, parent(s), or legal guardian if the participant’s age is <18 years as required by 
local regulati ons.
The invest igator will co llect pregnancy information on any female participant who be comes pregnant while 
participat ing in this study . The init ial informat ion will be recorded on the appropriate form and submitted to the 
sponsor within 24 hours of learning of a participant's pregnancy.
The parti cipant will be fo llowed to determine the outc ome of the pregnancy . The invest igator will co llect 
follow-up inform ation on the participant and the neonate and the informat ion will be forwarded to the sponsor. 
Generally, fo llow-up will not be required for longer than 6 to 8 weeks bey ond the estimated d elivery  date. Any 
termination o f pregnancy will be reported, regardless of gestational age, fetal status (presence or absence of 
anomalies) or indicat ion for the procedure.
Any pregnancy  com plicati on or el ective terminat ion of a pregnancy  for m edical reaso ns will be reported as an 
AE or SAE.
A spontaneous abortion (occurring at <20 weeks gestational age) or still birth (occurring at ≥20 weeks 
gestati onal age) is always considered to be an SAE and will be reported as such.
Any post -study pregnancy related SA E consi dered reasonably related to the study  interventi on by  the 
investigator will be reported to the sponsor as described in protocol Sect ion 8.3.1 .While the invest igator is not 
obligated to actively seek this informat ion in former study  parti cipants, he or she may learn of an SAE through 
spontaneous reporting.
Any female part icipant who becomes pregnant while participat ing in the study  willbe discont inued from the 
study .If the parti cipant i s discont inued fro m the study , follow the standard discont inuat ion process and 
continue directly to the fo llow-up phase. The fo llow-up on the pregnancy  outcom e shoul d continue 
independent of intervent ion or study  discontinuat ion.
Collection of pregnancy information
Male participants with partners who become pregnant
The invest igator will attempt to collect pregnancy informat ion on any male participant’s female partner who 
beco mes pregnant while the male parti cipant i s in this study and for 90 day s after the end of the study .
CONFIDENTIAL Protocol  I8F-MC-GPGV
62After obtaining the necessary  signed consent from the pregnant female partner direct ly, the invest igator will 
record pregnancy informat ion on the appropriate form and submit it to the spon sor wi thin 24 hours of learning 
of the partner’s pregnancy. The female partner will also be followed to determine the outcome of the 
pregnancy. Informat ion on the status of the mother and child will be forwarded to the sponsor. Generally, the 
follow-up wil l be no longer than 6 to 8 weeks fo llowing the estimated delivery date. Any terminat ion of the 
pregnancy will be reported regardless of gestational age, fetal status (presence or absence of anomalies) or 
indicat ion for the procedure.
8.3.3. Adverse Events of Special Interest
8.3.3.1. Hypoglycemia
Authorized study  personnel will train participant and parent or gu ardianabout si gns and symptoms of 
hypoglycemia and how to treat hy poglycemia. Participant or parent or guardian will co llect informat ion on 
each episode of hypoglycemia inthe e-diary.
Ahypoglycemic episode mustbe noted as having occurred any t ime a participant feels that (s)he is 
experiencing a sign or symptom associated with hypoglycemia AND/ OR has a BGlevel <70 mg/dL (3.9 
mmo l/L), even if asy mptom atic.
For each hypoglycemic episode, participant or parent or guardian shoul d record the participant’s BGlevel (if 
available) and treatment in the study  diaries provi ded.
The time and date of all SMBG readings shoul dbe recorded in the study  diari es as well as the date and time of 
weekly study  intervent ion administrati on.
Definitions and criteria for diagnosing hypoglycemia
Invest igators must use the fo llowing definit ions and cri teria when di agnosing and categorizing an episode 
considered to be related to hy poglycemia (ADA 2021b) . The BG values in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  Medicine 
plasma -equivalent glucose meters and strips which are provided to the participant by  the study  sponsor.
To avoid duplicate reporting, all consecutive BG values <70 mg/dL (3.9 mmo l/L) occurring within a 1 -hour 
period may be considered to be a single hypoglycemic event (Weinberg etal.2010; Danne et al. 2013).
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly categorized, the 
effect of the intervent ion be assessed, and the frequen cy of  hypoglycemia be evaluated. The role of dietary  
changes and physical exercise (or any  other contribut ing factor) in the development of an event should be 
established. The participant and parent or guardian should receive addit ional educat ion, if deeme d appropri ate. 
Please refer to Section 6.5.2 for guidance on Management of Increased Hypoglycemia Risk.
CONFIDENTIAL Protocol  I8F-MC-GPGV
63Level 1 hypoglycemia -Glucose <70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L )
Level 1 hypoglycemia can alert a person to take action such as treatment with fast -acting carbohydrates. 
Provi ders must continue to counsel part icipant and parent or guardian to treat hy poglycemia at this glucose 
alert val ue.
This table de fines Level  1Glucose Alert s.
Level 1 Glucose Alerts Definition
Documented symptomatic hypoglycemia Any time a participant feels that he or she is experiencing 
symptoms and/or signs associated with hypoglycemia and has a 
BG level of <70 mg/dL (3.9 mmol/L) .
Documented asymptomatic hypoglycemia Any event not accompanied by typical symptoms of 
hypoglycemia, but with a measured BG <70mg/dL (3.9 
mmol/L) .
Documented unspecified hypoglycemia Any event with no information about symptoms of 
hypoglycemia available, but with a measured BG <70 mg/dL 
(3.9mmol/L) .
Abbreviations: BG = blood glucose .
Level 2 hypoglycemia -Glucose <54 mg/dL (3.0 mmol/L )
Level 2 hypoglycemia is also referred to as documented or BGconfirmed hypoglycemia with glucose 
<54mg/dL (3.0 mmo l/L). This glucose threshold is clinically relevant regardless of the presence or absence of 
symptoms of hypoglycemia.
This table defines Level  2 Clinically  Significant Hypoglycemia .
Level 2 Clinically Significant Hypoglycemia Definition
Documented symptomatic hypoglycemia Any time a participant feels that he or she is experiencing 
symptoms and/or signs associated with hypoglycemia and has a 
BG level of <54 mg/dL (3.0 mmol/L) .
Documented asymptomatic hypoglycemia Any event not accompanied by typical symptoms of 
hypoglycemia, but with a measured BG <54mg/dL 
(3.0mmol/L) .
Documented unspecified hypoglycemia Any event with no information about symptoms of 
hypoglycemia available, but with a measured BG <54 mg/dL 
(3.0mmol/L) .
Abbreviations: BG = blood glucose .
Level 3 hypoglycemia -Severe hypoglycemia
Severe hypoglycemia is defined as an episode with severe cognit ive impairment requiring the assistance of 
another person to actively  administer carbohydrate, glucagon, or other resuscitative act ions. These episodes 
may be associated with sufficient neuroglycopenia to induce s eizure or com a. Bl ood gl ucose m easurements 
may not be available during such an event, but neurological recovery attributable to the restoration of BGto 
norm al is consi dered sufficient evidence that the event was induced by  a low BGconcentration.
The dete rminat ion of a hypoglycemic event as an episode of severe hypoglycemia is made by  the investi gator 
based on the medical need o f the participant to have required assistance and is not based on the report of a 
participant simply having received assistance.
CONFIDENTIAL Protocol  I8F-MC-GPGV
64If a hypoglycemic event meets the criteria of severe hypoglycemia, the invest igator must record the event as 
serious on the AE CRF and report it to Lilly  as an SAE.
Nocturnal hypoglycemia
Nocturnal hypoglycemia is a hypoglycemia event ,including severe hypoglycemia ,that occurs at night and 
presum ably during sleep.
8.3.3.2. Severe, Persistent Hyperglycemia
Severe, persistent hy perglycemia will be collected during the study to assess the risk of extreme imbalance in 
glycemic control.
Invest igators will be trained on the applicat ion of cri teria for deci ding when and how to intervene with 
participant s who do not reach glycemic targets.
Rescue medicat ion as outlined in Section 6.8.1 will be prescribed as an add -on to randomized treatment in the 
absence of intercurrent cause of the hyperglycemia if the average FBG value of at least 3values of FBG per 
week ,over 2 consecut ive weeks ,exceeds these values
>270 m g/dL (>15.0 mmol/L) fro m baseline to Week 6
>240 m g/dL (>13.3 mmol/L) fro m Week 7to Week 1 6, or
>200 m g/dL (>11.1 mmo
l/L) fro m Week 1 7to end of study .
Invest igators must first confirm that the participant is fully co mpliant wi th the assigned therapeutic regimen 
and that they  do not have an acute condit ion causing severe hyperglycemia .
If applicable, determine if the participant has appropriately  titrated the dose for basal insulin prior to deciding if 
severe, persistent hyperglycemia criteria has been met. Basal insulin shoul d be ti trated fi rst before adding any  
rescue therapy .
Protocol  allowed rescue therapies may  be added forparticipants who meet the severe, persistent hyperglycemia 
criteria,at the discret ion of invest igator ,in accordance wit h American Diabetes Association/European 
Associ ation for the Study  of Diabetes gui dance (ADA 2021c) . Rescue m edicati on will  be prescribed as add - on 
to study  intervent ion, and participants will continue to fo llow the protocol -specified visit schedule.
8.3.3.3. Pancreatitis
Diagnosis of acute pancreatitis
The di agnosis of acute pancreat itis requires 2 of the fo llowing 3 features (Banks and Freeman 2006; Koizumi  
2006):
abdo minal pain characteristic of acute pancreatit is,that is, epi gastric pain radiating to the back, often 
associ ated wi th nausea and vo miting
serum  amylase (total, pancreat ic, or both) and/or lipase ≥3X ULN, or
characterist ic findings of acute pancreat itis on CT scan or MRI .
If acute pancreat itis is suspected, the invest igator should
obtain appropriate laboratory  tests, including pancreatic amylase (p -amylase) and lipase
perform  imaging studies , such as abdo minal CT scan wit h or without contrast, or abdominal MRI , and
CONFIDENTIAL Protocol  I8F-MC-GPGV
65evaluate for possible causes of acute pancreatit is, including alcoho l use, gallstone/gall bladder disease, 
hypertriglyceridemia, and conco mitant medicat ions.
Discontinuation for ac ute pancreatitis
If acute pancreat itis is suspected, the participant must discont inue study  intervent ion.If acute pancreatit is is 
confirmed, study  intervent ionshoul d not be restarted.
Case adjudication and data entry
An independent clinical endpo int comm ittee (CEC) will adjudicate all suspected cases of acute or chroni c
pancreat itis. In addit ion, AEs o f severe or serious abdo minal pain o f unknown et iology will also be submitted 
to the adjudicat ion commit tee to assess for possible pancreat itis or other pan creati c disease. Relevant data from 
pediatric andadolescent participants with acute or chronic pancreat itis and those with severe or serious 
abdo minal pain will be entered into a specifically designed eCRF page by study  site. The adj udicati on 
committee representative will enter the resul ts of adjudicat ion in a corresponding eCRF page.
Asymptomatic elevation of serum amylase and/or lipase
Serial measures of pancreat ic enzymes have limit ed clinical value for predicting episodes of acute pancreat itis 
in asymptom atic participant s (Nauck et al. 2016; Steinberg et al. 2017a, 2017b). Therefore, further diagnostic 
follow-up of  cases of asymptomat ic elevat ion of pancreat ic enzymes (lipase and/or p- amylase ≥3X ULN) i s not 
mandated but may be performed based on the investigator’s clinical judgment and assessment of the 
participant’s overall clinical condit ion.
8.3.3.4. Thyroid C -Cell Hyperplasia and C -Cell Neoplasms
Individuals with personal or family history  of MTC and/or MEN2 will be excluded fro m the study .
The assessment of thyroid saf ety during the study  will include reporting of any  case of  thyroid malignancy 
including MTC and papillary  carcino ma and measurements of calcitonin. Calcitonin measurements willassess 
the potenti al of tirzepat ide to affect thyro id C-cell func tion, which m ay indicate development of C -cell 
hyperplasia and neoplasms. These data will be captured in specific eCRFs.
Ifanincreased calcitonin value ( ≥35 ng/L AND an increase by ≥50% com pared wi th baseline) is observed in a 
participant who has administered a medicat ion that is known to increase serum calcitonin, this medication must 
be stopped and calcitonin levels must be measured after an appropriate washout period. A consultation with a 
thyroid specialist or an endocrinologist, should be obtained. See Secti on 7.1for thyroid-related discont inuat ion 
criteria.
If the confirmed calcitonin value is <35 ng/L, tirzepatide should be restarted when it is safe to do so.
8.3.3.5. Arrythmias and Cardiac Conduction Disorders
Parti cipants who devel op any event from these groups of disorders should undergo an ECG. Additional 
diagnost ic tests to determine exact diagnosis should be performed, as needed. The specific diagnosis will be 
recorded as an AE. Events that meet criteria for serious condit ions as described in Appendix 3, Secti on 10.3
must be reported as SAEs.
After enro
llment, i f a clinically significant finding is ident ified by ECG including, but not limited to, changes 
from basel ine in QT /corrected QT interval , the investi gator or qualified designee will determine if any  change 
CONFIDENTIAL Protocol  I8F-MC-GPGV
66in study  parti cipant management is needed. This review of the ECG printed at the time of collect ion must be 
docum ented. Any new clinically  relevant findi ng must be reported as an AE or SAE (if applicable) .
8.3.3.6. Diabetic Retinopathy Complications
Visual acui ty evaluat ion will be performed as part of the ophthalmo logy assessments pri or to dilat ion. The 
resul ts from this exam  will be recorded on a specific eCRF. Dilated retinal fundoscopic examinat ion for all 
participants will be performed by a qualified eye care professio nal (ophthalmo logist or optom etrist)between 
Visit 2and Visit 3 or at aprevious exam ≤90 days of screening meet ing study  requi rements .The results fro m 
this examinat ion will be recorded on a specific retinopathy  eCRF as a baseline measure of retinopathy .
Additionalvisual acuit y checks and dilated fundoscopic examinat ionsshoul d be performed when clinically 
indicated by  any AE suspected of wo rsening retinopathy, and the findings must be recorded on the retinopathy 
eCRF.
A follow-up visual acuit y check and dilated fundoscopic examinat ion occur for all rando mized participants at 
Visit 19(Week 52) .
8.3.3.7. Hypersensitivity Reactions
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity react ions. If such a 
reacti on occurs, addi tional data describing each symptom must be provided to the sponsor in the eCRF .
Sites shoul dhave appropriately trained medical staff and appropriate medical equipment available when study  
participants are receiving study  intervent ion. It is recommended that participants who experience a systemic 
hypersensit ivity react ionbe treated per national and internat ional guidelines.
In the case of generalized urticaria or anaphylaxis, addit ionalblood samples shoul dbe co llected as described in 
Appendix 10,Secti on 10.10 .Laboratory results are provided to the sponsor via the central laboratory.
If the invest igator, after consultation with the sponsor -designated medical mo nitor, determines that a systemic 
hype rsensi tivity react ion has occurred related to study  intervent ionadministration, the participant should be 
perm anent ly discont inued fro m the intervent ion, and the sponsor’s designated medical mo nitor should be 
notified. If the invest
igator is uncertain about whether a systemic hypersensit ivity reacti on has occurred and 
whether discont inuat ion of study  intervent ion is warranted, the invest igator may consult the sponsor.
8.3.3.8. Injection Site Reactions
Symptom s and si gns of a local inject ionsite reaction (ISR) may include ery thema, indurat ion, pain, pruritus, 
and edema.
If an ISRis reported by a participant or parent or guardian or site staff , the ISRCRF will be used to capture
additional information about this reaction, for example, inject ionsite pain, degree and area of ery thema, 
induration, pruritis and edema .
At the time of AE occurrence in the tirzepat ide group, samples will be co llected for measurement of tirzepatide 
anti-drug bodi es (ADAs) and tirzepat ide concentration
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
6 7 8. 3. 3. 9. A nti -Dr u g A nti b o dies 
T he occ urre nce of a nt i- dr u g a nt i b o d y  f or mati o n will  b e assesse d as o utli ne d i n S ect i o n 8. 8 .
8. 3. 3. 1 0. He p at o bili ar y Dis or ders 
All e ve nts of treat m e nt -e mer ge nt biliar y c o lic, c h olec yst it is, or ot her s us pecte d e ve nts relate d t o gall bla d der 
dis ease s h o ul d be e val uate d a n d a d dit i o nal dia g n ostic tests perf or me d, as nee de d. I n cases of ele vate d li ver 
mar kers, he pat ic m o nit ori n g s h o ul d be i ni ti ate d as o utli ne d i n Sect i o n8. 2. 8 .
8. 3. 3. 1 1. Se vere G astr oi ntesti n al A d verse E ve nt 
Ti rze pati d e m a y ca use se vere GI A Es, s uc h as na usea, v o mit i n g, a n d diarr hea. I nf or mat i o n a b o ut se vere GI 
A Es as well as a ntie metic/a nti diarr heal use will be c ollecte d i n t he e C R F/ A E f o r m .
F or detaile d i nf or mat i o n c o ncer ni n g t he ma na ge me nt of GI A Es, refer t o Secti o n 6. 5. 4 .
8. 3. 3. 1 2. Ac ute Re n al E ve nts 
Re nal safet y  will  b e assesse d base d o n re peate d re nal f u nct i o nal assess me nt as well as assess me nt of A Es 
s u g gest i ve of ac ute or w orse ni n g of c hr o nic re nal di sease .Gastr oi ntesti nal A Es ha ve bee n re p orte d wit h 
ti rze pat i de i ncl u di n g na usea, diarr hea, a n d v o mit i n g. T hese are c o nsiste nt wit h ot her G L P -1 rece pt or a g o nists 
( Ar o da a n d Rat ner 2 0 1 1). T he se e ve nts ma y lea d t o de h y drati o n, w hic h c o ul d ca use a deteri orati o n i n re nal 
f u nct i o n, i ncl u di n g ac ute re nal fail ure. Parti ci pa nt or pare nt or g uar dia n s h o ul d be a d vise d t o n otif y  
i n vesti gat ors i n case o f se vere na usea, fre q ue nt v o mit i n g, or s y m pt o ms of de h y drat i o n. 
8. 3. 3. 1 3. M aj or De pressi ve Dis or der/ S uici d al I de ati o n 
T he pre vale nce of de pressi ve s y m pt o ms a n d dis or ders is i ncrease d i n pat ie nt s wi t h  T 1 D M or T 2 D M ( A D A 
2 0 1 9). A n y  A E of  m aj or de pressi ve di s or der or s uici dal i deat i o n s h o ul d be re p orte d. 
8. 3. 3. 1 4. Met a b olic Aci d osis, I ncl u di n g Di a betic Ket o aci d osis 
Ket oaci d osis, a seri o us life -t h reate ni n g c o n dit i o n re q uiri n g ur ge nt h os pitalizat i o n, has bee n re p orte d 
occasi o nall y i n partici pa nts wit h T 2 D M. Partici pa nts w h o prese nt wit h si g ns a n d s y m pt o ms c o nsiste nt wit h 
se vere m eta b o lic aci d osis s h o ul d be assesse d f or ket oaci d osis re gar dless of prese nt i n g B G le vels, as 
ket oaci d osis ma y  b e prese nt e ve n if B G le vels are less t ha n 2 5 0 m g/ d L. 
If ket oaci d osis is s us pecte d, partici pa nt s h o ul d be e val uate d, a n d pr o m pt treat me nt s h o ul d be i nst it ute d. 
Treat me nt of ket oaci d osis ma y  re q uire i ns uli n, fl ui d, a n d car b o h y drate re place me nt. 
Lact ic aci d osis has bee n re p orte d rarel y i n partici pa nts w it h T 2 D M ass ociate d wit h use of metf or mi n, e xcessi ve 
al c o h o l i nt a ke, a n d decrease d re nal f u nct i o n. R o uti ne bicar b o nate assess me nt will be perf or me d d uri n g t he 
c o urse of t he st u d y . If  l act ic aci d osis is s us pecte d, met f o r mi n, if use d, s h o ul d be te m p oraril y d isc o nt i n ue d u ntil 
t h e res ol ut i o n of t he e ve nt. 
8. 4. P h ar m ac o ki netics 
C haracterizati o n of P K pr o perties of t ir ze pat i de i n pe di atri ca n d a d ol esce nt partici pa nt s will be s u p p orte d b y  
c ollect i o n of P K bl o o d sa m ples per parti ci pa nt acc or di n g t o t he S o A ( Secti o n 1. 3 ). C CI 
C O N FI D E N TI A L Pr ot oc ol  I 8 F -M C -G P G V 
6 8  
 
T he date a n d ti me of t he m ost rece nt S C i nject i o n a d mi nistere d pri or t o c ollect i n g t he sa m ple m ust be rec or de d 
i n t he e- diar y . T he act ual  date a n d ti me at w hic h eac h sa m ple was dra w n m ust be rec or de d o n t he la b orat or y 
re q ui si ti o n  f or m . I nstr ucti o ns f or t he c ollect i o n a n d ha n dli n g o f bl o o d sa m ples will  b e pr o vi de d b y t he s p o ns or. 
T he date a n d ti me of t he m ost rece nt S C i nject i o n a d mi nistere d pri or t o c ollect i n g t he sa m ple m ust be rec or de d 
i n t he s o urce d oc u me nt . T he act ual  date a n d ti me at w hic h eac h sa m ple was dra w n m ust be rec or de d o n t he 
la b orat or y  re q uisi ti o n  f or m . I nstr ucti o ns f or t he c ol lect i o n a n d ha n dli n g of bl o o d sa m ples will be pr o vi de d b y 
t h e s p o ns or .
T he n u m ber a n d ti mi n g of P K sa m ples are e x pecte d t o be a de q uate i n e na bli n g c o m pre he nsi ve p o p ulati o n P K 
a n d e x p os ure- res p o nse m o deli n g a nal yses wit hi n t his s pecial p o p ulat i o n. 
C o nce ntrati o ns of tirze pat i de will be assa ye d usi n g a vali date d li q ui d c hr o mat o gra p h y  m ass s pectr o metr y  
met h o d. Bi oa nal yt ical  sa m ples c ollecte d t o m eas ure ti rze pati de c o nce ntrati o ns will  be retai ne d f or a ma xi m u m 
of  1 y e ar f ol l o wi n g l ast parti ci pa nt visit f or t he st u d y . D uri n g t hi s t i me, sa m ples re mai ni n g after t he 
bi oa nal yse s ma y  b e use d f or e x pl orat or y  a nal yses s uc h as meta b olis m w or k, pr otei n bi n di n g, a n d/ or 
bi oa nal yt ical met h o d cr oss -vali dati o n. 
8. 5. P h ar m ac o d y n a mics 
Bl o o d sa m ples f o r f ast i n g i ns uli n, C -pe pt i de, pr oi ns uli n, gl uc ose, a n d a di p o nect i n will be ta ke n t o assess t he 
effect of ti rze pat i de o n i ns uli n resista nce, al p ha cell  a n d beta cell f u nct i o n. 
8. 6. Ge netics 
A w h o le bl o o d sa m ple will be c o llecte d f or ge net ic  a nal ysis as s pecifie d i n t he S o A ( Secti o n 1. 3 ) w here l o c al  
re g ul at i o ns all o w. 
See A p pe n di x 5, Secti o n 1 0. 5 f o r i nf or mat i o n re gar di n g ge net ic researc h a n d A p pe n di x 1, Secti o n 1 0. 1. 1 2 f o r 
details a b o ut sa m ple rete nti o n a n d c ust o d y .
8. 7. Bi o m ar kers 
Bi o m ar ker resea rc h is perf or m e d t o a d dress q uesti o ns of rele va nce t o dr u g dis p osit i o n, tar get e n ga ge me nt, P D, 
mec ha nis m o f acti o n, vari a bili t y  of  p arti ci pa nt res p o nse, i ncl u di n g safet y,  a n d cli nical o utc o me. Sa m ple 
c ollect i o n is i nc or p orate d i nt o cli nical st u dies t o e na b le e xa mi nat i o n of t hese q uest i o ns t hr o u g h meas ure me nt 
of  bi o m ol ec ules, i ncl u di n g pr otei ns, li pi ds, a n d ot her cell ular ele me nts. 
Sa m ples f or bi o m ar ker researc h will be c o llecte d at t he ti mes s pecifie d i n t he S o A ( Secti o n 1. 3 .)w here l ocal 
re g ul at i o ns all o w. 
S a m ples will  b e use d f or researc h o n t he dr u g tar get, disease pr ocess, varia ble res p o nse t o tirze pat i de, 
pat h wa ys ass ociate d wit h T 2 D M, mec ha nis m of  acti o n of  ti rze pat i de, a n d/ or researc h met h o d or i n vali dat i n g 
di a g n osti c t o ol s or assa y (s) rel ate d t o T 2 D M. C CI 
CONFIDENTIAL Protocol  I8F-MC-GPGV
69All samples will be coded with the participant number. These samples and any data generated can be linked 
back to the participant only by the in vestigator site personnel. Samples will be retained at a facilit y selected by 
Lilly or i ts desi gnee for a maximum of 15 y ears after the l ast parti cipant vi sit for the study  or for a shorter 
period if local  regulat ions and ERBs impose shorter time limits. T his retention period enables use of new 
techno logies, response to regulatory  quest ions, and invest igation of variable response that may not be observed 
until later in the course of the development and commercializat ion of intervent ion.
All exploratory  biomarker storage sam ples shoul d be preferable taken in fast ing state and before dose of study  
intervent ion, if applicable.
In addit ion, samples will be stored, and analysis may be performed on immunogenicit y alo ng with a paired 
sample for PK analysis (see Sec tion 8.8), and bio marker variants thought to play  a role in T2DM including, but 
not limited to, serum/plasma analytes to evaluate their association w ith observed clinical responses to 
tirzepat ide.
8.8. Immunogenicity Assessments
At the visit s and t imes specified in the SoA (Section 1.3), venous blood samples will be collected for 
analysis to determine ant ibody  producti on against tirzep atideusing a validated assay method .ADA may be 
further characterized for cross -reactive binding to native GIP and GLP -1,their abilit y to neutralize the activit y 
oftirzepat ideand neutralizing antibodies to endogenous counterparts .To interpret the results of 
immunogenicit y,avenous blood sample will be collected at the same time points to determine 
theserum concentrations of tirzepat ide. All samples for immunogenicit y must be taken predose when 
applicable and possible. Treatm ent-emergent ADA are defined in Sect ion9.3.6 .
Samples may  be stored for a m aximum of 15 years (or according to local regulat ions) fo llowing the l ast 
participant’s l ast visi t for the study  at a facilit y selected by  the sponsor to enable further analysis o f immune 
responses to tirzepat ide.Samples m ayalso be used for development and control of animmunogenicit yassay .
8.9. Medical Resource Utilization and Health Economic s
Health economics and medical resource utilizat ion parameters are not evaluated in this study .
CONFIDENTIAL Protocol  I8F-MC-GPGV
709. Statistical Considerations
9.1. Statistical Hypotheses
The hypotheses relat ive to the primary and key second endpo ints are whether there is a difference in tirzepat ide 
5 mg and 10 m g (pool ed or separate) versus placebo at 30 weeks with changes in the diabet ic measures 
outlined in Sect ion3.
9.2. Analyses Sets
The fo llowing popul ations are defined:
Population Description
Screened Participants All participants who sign the ICF.
Randomized participants All participants who are randomly assigned to a treatment arm .
Modified Intent -to-Treat
(mITT) populationAll rando mly assigned participants who are exposed to at least 1 dose 
of study  intervent ion (that is tirzepat ide or placebo ), excl uding 
inadvertent ly enro lled participant swho have discont inued study  
intervent ionfor that reason .
EAS Data obtained during Double- Blinded Peri odfrom the mITT 
popul ation, excluding data after init iating rescue ant ihyperglycemic 
medicat ion or stopping study  intervent ion.
FAS Data obtained during Double- Blinded Peri odfrom the mITT 
popul ation, regardless o f adherence to study intervent ionor initiation 
of rescue ant ihyperglycemic medicat ion.
SS1 Data obtained during Double- Blinded Peri odfrom all rando mly 
assigned participants who are exposed to at least 1 dose of study  
intervent ion, regardl ess of adherence to study  intervent ionor initiation 
of rescue ant ihyperglycemic medicat ion.
SS2 Data obtained during Double -Blinded Peri od, Open -Label  Period and 
Safety Follow-up Peri od from all randomly  assigned parti cipants who 
are exposed to at least 1 dose of study  intervent ion, regardl ess of 
adherence to study  intervent ionor init iation of rescue 
antihyperglycemic medicat ion.
Abbreviations: EAS = Efficacy Analysis Set ;FAS =Full Analysis Set ;ICF = informed consent form ; mITT = modified Intend -to-
Treat ;SS=Safety Analysis Set.
9.3. Statistical Analyses
9.3.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y ofsponsor or its designee.
Any change to the data analysis methods described in the protocol will require an amendment only if it changes 
a principal feature of the protocol. Any  other change to the data analysis methods described in the protocol, and 
CONFIDENTIAL Protocol  I8F-MC-GPGV
71the justificati on for m aking th e change, will be described in the Statistical Analysis Pl an and the clinical study  
report (CSR) . Addi tional expl oratory  analyses of the data will be conducted as deemed appropriate.
All tests of treatment effects will be conducted at a 2-sided al pha level of 0.05/1 -sided alpha level o f .025, 
unless otherwise stated, and all confidence intervals (CIs) will be given at a 2 -sided [95%] level. In stati stical 
summaries and analyses, all data, including those collected during the open
-label period, willbe analy zed by
rando mized treatm ent assignment .In the event of a treatment error, pa rticipant s will be analyzed according to 
the treatment they  were randomly  assigned to.
Estimands
There will be 2 estimands o f interest in comparing efficacy o f tirzepati de doses w ith placebo. Fi rst estimand, 
the “efficacy” est imand, represents efficacy prior to discont inuat ion of study  intervent ionwithout confounding 
effects of ant ihyperglycemic rescue therapy. Second estimand, the “treatment -regimen” est imand, represents 
the efficacy  irrespect ive of adherence to study  intervent ionor init iation of rescue ant idiabet ic drugs.
The primary  efficacy  assessment, gui ded by the “efficacy” est imand, will be conducted using the EAS. The 
primary  efficacy  assessment, gui ded by  the “treatment -regimen” est imand, will be conducted using the full 
analysis set.
Since analysis aligned to efficacy and treatment -regimen est imands are intended for different purposes, 
primary  and key  secondary  efficacy assessments relat ive to efficacy and treatment -regimen est imands will be 
conducted separately at a family -wise ty pe 1 error rate of 0.05. Addit ional details, including a nalysis methods 
for key  secondary endpoints and a strategy  for controlling the overall family -wise t ype 1 error rate at an alpha 
of 0.05 for primary  and key  secondary
 endpoint eval uation will be provided in the SAP .
Unless specified otherwise, safet y asses sments will be guided by  an est imand co mpar ing safety  of each 
treatm ent group , irrespect ive of adherence to study intervent ionor ini tiation of ant ihyperglycemic rescue 
therapy . Thus, the safet y analysis will be conducted using the safet y analysis set ( SS). Selected safety analysis 
(for example, hypoglycemia) may be conducted excluding data after introducing another ant ihyperglycemic 
therapy .
Summary statistics
Summary  statistics for continuous m easures will  include sample size, mean, standard deviat ion (SD), median, 
minimum, and maximum. The analysis model to make comparisons among treatment arms relat ive to 
continuous measurements assessed over time will be an mixed model for repeated measures ( MMRM ), with 
terms of treatm ent, visit and treatment -by-visit i nteracti on, age group (10 to 14 y ears versus 15 to <18 years), 
baseline ant ihyperglycemic medicat ion use (met formin only, or basal insulin only, or metformin and basal 
insulin) , and baseline measurement as a covariate. An unstructured covariance matrix wil l model the 
relationship of wit hin-participant errors.
The Kaplan -Meier m ethod will be used for estimatio n of cumulative event -free survival rates over time, and 
cox proportional hazards regressio n analysis will be used to compare hazard rates among treatm ents.
Summary  statistics for categorical measures, including categorized continuous measures, will include sample 
size, frequency , and percentages. Fisher’s exact test will be used to examine the treatment difference in 
categori cal outcom es. Logi stic regre ssion may be used to examine the treatment difference in binary  efficacy  
outcom es. Summary  stati stics for discrete count measures will include sample size, mean, SD, median, 
minimum, and maximum. The negat ive binomial regressio n model will be used for the treatm ent comparison 
of discrete count m easures.
CONFIDENTIAL Protocol  I8F-MC-GPGV
72Other stati stical methods may be used, as appropriate, and details will be documented in the SAP. The SAP
will include a more technical and detailed descript ion of the statist ical analyses described in this sect ion. This 
section is a summary o f the planned stati stical analyses of the most important endpoints including primary  and 
key secondary  endpoints.
9.3.2. Trea tment Arm Comparability
9.3.2.1. Participant Disposition
Frequency counts and percentages of all part icipants screened, randomized, and receiving at least 1 dose of 
study  interventi on, will be presented by  treatm ent arm . Of the participants in the modified intent -to-treat 
(mITT
)populat ion, frequency, counts and percentages of participants complet ing the study, prematurely 
discontinuing the study , including the reason for premature discont inuat ion, will be presented by treatment 
arm.
9.3.2.2. Participant Characteristics
Dem ographics, medical history , and conco mitant illness will be summarized by treatment arm using the mITT 
popul ation.
9.3.2.3. Concomitant Therapy
Stratificat ion will be used to ensure a balance across treatm ent arms of participant s using metformin and/or 
basal insulin as a background therapy . These stratificat ion factors will be included in all analysis mo dels to 
further adj ust the treatm ent effect estimates for background usage of metformin and/or basal insulin usage.
Concomitant medicat ions, including previous therap y for diabetes, will be summarized by  anatomical 
therapeuti c chemical classificat ion and treatment arm using the mITT population. The incidence of rescue 
therapy  for severe, persi stent hy perglycemia will be analyzed as an additional secondary safet y endpoi nt.
9.3.2.4. Treatment Compliance
Treatment compliance will be summarized by  all treatm ent arms, by  study  period, and overall. The compliance 
calculat ion will  be detailed in the SAP.
9.3.3. Efficacy Analyses
9.3.3.1. Primary Endpoints
There will be 2 primary efficacy analyses conducted to establish superiorit y of pool ed tirzepat ide 5 mg and 10 
mg to pl acebo relative to mean change in HbA1c from baseline to the 30 week visit.
Primary efficacy analysis will be guided by the “ treatm ent-regimen estimand”, using an analysis o f covar iance 
(ANCOVA) of all available data up to Week 30 .
The ANCOVA model will include
treatm ent (tirzepat ide 5 mg, 10 mg or placebo)
age group ( 10 to 14 years versus 15 to <18 years)
baseline ant ihyperglycemic medicat ion use (met formin only, or basal insulin only, or m etformin and 
basal insulin) ,and
baseline HbA1c as a covariate.
CONFIDENTIAL Protocol  I8F-MC-GPGV
73A linear contrast , averag ing est imates from the individual t irzepat ide doses , will  be used to estimate the 
treatm ent effect of pool ed tirzepat ide arms compared wi th placebo. Analysis will be conducted wi th multiple 
imputati ons of missing HbA1c data at the 30 -week visit with statist ical inference over mult iple imputations 
guided by  the method proposed by  Rubin (1987). Missing HbA1c value imputation will be based on observed 
HbA1c data from subjects in the same treatment armwho had thei r HbA1c measured at the Week 30 visit after 
early  discontinuat ion of study  intervent ion(retri eved dropouts). In cases where there are not enough retrieved 
dropouts to provide a reliable imputation model, the missing data in an endpo int from each treatm ent group are 
imputed using observed endpo int data fro mthe placebo arm.
For all other purposes, the primary efficacy  analysis will  be guided by the “efficacy” est imand defined in 
Secti on 9.3.1 .This assessment will be conducted using EAS.
The primary  analysis m odel for HbA1c measurements over time will be a MMRM. The response variable of 
the MMRM will be change in HbA1c from baseline values obtained at each scheduled postbaseline visit. The 
independent variables of the MMRM model are
treatm ent(tirzepat ide 5mg, 10mg or placebo)
visit
treatm ent-by-visit interaction
age group
baseline ant ihyperglycemic medicat ion (metformin only, or basal insulin only, or met formin and basal 
insulin) as fixed effects, and
baseline HbA1c as a covariate.
A linear contrast, averaging est imates from the individual t irzepat ide doses, will be used to estimate the 
treatm ent effect of pool ed tirzepat ide arms compared with placebo .
9.3.3.2. Secondary Endpoint (s)
The secondary  study  objectives subject to Type I Error rate control are as fo llows:
Superi ority of tirzepati de QW (5 mg and 10 m g, pool ed) to pl acebo at 30 weeks i n pediatri c and 
adolescent participants for
ochange in BMI SDS fro m baseline
oinciden ceof HbA1c ≤6.5%
ochange in fast ing serum glucose from  baseline
Superi ority of each ti rzepati de dose to pl acebo at 30 weeks in pediatri c and adolescent participants for
ochange in BMI SDS fro m baseline
oincidence of HbA1c ≤6.5%
ochange in fast ing serum glucose from  baseline , and
ochange in HbA1c from baseline .
Analysis of change fro m baseline in BMI SDS /fasting serum glucose at the 30-week visit will be conducted in 
a manner similar to the primary  efficacy analyses with change in BMI SDS/fasting serum glucose from 
baseline as the response variable, baseline BMI SDS/fast ing serum glucose as a covariate .
Com parisons am ong treatm ents relative to the proportion of participants achieving the HbA1c target value of 
≤6.5% ( 48 mmo l/ mol) at the 30-week visit will be conducted using a logistic regressio n analysis wit h terms of 
treatm ent, country , metf ormin use (Yes or No), and baseline HbA1c as a covariate.
CONFIDENTIAL Protocol  I8F-MC-GPGV
74In the analysis o f participants achieving the HbA1c target value relative to the “efficacy” estimand, missing 
values at the 30-week visit will be imputed from an MMRM model and then dichotomized .
In the analysis of parti cipants achieving the HbA1c target value relative to the “treatment -regimen” estimand, 
missing values at the 
30-week visit will be imputed based on observed data at respective visits fro m 
participants in the same treatment arm who had their efficac y assessed after early discont inuat ion of study  
intervent ionand/or init iation of rescue medicat ion. The analysis will be conducted with mult iple imputations 
and statist ical inference over m ultiple imputati ons will be guided by  the method proposed by  Rubin (1987) .
9.3.3.3. Tertiary/ Exploratory Endpoint (s)
Details o f tertiary and expl oratory  analysis will be provided in the SAP .
9.3.4. Safety Analyse s
Unless specified otherwise, safet y assessments will be guided by  an est imand co mpar ing safety  of tirzepati de 
doses wi th placebo i rrespect ive of adherence to study  intervent ionor ini tiation of rescue therapy . 
Safety 
analyses for the doubl e-blind period will be conducted using the SS 1.For overall study safet y (including
doubl e
-blind period, open -labelperiodand safety  follow-up peri od), summary statistics will b eprovided using 
the SS2.Selected safet y analyses may  be conducted excluding data after the introduction of another 
antihyperglycemic therapy.
Adverse events will be coded from the actual term using the Medical Dict ionary for Regul atory  Activit ies 
(MedDRA) and reported with prefe rred terms and system organ class. Selected notable AEs o f interest m ay be 
reported using high -level term s or Standardized MedDRA Queries. Summary statist ics will be provided for 
incidence of TEAEs, SAEs, study  discontinuati on due to AEs, study  intervent iondiscontinuati on due to AEs, 
deaths, and other CV endpo ints. Counts and proportions of subjects experiencing AEs will be reported for each 
treatm ent group, and Fisher’s exact test will be used to compare the treatment groups.
9.3.4.1. Hypoglycemic Events
Incidence of docum ented symptom atic hypoglycemia events and severe hypoglycemia in each category will be 
compared between tirzepatide doses and placebo using negat ive binomial regressio n analysis. 
9.3.4.2. Gastrointestinal Events
Summaries and analyses for incidence and se verity of nausea, vo miting, and diarrhea will be provided by each 
treatm ent.
9.3.4.3. Central Laboratory Measures, Vital Signs and Electrocardiograms
Values and change from baseline to postbaseline values of central laboratory  measures, vital signs, and 
selected EC G parameters will be summarized at each scheduled visit. The analysis model to make comparisons 
among treatm ent groups, rel ative to continuous change fro m baseline values assessed over time will be an 
MMRM similar to the primary  efficacy analysis and with baseline measurement as a covariate. An 
unstructured covariance structure will model the relat ionship of wit hin-patient errors.
The percentages of partici pants with Treatm ent-emergent ( TE)abnormal, high, or low laboratory  measures at 
any time will be summarized and com pared between treatment groups by
 using Fisher’s exact test. A TE
abnorm al value i s defined as a change from normal value at baseline to a value greater than the high limit at 
any time during doubl e-blind period, open -label period and saf ety follow-up. A TE l ow resul t is defined as a 
CONFIDENTIAL Protocol  I8F-MC-GPGV
75change from a value greater than or equal to the low limit at baseline to a value less than the low limit at any
time during doubl e-blind period, open -label period and safet y follow-up. Hi gh and l ow laboratory limits will 
be determined by the central laboratory  reference ranges.
9.3.5. Pharmacokinetic/Pharmacodynamic An alyses
Tirzepati de concentrati on data will be analyzed using a populat ion PK approach via nonlinear mixed -effects 
modeling wi th the NONMEM software. Th e relationships between tirzepat ide dose and/or concentratio n and 
efficacy , tolerabilit y, and safet y endpo ints will be characterized.
If ADA titers are detected from immunogenicit y testing, then the impact of immunogenicit y titers on 
tirzepat ide PK or any relevant PD parameters may also be examined.
9.3.6.
Evaluation of Immunogenicity
The frequency and percentage of participant s with preexist ing ADA, with TE ADA and with neutralizing TE 
ADA to tirzepat ide may be tabulated by  tirzepat ide dose. Treatment -emergent AD A are defined as those with a 
titer 2-fold (1 dilution) greater than the minimum required dilut ion (MRD) if no ADAs were detected at 
baseline (treatment -induced ADA) or those with a 4 -fold (2 dilutions) increase in titer compared to baseline if 
ADAs were d etected at baseline (treatment -boosted ADA). For TE ADA partici pants, the distribut ion of 
maximum t iters maybe described. The frequency  of neutralizing antibodies to tirzepat ide and/or cross -reactive 
and neutralizing ant ibodies to endogenous counterparts maybe tabulated in participant s with TE ADA.
The rel ationship between the presence of ant ibodies and tirzepatide PK and PD response including safet y and 
efficacy  to tirzepat ide may be assessed.
9.3.7. Other Analyse(s)
9.3.7.1. Patient Reported Outcomes
Analyses of actual and change fro m baseline in patient reported outcomes ( PRO) scores will be conducted 
using linear models with baseline PRO scores, treatment, and other factors that may be considered relevant. 
These variables will be specified in the SAP .
9.3.7.2. Subgroup Analyses
The fo llowing s ubgroup analyses of mean change in HbA1c fro m baseline to Week 30 will be considered (but 
not limited to):
agegroup (≤14 years ol d, >14 y ears ol d),
race,
ethnicit y,
region (US and non -US),
gender,
durati on of  diabetes (<median and ≥median),
baseline BMI (<median and ≥median) ,
baseline body  weight (<median and ≥median) ,
CONFIDENTIAL Protocol  I8F-MC-GPGV
76baseline met formin use ,
baseline insulin usage ,and
baseline HbA1c ( ≤8.0% or >8.0% [≤64, ˃64 mmo l/mol]).
Other analyses may include analyses of assessments, which are not defined as endpo ints, that need to be pre -
specified and not necessarily be reported in the CSR such as, but not limited to, immunogenicit y, bio markers, 
popul ation PK, heal th care utilizati onendpo ints and healt h techno logy assessment rel ated endpoints .
9.4. Interim Analyses
No interim analyses of efficacy for early  terminat ionare planned for this study . 
An external DMC will have the 
responsibilit y to revi ew unblinded interim analyses results tomonitor the safet y of the parti cipants in the study . 
If an unplanned interim analysis is deemed necessary , the appropri ate Lilly  medical di rector, or desi gnee, will 
be consulted to determine whether it is necessary  to am end the protocol . 
Unblinding details are specified in the unblinding plan sect ion of the SAP or in a separate unblinding plan 
docum ent.
9.5. Sample Size Determination
The s tatistical power calculat ionassumes that the evaluat ion of superi ority of pool ed tirzepat ide 5 mg and 10 
mg QW against placebo will be conducted at a 2 -sided significance level o f 0.05, rel ative to the primary  
endpo int (change in HbA1c fro m baseline at 30 weeks) in an analysis ut ilizing all data, on or off intervent ion. 
Addit ionally , itassumes a1.1% greater mean reductio n in HbA1c (placebo adjusted) for pooled tirzepatide (5 
mg and 10 mg) at Week 30 visit, anda commo n SDof 1.5% fro m change in HbA1c at Week 30 visit  
(accounting for increase in SD due to the inclusio n of data on rescue medicat ions and after premature trea tment 
discontinuat ion and imputation of missing data) .
Based on these assumpt ions, randomizing atleast 90 participants in a 1:1:1 ratio to each study arm unt il an
expected accrual o f 90 evaluable participants will provide 90% power to demonstrate superior ity of the pool ed 
tirzepat ide 5 mg and 10 mg to placebo. Evaluable participants are those who have been rando mized and 
exposed to at least one dose of study  treatm ent wi th HbA1c m easurements at baseline and at the Week 30 visit .
CONFIDENTIAL Protocol  I8F-MC-GPGV
7710. Supporting Documentation an d Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical principles derived from international guidelines including the Declarat ion of 
Helsinki and Council for Internat ional Organizat ions of Medical Sciences (CIOMS) 
International Ethical Guidelines
Applicable ICH Good Clinical Practice ( GCP )Guidelines
Applicable laws and regulati ons
The protocol, protocol amendments, ICF /assent , IB, and other relevant documents ( for example , 
advert isements) must be submitted to an Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC) by the investigator and reviewed and appro ved by the IRB/IEC before the study  is 
initiated.
Any amendments to the protocol will require IRB/IEC approval before implementation of changes 
made to the study  design, except for changes necessary  to eliminate an immediate hazard to study  
participants.
Protocol s and any substantial amendments to the protocol will require healt h authorit y approval  prior to 
initiation except for changes necessary to eliminate an immediate hazard to study participants.
The invest igator will be responsible for the fo llowing:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by the 
IRB/IEC
Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as requi red by  IRB/IEC 
procedures
Provi ding oversight of study  for parti cipants under their respo nsibili tyand adherence to 
requi rements of 21 CFR, ICH gui delines, the IRB/IEC, European regulat ion 536/2014 for 
clinical studies (if applicable), and all other applicable local regulat ions
Invest igator sites are compensated for participat ion in the study as detailed in the clinical trial
agreem ent.
10.1.2. Financial Disclosure
Invest igators and sub -invest igators will provide the sponsor with sufficient, accurate financia l information as 
requested to allow the sponsor to submit co mplete and accurate financial cert ificat ion or disclosure statements 
to the appropriate regulatory  authori ties. Invest igators are responsible for providing informat ion on financial 
interests durin g the course of the study  and for 1 year after complet ion of the study .
CONFIDENTIAL Protocol  I8F-MC-GPGV
7810.1.3. Informed Consent Process
The invest igator or his/her representative will explain the nature of the study, including the risks and 
benefits, to the participant or his/her legally author ized representative and answer all quest ions 
regarding the study .
Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or thei r legally  
acceptable representative, parent(s), or legal guardian will be required to provide a statement of 
inform ed consent/assent that meets the requirements of 21 CFR 50, local regulat ions, ICH guidelines, 
HIPAA requirements, where applicable, and the IRB/IEC or study  center.
The m edical  record m ust include a statem ent that legally acceptable representative, parent(s), or legal 
guardi an) consent and child/ado lescent assent (if deemed appropriate by local ethics review) was 
obtained before the participant was enro lled in the study and the date the written consent was obtained. 
The m edical  record should also describe how the clinical invest igator determined that the person 
signing the ICF was the participant’s legally  acceptabl e representative, parent(s), or legal guardian). 
The acceptable person obtaining the informed consent must also sign the I CF.
Parti cipants and thei r legally acceptable representative, parent(s), or legal guardian must be re -
consented and re -assented to the most current version of the ICF(s) during their participat ion in the 
study .
Minor participants must be re -consented if th ey reach the age of m ajority during the course of the study , 
tocontinue parti cipat ing.
A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s legally  acceptable 
representative, parent(s), or legal guardian
10.1.4. Data Protection
Parti cipants will be assigned a unique ident ifier by the sponsor. Any part icipant records ,datasets or 
tissue samples that are transferred to the sponsor will contain the ident ifier only; participant names or 
any informat ion which would make the participant identi fiable will not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used by  the sponsor in 
accordance with local data protection law. The level of disclo sure m ust al so be explained to the 
participant who will be requi red to give consent for his/her data to be used as described in the informed 
consent .
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by Clinical Qualit y 
Assurance auditors or other authorized personnel appointed by the s ponsor, by  appropri ate IRB/IEC 
members, and by inspectors from regulatory  authori ties.
The sponsor has processes in place to ensure data protection, informat ion securit y and data integri ty. 
These processes include appropriate contingency plan(s) for approp riate and timely  response in the 
event of a data securit y breach.
Rationale for collection of full date of birth
This study  includes children, adolescents, and y oung adul ts. Wi thin this age range, participants’ expected 
height and weight, as well as normal ranges for l aboratory  tests, vary  by both age and sex. Therefore, it is 
necessary  to collect the full date of birth (day , month, y ear) f or all  pediatri c and adolescent participants to 
appropriately  analyze and interpret changes in growth and laboratory  parameters.
CONFIDENTIAL Protocol  I8F-MC-GPGV
79In countri es where l ocal regulat ions do not permit collect ion of the full date of birth, if the supporting 
regul atory /ethics documentati on is available, at a minimum, the month and year of birth must be collected on 
the eCRF.
10.1.5. Committee Structure
An external DMC will have the responsibilit y to review unblinded interim analyses results tomonitor the 
safet y of the parti cipants in the study  until the last participant completes the Week 52visit. More details will be 
included in the DMC charter.
Study sites will receive informat ion about interim results ONLY if deemed necessary for the safet y of the 
participants.
10.1.6. Dissemination of Clinical Study Data
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on pu blicly  
available websites where required by local law or regulat ion.
Data
The sponsor provides access to all individual part icipant data collected during the study , after anonymizat ion, 
with the excepti on of  PK or genet ic data.   Data are available to request 6 months after the indicat ion studi ed 
has been approved in the US and EU and after primary publicat ionacceptance, whichever is later.   No 
expirat ion date of data requests is currently set once data are made available.
Access i s provi ded af ter a pr oposal has been approved by an independent review committee ident ified for this 
purpose and after receipt of a signed data sharing agreement.   Data and documents, including the study 
protocol , stati stical analysis plan, CSR , blank or annotated CRFs , will b e provi ded in a secure data sharing 
environment for up to 2 years per proposal.
For details on submitting a request, see the instructions provided at www.vivli.org .
10.1.7. Data Quality Assurance
Investigator responsibilities
All participant data relat ing to the study  will be recorded on printed or electronic CRF unless transmit ted to the 
sponsor or designee electronically  (for example , laboratory  data). The investigator is responsible for verifying 
that data entries are accurate and correct by  physically  or electronically  signing the CRF.
The invest igator must maintain accurate documentation (source data) that supports the information entered in
the CRF.
The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, and regulatory  agency  
inspections and provi de di rect a ccess to source data documents.
Data monitoring and management
Moni toring details describing strategy  (for example , risk-based init iatives in operations and qualit y such as risk 
management and mit igation strategi es and analy tical risk-based monitori ng), methods, responsibilit ies and 
CONFIDENTIAL Protocol  I8F-MC-GPGV
80requi rements, including handling of nonco mpliance i ssues and m onitoring techniques are provided in the 
Moni toring Pl an.
The sponsor or designee is responsible for the data management of this study  includin gqualit y checking of the 
data.
The sponsor assumes accountabilit y for acti ons delegated to other individuals (e.g. , contract research 
organi zations).
Study  monitors will perform  ongoing source data verification to confirm that data entered into the CRF by 
authori zed si te personnel  are accurate, com plete, and verifiable from source documents; that the safety  and 
rights of participants are being protected; and that the study  is being conducted in accordance with the 
currently approved protocol and any other s tudy agreem ents, ICH GCP, and all applicable regu latory 
requi rements.
Records retention and audits
Records and documents, including signed ICFs, pertaining to the conduct of this study  must be retained by  the 
investigator for the time period outlined in th e clinical trial agreement unless local regulat ions or institutional 
policies require a longer retention period. No records may be destroyed during the retention period without the 
written approval  of the sponsor. No records may be transferred to another l ocati on or party  without wri tten 
notification to the sponsor .
In addit ion, the sponsor or its representatives will periodically  check a sample of the parti cipant data recorded 
against source documents at the study  site. The study  may be audi ted by the sponsor or its representatives, 
and/or regulatory  agencies at any  time. Invest igators will be given notice before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness of the data 
reported to the sponsor.
Electronic data capture system
An electronic data capture sy stem  (EDC )will be used in this study  for the collect ion of CRF data. The 
investigator maintains a separate source for the data entered by  the invest igator or designee into the 
sponsor -provided EDC system. The invest igator is responsible for the identificat ion of an y data to be 
considered source and for the confirmat ion that data reported are accurate and complete by  signing the CRF .
Clinical outcome assessments ( COA)
Some of the clinician -administered questionnaire data will be co llected by the study  personnel via a paper 
source document and will be transcribed by the study  personnel into the EDC system .
Patientreported and clinician -administered questionnaires, other than those collected via paper, will be directly 
recorded by  the participant and study  personnel int o an instrument ( for example, hand -held smart phone or 
tablet). The el ectroni c clinical  outcom e assessment (eCOA) data will serve as the source documentation and 
the invest igator does not maintain a separate, written or electronic r ecord of these data.
Data storage and access
Data collected via the sponsor- provided data capture system (s)will be stored at third- parties. The investigator 
will have continuous access to the data during the study  and until decommissioning of the data cap ture 
CONFIDENTIAL Protocol  I8F-MC-GPGV
81system (s).Prior to decommissio ning, the invest igator will receive or access an archival copy  of pertinent data 
for retenti on.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically  in the central  
vendor’s databa se system  and reports/el ectroni c transfers will be provi ded to the investigator for review and 
retenti on. Data will subsequent ly be transferred from the central vendor to the sponsor data warehouse.
Data from co mplaint forms submitted to sponsor will be en coded and stored in the global PCmanagement 
system .
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the integrit y of 
the data collected. Source documents are filed at the invest igator’s site.
Data r eported on the CRF or entered in the eCRF that are transcribed fro m source documents must be 
consistent with the source documents or the discrepancies must be explained. The invest igator may 
need to request previous medical records or transfer records, dep ending on the study. Also, current 
medical records must be available.
Definit ion of what constitutes source data can be found in Section 10.1.7 .
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruit ment of parti cipants.
The sponsor designee reserves the right to close th e study  site or terminate the study  at any  time for any  reason 
at the sol e discreti on of  the sponsor. Study  sites will  be closed upon study  com pletion. A study  site is 
considered closed when all required documents and study  supplies have been collected and a study site cl osure 
visit has been performed.
The invest igator may init iate study site closure at any  time, provi ded there i s reasonable cause and sufficient 
notice is given in advance of the intended terminatio n.
Reasons for the early closure of a study site by the sponsor or investigator may  include but are not limited to:
●Failure of the invest igator to comply wit h the protocol, the requirements of the IRB/IEC or local 
healt h authorit ies, the sponsor's procedures, or GCP guidelines
●Inadequate recrui tment of  parti cipants by  the investi gator
●Discontinuati on of  further study  intervent iondevelopm ent.
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the invest igators, the 
IECs/IRBs, the regulatory  authori ties, and any contract research organizat ion(s) used in the study  of the reason 
for terminat ion or suspensio n, as specified by the applicable regulatory  requi rements. The invest igator shall 
prom ptly inform the participant and parent or guardian and shoul d assure appropriate participant therapy  and/or 
follow-up.
CONFIDENTIAL Protocol  I8F-MC-GPGV
8210.1.10. Publication Policy
In accordance with the sponsor’s publication po licy,the resul ts of this study  will be submitted for publicat ion 
by a peer -reviewed journal.
10.1.11. Investigator Information
Researchers with appropri ate educati on, training, and experience, as determined by the sponsor, will participate 
as investigators in this clinical study .
10.1.12. Sample Retention
Sample retenti on enables the use of new techno logies, response to regulatory  quest ions, and inves tigation of  
resul ts that may  not be observed unt il later in the development .
Sample Type Custodian Retention Period After Last Patient Visit*
Pharmacokinetic Sponsor or Designee 1 year
Explo ratory  Biomarker Samples Sponsor or Designee 15 years
Genetic s Sponsor or Designee 15 years
Immunogenicity Sponsor or Designee 15 years
*Retention periods may differ locally.
CONFIDENTIAL Protocol  I8F-MC-GPGV
8310.2. Appendix 2: Clinical Laboratory Tests
The tests detailed in the table below will be performed by the central laboratory unless specified otherwise .
Local  laboratory  resul ts are only  required ifthe central  laboratory  resul ts are not available in t ime for either 
study  interventi onadministrati on and/or response evaluat ion. If a l ocal sample is required, it is important that
the sam ple for central  analysis is obtained at the same time.
In circumstances where the sponsor approves local laboratory  testing in lieu of central laboratory  testing (in the 
table bel ow), the l ocal laboratory  must be qualified in accordance with applic able l ocal regulat ions.
Protocol -specific requirements for inclusio n or exclusio n of participants are detailed in Sect ion5of the 
protocol .
Addit ional tests m ay be perform ed at any  time during the study  as determined necessary  by the investigator or 
requi red by l ocal regulat ions.
Pregnancy Testing will be perform ed as detailed in SoA,Section 1.3.
One of the fo llowing m easures will  be offered to reduce pain associated with venipuncture: anesthet ic creams, 
anesthet ic patches, or high pressure anesthet ic delivery system immediately befo re venipuncture.
Invest igators must document their review of thelaboratory  resul ts.
CONFIDENTIAL Protocol  I8F-MC-GPGV
84Clinical Laboratory Tests
Clinical Laboratory Tests Comments
Hematology Assay ed by Lilly -designated laboratory
Hemoglobin
Hematocrit
Erythrocy te count (RBCs -red blood cells)
Mean cell volume
Mean cell hemoglobin concentration
Leukocytes (WBCs -white blood cells)
Differential:
  Neutrophils, segmented
  Lymphocytes
  Monocytes
  Eosinophils
  Basophils
Platelets
Cell morphology (RBCs and WBCs)
Clinical Chemistry Assay ed by Lilly -designated laboratory
Sodium
Potassium
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine
Uric acid
Calcium
CONFIDENTIAL Protocol  I8F-MC-GPGV
85Glucose
Special Chemistry Assay ed by Lilly -designated laboratory
HbA1c
Insulin Results will not be provided to the investigative sites
C-peptide Results will not be provided to the investigative sites
Calcitonin
Thyr oid-stimulating hormone (TSH)
Thyr oxine (T4, free)
Biomarkers Assay ed by Lilly -designated laboratory.
Results will not be provided to the investigative sites
Adiponectin, total
Proinsulin, intact
Glucagon
Lipid Panel Assay ed by Lilly -designated laboratory
Total cholesterol
Low density lipoprotein (LDL) Value will be calculated. If triglycerides are 
>400mg/dL, the direct LDL will be assayed
High density lipoprotein (HDL)
Very  low density  lipoprotein (VLDL)
Triglycerides
Hormones (female)
Serum pregnancy Assay ed by Lilly -designated laboratory
Urine pregnancy Evaluated locally at study site
Urine Chemistry Assay ed by Lilly -designated laboratory 
Albumin
Creatinine
Pancreas (Exocrine panel) Assay ed by Lilly -designated laboratory
Pancreatic amylase
Lipase
Calculations Will be calculated by the central laboratory and 
included in laboratory result reports
CONFIDENTIAL Protocol  I8F-MC-GPGV
86eGFR (CKD -EPI)
Urinary  albumin/creatinine ratio
Pharmacokinetic Samples for Tirzepatide Assay ed by Lilly -designated laboratory.
Results will not be provided to the investigative sites
Genetics Sample Assay ed by Lilly -designated laboratory.
Results will not be provided to the investigative sites
Exploratory Biomarker Stored Samples Assay ed by Lilly -designated laboratory.
Results will not be provided to the investigative sites
  Serum
  Plasma (EDTA)
  Plasma (P800)
Immunogenicity Samples Assay ed by Lilly -designated laboratory
Islet Cell Antibody 2 (IA2)
GAD65
Tirzepatide anti -drug antibody Results will not be provided to the investigative sites
Tirzepatide PK sample for immunogenicity Results will not be provided to the investigative sites
CONFIDENTIAL Protocol  I8F-MC-GPGV
8710.3. Appendix 3: Adverse Events and Serious Adverse Events: Definitions and 
Procedures for Recording, Evaluating, Follow -up, and Reporting
The definit ions and procedures detailed in this appendix are in accordance wit h International 
Organizat ion for Standardizat ion (ISO) 14155.
Both the invest igator and the sponsor will comply with all local medical device reporting requirements.
The detecti on and docum entati on procedures described in this protocol apply  to all  sponsor m edical  
devices provided for use in the study  
(See Sec tion 6.1.2 for the list of sponsor medical devices).
10.3.1. Definition of AE
AE Definition
An AE is any  untoward m edical occurrence in a participant administered a pharmaceutical product and which 
does not necessarily  have a causal  relati onship wi th the study  interventi on. An AE can therefore be any  
unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or disease (new or 
exacerbated) temporally associ ated wi th the use of a m edicinal (invest igational) product, whether or not 
related to the medicinal (invest igational) product.
An AE is any  untoward m edical occurrence, unintended disease or injury , or untoward clinical signs 
(including abnormal laboratory  finding) in study  parti cipants, users, or other persons, whether or not related 
to the invest igational medical device. This definit ion includes events related to the invest igational medi cal 
device or comparator and events rel ated to the procedures invo lved except for events in users or other 
persons, which only include events related to investigat ional devices.
Events Meeting the AE Definition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or urinalysis) or other safet y 
assessments ( for example , ECG, radi ological  scans, vi tal signs measurements), including those that worsen 
from baseline, considered clinically significant in the medical and scient ific judgment of the invest igator 
(that is, not related to progression of underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an increase in frequency 
and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study intervent ionadmin istrati on even though they may have 
been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  intervent ion or a 
concomitant medicat ion. Overdose per se will not be reported as an AE/SAE unless it is an intent ional 
overdose taken with possible suicidal/self -harming intent. Such overdose must be reported regardless of 
sequelae.
“Lack of efficacy ”or “failure of ex pected pharmacol ogical act ion”per se will not be reported as an AE or 
SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms, and/or 
CONFIDENTIAL Protocol  I8F-MC-GPGV
88clinical sequelae result ing from lack of efficacy will be reported as AE or SAE if they fulfil lthe defini tion of 
an AE or SAE.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y assessments which are 
associ ated wi th the underlying disease, unless judged by  the invest igator to be more severe than expected for 
the participant’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the disease/disorder being 
studi ed, unless m ore severe than expected for the participant’s condi tion.
Medical or surgical procedure ( for example , endoscopy , appendectomy ): the condi tion that l eads to the 
procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or convenience admissio n to a 
hospi tal).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or detected at the start 
of the study  that do not worsen.
10.3.2. Definition of SAE
A SAE is defined as any untoward medical occurrence that, at any dose , meets one or more 
of the criteria listed :
a.Results in death
b.Is life -threatening
The term  life-threatening in the definit ion of serious refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
c.Requires in patient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been admi tted to hospi tal or 
emergency ward (usually invo lving at least an overnight stay ) for observat ion and/or treatment 
that woul d not have been appropriate in the physic ian’s office or out patientsetting. Complicat ions 
that occur during hospitalization are AEs. If a complicat ion prol ongs hospi talizat ion or fulfills any  
other serious criteria, the event is serious. When in doubt as to whether “hospitalization” occurred 
or was necessary , the AE shou ld be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not worsen fro m 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
The term disabili ty means a substant ial disrupt ion of a per son’s abilit y to conduct norm al life 
funct ions.
CONFIDENTIAL Protocol  I8F-MC-GPGV
89This definit ion is not intended to include experiences of relat ively minor medical significance 
such as unco mplicated headache, nausea, vo miting, di arrhea, influenza, and accidental trauma 
(for example , sprai ned ankle) which may  interfere wi th or prevent every day life functions but do 
not consti tute a substant ial disrupt ion.
e.Is a congenital anomaly/birth defect
Abnorm al pregnancy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
f.Other situations:
Medical or scient ific judgment should be exercised by the invest igator in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the 
participant or m ay requi re medical or surgi cal intervent ion to prevent one of the other outcomes 
listed in the above definit ion. These events should usually be considere d seri ous.
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room  or at hom e for allergic bronchospasm, blood dy scrasias or convulsio ns that do 
not resul t in hospitalizat ion, or development of drug dependenc y or drug abuse.
g.Resulted in medical or surgical intervent ion to prevent life -threatening illness or injury or 
perm anent impairment to a b ody structure or a body  function.
10.3.3. Definition of Product Complaints
Product Complaint
A PCis any written, electronic, or oral co mmunication that alleges deficiencies related to the 
ident ity, qualit y, durabilit y, reliabilit y, safet y, effectiveness or performance o f a study  intervent ion.
When the abilit y to use the study  intervent ionsafely  is impacted, the fo llowing are al so PCs:
Deficiencies in labeling informat ion, and
Use errors for device or drug-device combination products due to ergonomic design 
elements of the product.
PCsrelated to study interventi ons used in clinical studi esare collec ted toensure the safet y of 
participants, m onitor quali ty, and to facili tate process and product improvements.
Invest igators will instruct participant and parent or guardian to contact the site as soon as possible 
if he or she has a PCor probl em wi th the study  intervent ionso that the si tuation can be assessed.
An event may meet the definit ion of both a PCand an AE/SAE. In such cases, it mustbe reported 
as both a PCand as an AE/SAE.
CONFIDENTIAL Protocol  I8F-MC-GPGV
9010.3.4. Recording and Follow -Up of AE and/or SAE and Product Complaints
AE,SAE ,and PCRecording
When an AE/SAE /PC occurs, i t is the responsibility  of the invest igator to review all documentation ( for 
example , hospi tal progress notes, l aboratory  reports, and di agnostics reports) related to the event.
The invest igator will then record all relevant AE/ SAE /PCinformat ion in the participant’s medical records, in 
accordance with the invest igator’s normal clinical practice. AE/SAE informat ion is reported on the 
appropriate (e)CRF page and PCinformat ion is reported on the Product Comp laint Form .
Note : An event may  meet the definit ion of both a PCand an AE/SAE. In such cases, it must be 
reported as both a PCand as an AE/SAE.
It is notacceptable for the invest igator to send photocopies of the participant’s medical records to sponsor or 
designee in lieu of complet ion of the (e)CRF page for AE/SAE and the Product Complaint Form for PCs.
There m ay be instances when copies of medical records for certain cases are requested by  sponsor or 
designee . In thi s case, all part icipant identifiers, with the exception of the participant number, will be 
redacted on the copies of the medical records before submissio n to sponsor or designee .
The invest igator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other 
clinic al informat ion. Whenever possible, the diagnosis (not the individual signs/symptoms) will be 
docum ented as the AE/SAE.
Assessment of Intensity
The invest igator will make an assessment of intensit y for each AE and SAE reported during the study and 
assign it to oneof the fo llowing categori es:
Mild: A type of AEthat is usually  transient and may  requi re only  minimal  treatm ent or therapeuti c 
intervention. The event does not generally interfere with usual act ivities of daily living.
Moderate: A type of AEthat is usually alleviated with addit ional specific therapeut ic intervent ion. 
The event interferes with usual act ivities of daily living, causing di scomfort but poses no significant 
or perm anent risk of harm to the research participant.
Severe: A type of AEthat interrupts usual act ivities of daily living, or significant ly affects clinical 
status, or may require intensive therapeutic intervent ion. An AE that i s assessed as severe should not 
be confused wit h a SAE. Severe is a category  utilized for rating the intensit y of an event; and both 
AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least oneof the predefi ned outcom es as described in the 
definit ion of an SAE, notwhen it is rated as severe.
CONFIDENTIAL Protocol  I8F-MC-GPGV
91Assessment of Causality
The invest igator is obligated to assess the relationship between study  intervent ionand each occurrence of 
each AE/SAE. The invest igator will use clinical judgment to determine the relationship.
A “reasonable possibilit y”of a rel ationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relat ionship, rather than a relat ionship cannot be ruled o ut.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the 
temporal  relationship of the event to study interventi onadministration will be considered and invest igated.
The invest igator will also consu lt the IB in his/her assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she has reviewed the 
AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred ,and the invest igato r has minimal informat ion to 
include in the init ial report to sponsor or designee . However, i t is very  important that the invest igator always 
make an assessment of causalit y for every  event before the init ial transmission o f the SAE data to sponsor or 
designee .
The invest igator may change his/her opinio n of causalit y in light of fo llow-up inform ation and send a SAE 
follow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  reporti ng requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental measurements and/or 
evaluat ions as m edically indicated or as requested by  sponsor or desi gnee to elucidate the nature and/or 
causalit y of the AE or SAE as fully  as possible. This may  include addi tional laboratory  tests or 
investigat ions, histopathological examinat ions, or consultation wit h other health care professio nals.
If a participant dies dur ing participation in the study or during a recognized fo llow-up period, the 
investigator will provide sponsor or desi gnee with a copy  of any post -mortem findings incl uding 
histopathology .
10.3.5. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collect ion tool .
If the electronic system is unavailable, then the site will use the SAE paper form(see next secti on) toreport 
the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will be taken off -line to 
prevent the entry  of new data or changes to exist ing data.
CONFIDENTIAL Protocol  I8F-MC-GPGV
92If a site receives a report of a new SAE fro m a study  parti cipant or receives updated data on a previo usly 
reported SAE after the electronic data collect ion tool  has been taken off -line, then the site can report this 
inform ation on a SAE paper form (see next section) or by  telephone.
Contacts for SAE reporting can be found in the site training documents .
SAE Reporting via Paper Form (back -up)
Facsimile transmissio n of the SAE paper formis the preferred method to transmit this informat ion to the
sponsor or sponsor’s designee .
Initial notificati on via telephone does not replace the need for the invest igator to complete and sign the SAE 
CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in site training d ocuments .
10.3.6. Regulatory Reporting Requirements
SAE Regulatory Reporting
Prom pt notificat ion by the invest igator to the sponsor of a SAE is essent ial so that l egal obligat ions 
and ethical responsibilit ies towards the safet y of parti cipants and the safet y of a study  intervent ion
under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and other 
regul atory  agencies about the safet y of a study  interven tionunder clinical investigation. The sponsor 
will co mply wi th country -specific regulatory  requirem ents relating to safet y reporti ng to the 
regul atory  authori ty, IRB/IEC , and invest igators.
An invest igator who receives an invest igator safety report descri bing a SAE or other specific safety  
inform ation (e.g., summary  or list ing of SAEs) from the sponsor will review and then file it along 
with the IBand will notify the IRB/IEC, if appropriate according to local requirements.
CONFIDENTIAL Protocol  I8F-MC-GPGV
9310.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Definitions
Women of Childbearing Potential (WOCBP)
Female sare considered a woman ofchildbearing potential (WOCBP) if
Menarche has occurred (any  amount of  bleeding, even just spotting, can be considered menarche)
,OR
They have breast development Tanner 2 or more (see Tanner Staging, Appendix 9., Secti on 10.9).
Women notof Childbearing Potential
Female sare considered women not ofchildbearing potential if
they have breast development Tanner 1 , or
they have a congenital ano maly such as Mullerian agenesis , or
they are infertile due to surgical sterilizat ion.
Examples of surgical sterilizat ion include hysterectomy, bilateral oophorec tomy , and tubal  ligat ion.
CONFIDENTIAL Protocol  I8F-MC-GPGV
9410.4.2. Contraception Guidance
Contraception Requirements for Females of Childbearing Potential
Allparticipants of childbearing potential must follow the contraception guidance in the tables below for the 
entirety of the study  and f or 30 day s thereafter.
Females of childbearing potential who are completely abst inent as their preferred and usual 
lifest yle, or in a same sex relationship, as part of their pref erred and usual lifest yle…
Must… Must not…
agree to either remain abstinent, oruse periodic abstinence methods
ocalendar
oovulation
osymptothermal, or
opost-ovulation
declare abstinence just for the duration of 
a trial, or
stay in a same sex relationship without sexual 
relationships with malesuse the withdrawal method
This table describes guidance for females of childbearing potential who are NOT completely abst inent as their 
preferred and usual lifestyle, or in a same sex relat ionship, as part of thei r preferred and usual lifest yle.
Topic Condition
Pregnancy testing Negative serum result at screening and a 
negative urine result at Visit 3 prior to treatment 
exposure.
Note: follow pregnancy testing schedule in the 
Schedule of Activities , Section 1.3.
Contraception Agree to use 2 forms of effective contraception, 
wher e at least one form must be highly effective 
(less than 1% failure rate) .
CONFIDENTIAL Protocol  I8F-MC-GPGV
95Contraception Requirements for Male Participants
Male participants who have reached pubert y and are sexually act ive,
arerequired to use contraception in co mpliance with specific local government study  requi rements
must refrain fro m sperm  donat ion and
must follow contracepti on gui dance for the duration of the study  and until their tirzepat ide plasma 
concentrations are below the level that could result  in a relevant potential exposure to a possible fetus, 
predi cted to be 90 days afterthe endof study .
The table below describes contraception guidance for all men.
Topic Guidance
For all men Do not donate sperm for the duration of the study 
and for 90 days after the end of study .
Contraception for men with partners of 
childbearing potential either remain abstinent ,if this is their 
preferred and usual lifestyle
OR
must use condoms during intercourse for 
the duration of the study, and
for 90 days after the end of the study.
Contraception for men in exclusively same sex 
relationships, as their preferred and usual lifestyleAre not required to use contraception .
CONFIDENTIAL Protocol  I8F-MC-GPGV
96Forms of Contraception
This table describes the different forms of contraception .
Methods Examples
Highly effective contraception combination oral contraceptive pill and 
mini-pill
implanted contraceptives
injectable contraceptives
contraceptive patch (only women <198 
pounds or 90 kg)
total abstinence
vasectomy (if only sexual partner)
fallopian tube implants (if confirmed by 
hysterosalpingogram)
combined contraceptive vaginal ring, or
intrauterine devices
Effective contraception male or female condoms with spermicide
diaphragms with spermicide or cervical 
sponges
barrier method with use of a spermic ide
ocondom with spermicide
o diaphragm with spermicide, or
ofemale condom with spermicide
Note: The barrier method must include use of a 
spermicide to be considered effective, for 
example, condom with spermicide, diaphragm 
with spermicide, female condom with spermicide.
Ineffective forms of contraceptionspermicide alone
immunocontraceptives
periodic abstinence
fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, symptothermal)
withdrawal
post coital douche
lactat ional amenorrhea
CONFIDENTIAL Protocol  I8F-MC-GPGV
9710.5. Appendix 5: Genetics
Use/Analysis of DNA
●Genet ic variat ion may impact a participant’s response to study  intervent ion, suscept ibilit y to, 
and severit y and progression o f disease. Vari able response to study  intervent ion may be due to 
genet ic determinants that impact drug absorption, distribut ion, metabo lism, and excreti on; 
mechanism o f action of  the drug; di sease et io
logy; and/or m olecular subt ype of the disease 
being treated. Therefore, where local regulat ions and IRB/IEC allow, a blood sample will be 
collected for DNA analysis fro m consenting participants .
●DNA samples will be used for research related to tirzepat ideor T2DM and related diseases. 
They  may also be used to develop tests/assays including diagnost ic tests related to tirzepati de
and/or intervent ions of this drug class and T2DM . Genet ic researc h may consist of the analysis 
of one or m ore candi date genes or the analysis of genet ic markers throughout the geno me,as 
appropriate.
●The samples may  be analyzed as part of a mult i-study  assessment of genetic factors involved in 
the response to tirzepat ideor study interventi ons of this class to understand study  disease or 
related condi tions.
●The results of genet ic analyses may be reported in the CSR or in a separate study summary.
● The sponsor will store the DNA samples in a secure storage space with adequate measures to 
protect confident iality.
●The samples will be retained while research on tirzepati de and/ or intervent ions of this drug cl ass
continues but no longer than 15years or other period as per local requirements.
CONFIDENTIAL Protocol  I8F-MC-GPGV
9810.6. Appendix 6: Liver Safety: Suggested Actions and Follow- up Assessments
See protocol Sect ion 8.2.7 for guidance on appropriate test select ion.
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except for 
microbio logy testing.
Local  testing m ay be per formed in addit ion to central testing when necessary for immediate participant 
management.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
  Neutrophils, segmented Gamma -glutamyl transferase (GGT)
  Lymphocytes Creatine kinase (CK)
  MonocytesOther Chemistry
  Basophils Acetaminophen
  Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl alcohol (EtOH)
Prothrombin time, INR (PT -INR) Haptoglobin
SerologyImmunoglobulin IgA (quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
  HAV total antibody Immunoglobulin IgM (quantitative)
  HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing:Urine Chemistry
  Hepatitis B surface antigen (HBsAg) Drug screen
  Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG) (quantitative)
  Hepatitis B core total antibody (anti -HBc)Other Serology
  Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
  Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
CONFIDENTIAL Protocol  I8F-MC-GPGV
99  HBV DNA b Anti- actin antibody c
Hepatis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
  HCV antibody   EBV antibody
  HCV RNA b   EBV DNA b
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
  HDV antibody   CMV antibody
Hepatitis E virus (HEV) testing:   CMV DNA b
  HEV IgG antibody Herpes simplex virus (HSV) testing:
  HEV IgM antibody   HSV (Type 1 and 2) antibody 
  HEV RNA b   HSV (Type 1 and 2) DNA b
Microbiology d Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
  Blood
  Urine
aNot required if anti -actin antibody is tested.
bReflex/confirmation dependent on regulato ry requirements, testing availability, or both.
cNot required if anti -smooth muscle antibody (ASMA) is tested.
dAssay ed ONLY by investigator -designated local laboratory, no central testing available.
CONFIDENTIAL Protocol  I8F-MC-GPGV
10010.7. Appendix 7: Medical Device Adverse Events (AEs), Adverse Device Effects 
(ADEs), Serious Adverse Events (SAEs) and Device Deficiencies: Definition and 
Procedures for Recording, Evaluating, Follow -up, and Reporting
Refer to Appendix 3, Secti on 10.3 for definit ions and procedures for recording, evaluat ing, fo llow-up, and 
reporting of all events .
CONFIDENTIAL Protocol  I8F-MC-GPGV
10110.8. Appendix 8: Criteria for the Diagnos is of Diabetes
Criteria for the diagnosis of diabetes mellit usa(ADA 202 1b; IDF Guideline, 201 8)
1.Symptom s of diabetes plus random  plasma glucose concentration ≥11.1 mmo l/L (200 mg/dL) .
Random is defined as any t ime of day wit hout regard to time since last meal.
or
2.Fasting plasma glucose ≥7.0 mmo l/L (≥ 126 mg/dL)a.
Fasting is defined as no caloric intake for at least 8 hours.
or
3. 2- hour postload glucose ≥11.1 mmo l/L (≥200 mg/dL) during an oral glucose tolerance test (OGTT).
The test should be performed as described by  World Heal th Organizat ion, using a gl ucose l oad 
containing the equivalent of 75 g anhydrous glucose disso lved in water or 1.75 g/kg of body  weight to a 
maximum o f 75 g.
4.HbA1c ≥ 6.5 %(48 mmo l/
mol).
However, there are difficult ies wi th assay  standardizat ion and individual variat ion in the relat ionship 
between BGand HbA1c, which may  outwei gh the convenience of this test.
aIn the absence of unequivocal hyperglycemia, diagnosis requires two abnormal te st results from the same sample or in two 
separate test samples (ADA 2021b).
CONFIDENTIAL Protocol  I8F-MC-GPGV
10210.9. Appendix 9: Tanner Stag ing
Tanner Stages guidelines for measur ement of pubescence (Marshall and Tanner 1969 , 1970).
Boys: Development of external genitalia
Stage 1: Prepubertal 
Stage 2: Enlargement of scrotum and testes; scrotum skin reddens and changes in 
texture 
Stage 3: Enlargement of penis; further growth of testes 
Stage 4: Increased size of penis; testes and scrotum larger, scrotum skin darker 
Stage 5: Adult genitalia 
Girls: Breast development
Stage 1: Prepubertal ( no gl andular tissue: areola follows the skin contours of the chest)
Stage 2: Breast bud stage with enlargement of areola (breast bud forms, with small area 
of surrounding glandular tissue; areo la begins to widen)
Stage 3: Further enlargement of breast and areola ( breast begins to become more 
elevated, and extends bey ond the borders of the areola, which cont inues to 
widen but rem ains in contour with surrounding breast)
Stage 4: Areola and papilla form a mound ( increased breast size and elevat ion; areola 
and papilla form a secondary  mound proj ecting from the contour of the 
surrounding breast)
Stage 5: Mature stage ( breast reaches final adult size; areo la returns to con tour of the
surrounding breast, with a project ing central papilla)
Boys and girls: Pubic hair
Stage 1: Prepubertal (no pubic hair at all; can see vellus hair similar to abdominal wall) 
Stage 2: Sparse growth of long, slight ly pigmented hair, straight or curled ( small amount 
of long, downy  hair with slight pi gmentati on at the base of the penis and 
scrotum  [males] or on the l abia maj ora [females])
Stage 3: Darker, coarser and more curled hair, spreading sparsely over junct ion of pubes 
Stage 4: Hair adul t in type, but covering smaller area than in adult; no spread to medial 
surface of thighs 
Stage 5: Adult in t ype and quant ity, with horizontal  distributi on ("feminine")
CONFIDENTIAL Protocol  I8F-MC-GPGV
10310.10. Appendix 1 0: Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event
Purpose of collecting samples after a systemic hypersensitivity event
The samples listed in this appendix are not collected for acute study  parti cipant m anagement. The sponsor will 
use the l aboratory  tests resul ts from these sam ples to characterize hypersensit ivity events across the clinical 
development program.
When to collect samples after a systemic hypersensitivity event occurs
Collect the samples listed below if a systemic hypersensit ivity event is suspected. The ti ming should be as 
designated in the table, assuming the participant has been stabilized.
Obtain fo llow-up pre -dose samples at the next regularly scheduled laboratory  sample collect ion (ideally  prior 
to the next dose after the event) to assess post -event re turn-to-baseline values.
Timing Sample Type Laboratory Testa
Collect from 30 minutes to 4 hours 
after the start of the event. 
●Note: The optimal collection 
time is f rom 1 to 2 hours after 
the start of event.Serum total try ptase
Serum complements ( C3, C3a, and C5a)
Serumcytokine panel ( IL-6, IL ‐1β, IL‐10 or any cytokine panel 
that includes these 3 cytokines) 
Collect only if not already collected 
on the same day as the event.
●Note: If collecting, collect up 
to 12 hours after the start of the 
event.Serum Tirzepatide anti-drug antibodies (ADA)
Serum/plasma Tirzepatide concentration
a All samples for hypersensitivity testing will be assayed by Lilly -designated laboratory. Results will not be provided to the study 
site. If samples are not collected or are collected outside the specified time period, this will not be considered a protocol deviation.
Abbreviations: ADA = anti -drug antibodies; IL = interleukin.
What information to record
Record the date and time when the samples are collected.
Allowed additional testing for participant management
The invest igator may perform addit ional tests locally, if clinically indicated, for acute study  parti cipant 
management.
CONFIDENTIAL Protocol  I8F-MC-GPGV
10410.11. Appendix 11: Standardiz ed Protocols for the Measurement of Height, Weight, 
Waist Circumference, Vital Signs
The fo llowing inform ation has been adapted fro m standardized physical measurement protocols for the World 
Health Organizat ion’s STEP wise approach to Surveillance (STEPS) Manual (WHO).
Measuring Height
Step 1. Ask the part icipant to remove their footwear and any headgear (light headgear worn for religious 
reasons can remain, but this shoul dbe worn by  the parti cipant at every  clinic visi t when thei r height is 
measured).
Step 2. Ask the participant to stand on the calibrate d height measuring board (stadiometer) or against a wall 
with their feet together and their knees straight with their heels against the backboard, the stadi ometer or the 
wall.
Step 3. Ask the participant to look straight ahead wit hout tilt ing their head u
p.
Step 4. Ask the participant to breathe in and stand tall. If using a stadio meter or fixed measuring device, move 
the device’s measurement arm gent ly down onto the top of the participant’s head. Record the participant’s 
height in cent imeter (cm) to 1 de cimal place .
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrated electronic scale 
capable of measuring weight in kilogram.
All weights for a given participant should be measured using the same scale, whenever possible, at 
approximately  the same t ime in the morning after evacuat ion of bladder contents.
Parti cipants shoul dbe light ly clothed but not wearing shoes while their weight is measured.
Step 1 .Ask the participant to remove their footwear, outerwear (coat, jacket, etc), and any headgear (light 
headgear worn for religious reasons can remain, but this shoul dbe worn by  the parti cipant at every  clinic visit 
when weight is measured).
Step 2 .Make s ure the scale is placed on a firm, flat, even surface (not on carpet, on a sloping surface, or a 
rough, uneven surface).
Step 3 . Ask the participant to step onto the scale wit h 1 foot on each side of the scale.
Step 4 . Ask the participant to stand still wi th arms by sides and then record wei ght in kilogram (kg) to the 
nearest one -tenth kg.
CONFIDENTIAL Protocol  I8F-MC-GPGV
105Measuring Waist Circumference
Use non -stretchy  tape
Waist circumference shoul dbe measured at midpoint, between lower margin o f last pal pable rib and top of 
iliac crest (~1 i nch [2.54 cm ] above the navel)
Parti cipants shoul d be light ly clothed , and
Measure to the nearest 0.5 cm .
Step 1. Ask the participant to stand with their feet close together, and arms at their side with their body weight 
evenly distributed.
Step 2. Ask participant to relax.
Step 3. Measurements shoul dbe recorded at the end of a normal expirat ion.
Vital Sign Measurements (blood pressure and heart rate)
Vital sign m easurements (m easured by pulse) should be taken before obtaining an ECG tracing and 
before collecti on of  blood sam ples for l aboratory  testing.
An appropriately sized cuff (cuff bladder encircling at least 80% of the arm) should be used to ensure 
the accuracy  of BPmeasurements.
Blood pressure shoul d be taken wi th an autom ated bl ood pressure instrument.
If blood pressure and pulse measurements are taken separately, pulse should be taken prior to blood 
pressure.
Step 1. The parti cipant shoul dsit quietly for 5 minutes before vital signs measurements are taken.
Step 2. For each paramete r, 3measurements will be taken using the same arm, preferably the nondo minant 
arm.
Step 3. The recordings shoul d be taken at least 1 minute apart. Each measurement of sitting pulse and blood 
pressure needs to be recorded in the eCRF.
Note: In the event pulse measurement cannot be taken via an automated blood pressure instrument, the 
preferred l ocati on for measurement of pulse is the radial artery .
CONFIDENTIAL Protocol  I8F-MC-GPGV
10610.12. Appendix 1 2: Provisions for Changes in Study Conduct During Exceptional 
Circumstances
Imple mentation of this appendix
The changes to procedures described in this appendix are temporary measures intended to be used only during 
specific t ime periods as directed by the sponsor in partnership with the invest igator.
Exceptional circumstances
Except ional circumstances are rare events that may cause di srupt ions to the conduct of the study . Exam ples 
include pandemics or natural disasters. These disruptions may limit the abilit y of the invest igators, participants, 
or both to attend on -site visits or to co nduct planned study  procedures.
Implementing changes under exceptional circumstances
In an except ional circumstance, after receiving the sponsor’s written approval, sites may  implement changes if 
permitted by  local regulat ions.
After approval by local ERBs , regul atory  bodi es and any  other rel evant l ocal authori ties, implementati on of  
these except ional circumstance changes will not typically require addit ional notificati on to these groups, unless 
they have specific requirements in which notification is requi red (f or exam ple, upon im plementati on and 
suspension o f changes). All approvals and notificatio ns must be retained in the study  records.
If the sponsor grants written approval for changes in study  conduct, the sponsor will also provide additional 
written g uidance, if needed.
Considerations for making a change
The prevailing considerat ion for making a change is ensuring the safet y of study  parti cipants. Addit ional 
important considerations for making a change are compliance wit h GCP , enabling participants to continue 
safely in the study  and m aintaining the integrit y of the study .
Informed consent
Addit ional consent/assent fro m the parti cipant will be obtained for the below items, as required by ERB’s and 
local regulati ons:
participat ion in remote visits, as defined below in Secti on “Remote Visits,”
dispensat ion of addit ional study  interventi on during an extended treatment period,
alternate delivery  of study  interventi on and ancillary  supplies, and
provi sion of their personal or medical  information requi red pri or to implementation of these act ivities.
Minor participants must be re -consented if they reach the age of majorit y during the course of study , 
to
continue participating.
Changes in study conduct during exceptional circu mstances
Changes in study  conduct not described in this appendix, or not consistent with applicable local regulations, are 
not allowed.
The fo llowing changes in study  conduct will not be considered protocol deviat ions.
CONFIDENTIAL Protocol  I8F-MC-GPGV
107Remote visits
Types of remote visits
Telemedicine: Telephone or techno logy-assisted virtual  visit s, or both, are acceptable to complete appropriate 
assessments. Assessments to be completed in this manner include, but are not limited to a review of
concomitant medicat ions
study  participant e-diary (including study  drug compliance)
contraception as applicable , and
last m enstrual  cycle, as applicable.
Mobile healthcare :
Healthcare visi ts may be perform ed by  a mobile heal thcare provi der at l ocati ons other than the study  site when 
participants can not travel to the site due to an exceptional circumstance if written approval is provided by the 
sponsor . Procedures performed at such visits include, but are not limited to
height, weight and waist measurements
physical assessments
vital signs
review of p atientreported outcom e measures
collect ion of blood samples ,and
collect ion of healt h information .
Other alternative locations :
Laboratory draws may be done at an alternate location in except ional circumstances except for PK, 
immunogenicit y, genet ics and exploratory  biomarker sam ples.
Data capture
In source documents and the CRF, the study  site must capture the visit method, with a specific explanation for 
any data missing because of missed in -person si te visi ts.
Safety reporting
Regardless of the ty pe of  remote visi ts implemented, the protocol requirements regarding the reporting of AEs, 
SAEs, and PCsremain unchanged.
Return to on -site visits
Every effort mustbe made to enable participants to return to on -site visi ts as soon as reasonably possible, while 
ensuring the safet y of both the parti cipants and the site staff.
Local laboratory testing option
Local  laboratory  testing m ay be conducted in lieu of central laboratory  testing with sponsor approval . The l ocal 
laboratory  must be qualified in accordance with applicable local regulat ions.However, central laboratory  
testing must be retained for PK,immunogenicit y, genet ics, intact proinsulin, adiponectin and expl oratory  
biomarker samples .
Study intervention and ancillary supplies (including participant diaries)
When a participant i s unable to go to the site to receive study  supplies during norm al on-site visi ts, the si te 
shoul d work wi th the sponsor to determine appropriate actions. These actions may include:
CONFIDENTIAL Protocol  I8F-MC-GPGV
108asking the participant to go to the site and receive study  supplies from  site staff wi thout com pletion 
of a full study  visit,
asking the participant’s designee to go to the site and receive study  supplies on a participant’s 
behalf, and
arranging delivery  of study  supplies .
Thes e requi rements m ust be m et before acti on is taken:
Alternate delivery  of study  interventi on shoul d be perform ed in a manner that does not compromise 
treatm ent blinding and ensures product integrit y. The exist ing protocol requirements for product 
accountabi lity remain unchanged, including verification of participant’s receipt of study  supplies.
When delivering supplies to a locat ion other than the study  site (for example, parti cipant’s home), 
the invest igator, sponsor, or both should ensure oversight of the shipping process to ensure 
accountabilit y and product qualit y (that i s, storage condit ions maintained and intact packaging upon 
recei pt).
Instructi ons may  be provi ded to the parti cipant or designee on the final disposit ion of any  unused or 
completed study  supplies .
Screening period guidance
To ensure safet y of study  participants, l aboratory  values and other eligibilit y assessments taken at the screening 
visit are valid for a maximum o f 60days, with the excepti on of  the serum  pregnancy test which is valid for a 
maximum o f 28 day s. The foll owing rul es will be applied for active, nonrandomized participants whose 
participat ion in the study must be paused due to exceptional circumstances .
If screening is paused for less than 60days fro m the start date of screenin g,the participant will proceed to the 
next study  visit per the usual  SoA, provi ded that the randomization visit isconducted within 60days from  first 
screening.
The site should conduct the next visit if the participant’s eligibilit y criteria are confirmed, and the site should 
docum ent the reason for delay.
Due to the pause in screening, sites should also reconfirm the impacted participant’s consent or assent and 
docum ent this confirmat ion in the source documentation.
If screening is paused for mor e than 60days from the start of the screening , the participant must be 
discontinued because of screening interruption due to an except ional circumstance. This is documented as a 
screen failure in the CRF. The participant can reconsent and be rescreened as a new parti cipant. This rescreen 
is in addit ion to the one allowed by the main protocol. The screening procedures per the usual SoA shoul d be 
followed, starting at the screening visit to ensure participant eligibilit y by the rando mizat ion visit.
Adjustmen ts to visit windows
Whenever possible and safe to do so, as determined by the invest igator’s discretion, participant or parent or 
guardi anshoul d com plete the usual  SoA. To maximize the possibilit y that these visits can be conducted as on -
site visi ts, the windows for visits may be adjusted, upon further guidance fro m the sponsor. This minimizes 
missing data and preserves the intended conduct of the study.
CONFIDENTIAL Protocol  I8F-MC-GPGV
109This table describes the allowed adjust ments to visit windows.
Visit Number Acceptable Tolerance
(instead of what is mentioned in the Schedule of Activities)
Visit 4, Visit 14 -3 to +7 days
Visit 5, Visit 7 toVisit 
11± 10days
Visit 13 (primary 
endpoint visit)±14days (i.e. the visit may be brought forward no sooner than 14days [Week 28] or 
extended up to 14days [Week 32])
Visit 15 and Visit 17 ±14 days
Visit 16and Visit 18 ± 10 day s
Visit 19 ±28 days (i.e. the visit may be brought forward no sooner than 28 days [Week 48] or 
extended up to 28 days [Week 56]) 
Visit 801 -7 to+14 days
For parti cipants whose visits have extended windows, additional study  interventi on may  need to be provi ded to 
avoid int errupti on and maintain overall integrit y of the study .
Documentation
Changes to study conduct w ill be documented
Sites will ident ify and document the details o f how participants, visits t ypes, and conducted activit ies were 
affected by  except ional circumstances. Dispensing/shipment records of study  intervent ion and rel evant 
communicat ions, including delegat ion, must be filed wi th site study  records.
Source documents at alternate locations
Source documents generated at a location other than the study site should be part of the invest igator’s source 
docum entati on and shoul d be transferred to the site in a secure and time ly manner.
CONFIDENTIAL Protocol  I8F-MC-GPGV
11010.13. Appendix 1 3: Abbreviations and Definitions
Term Definition
ADA American Diabetes Association
AE adverse event: Any untoward medical occurrence in a participant or clinical 
investigation subject administered a pharmaceutical product that does not necessarily 
have a causal relationship with this treatment. An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory findi ng), sy mptom, 
or disease temporally associated with the use of a medicinal (investigational) product, 
whether o r not related to the medicinal (investigational) product.
AESI Adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotra nsferase
ANCOVA analy sis of covariance
ANOVA analy sis of variance
ACR albumin/creatinine ratio
assent Agreement from a child or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and risks involved in participating 
in a study (required by some ethical review boards [ERBs]). 
AST aspartate aminotransf erase
AUC area under the curve
BG blood glucose
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A dou ble-blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
BMI body mass index
CI confidence interval
CEC Clinical Endpoint Committee
CIOMS Council for International Organizations of Medical Sciences
COA clinical outcome a ssessment
CONFIDENTIAL Protocol  I8F-MC-GPGV
111Companion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or eff icacy , or 
perfo rmance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF/eCRF case report form/electronic case report form: Sometimes referred to as clinical report 
form: A printed or electronic form for recording study participants’ data during a 
clinical study, as required by the protocol.
CRP clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CSR clinical study report
CT compute d tomography scan
CV cardiovascular
DBP diastolic blood pressure
Device defi ciencies Equivalent to product complaint
DMC data monitoring committee . A DMC , or data monitoring board (DMB) is a group of 
independent scientists who are appointed to monitor the safety and scientific integrity of 
a human research intervention, and to make recommendations to the sponsor regarding 
the stopping of a study for efficacy, or for harms, or for futility. The composition of the 
committee is dependent upon the scientific skills and knowledge required for 
monitoring the particular study.
DPP -IV inhibitor dipeptidy l peptida se-IV inhibitor: A class of oral hypoglycemic drugs used to treat 
participant s with T2DM.
DSMT Developmental Safety Management Team
DSST Developmental Safety Surveillance Team
EBV Epstein -Barr virus
ECG Electrocardiogram
EDC electronic data capture system
EFD embryo -fetaldevelopment
eGFR estimated glomerular filtration rate: A measure of kidney function.
efficacy The ability of a treatment to achieve a beneficial intended result under controlled 
conditio ns.
CONFIDENTIAL Protocol  I8F-MC-GPGV
112EMA European Medicines Agency
end of study (trial) The date of the last visit or last scheduled procedure shown in the Study Schedule for 
the last participant . 
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assign ed to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERB ethical review board: A board or committee (institutional, regional, or national) 
composed of medical and nonmedical members whose responsibility is to verify that 
the safety, welfare, and human rights of the participant s participating in a clinical study 
are protected.
ET Early  termination
EU European Union
FAS Full Analy sis Set
FBG fasting blood glucose
FSG fasting serum glucose 
GAD65 glutamic acid decarboxylase 65 autoantibodies: A marker of type 1 diabetes mellitus 
(T1DM).
GCP good clinical practice
GI gastrointestinal
GIP glucose -dependent insulinotropic polypeptide
GLP -1 glucagon -like peptide -1
GLP -1 RA glucagon -like peptide -1 receptor agonist: A class of injectable hypoglycemic drugs 
approved to treat adult participant s with T2DM.
HbA1c glycated hemoglobin A1c
HF human factor
HR heart rate
IA2 tyrosine phosphatase -like insulinoma antigen 2 autoantibodies: A marker of T1DM.
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
CONFIDENTIAL Protocol  I8F-MC-GPGV
113IMP Investigational Medicinal Product
Informed consent A process by which a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participa nt’s decision to participate. Informed consent is 
documented by means of a written, signed and dated informed consent form .
Intervention A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, incl uding products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the auth orized form.
investigator A person responsible for the conduct of the clinical study at a study site. If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible 
leader of the team and may be called the principal investigator.
IRB/IEC Institutio nal Review Board/Independent Ethics Committee
ITT intention to treat: The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a participant (that is, the 
planned treatment regimen) rather than the actual treatment given. It has the 
consequence that participant allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatment.
IV intravenous
IWRS interactive web -response sy stem
legal representative An individual, judicial, or other body authorized under applicable law to consent, on 
behalf of a prospective participant , to the participant ’sparticipation in the clinical study.
MEN 2 multiple endocrine neoplasia syndrome type 2
mITT modified intent-to-treat
MMRM mixed model for repeated measures
MTC medullary thyroid carcinoma
NAFLD Nonalcoholic fatty liver disease
NIMP Non-investigational Medicinal Product
NOAEL no-observed -adverse -effect level
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipient of an investigational medicinal product or as a control
p-amylase pancreatic amylase
PC product complaint
CONFIDENTIAL Protocol  I8F-MC-GPGV
114PedsQL Pediatric Quality of Life Inventory
PK/PD pharmacokinetics/pharmacodynamics
PND postnatal delay
PPS per-protocol set: The set of data generated by the subset of participant who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underlying scientific model.
PRO/ePRO participant -reported outcomes/electronic participant -reported outcomes
QTc corrected QT inter val
QW once weekly
RA receptor agonist
randomize The process of assigning participant s to an experimental group on a random basis.
RISE Restoring Insulin Secretion
SAD single -ascending dose
SAE serious adverse event
SAP statistical analysis plan
SC subcutaneous
SDP single dose pen
SDS standard deviation score
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SMBG self-monitored blood glucose
SoA schedule of activities
T1DM type 1 diabetes mellitus
T2DM type 2 diabetes mellitus
TBL total bilirubin
TEAE Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
ULN upper limits of normal
CONFIDENTIAL Protocol  I8F-MC-GPGV
115US United States
CONFIDENTIAL Protocol  I8F-MC-GPGV
11611. References
American Diabetes Associat ion(ADA) . 13. Children and Adolescents: Standards of Medical Care in Diabetes
–2021. Diabetes Care .2021a;44( Suppl . 1 ): S180 -S199. https://doi.org/10.2337/dc21 -S013
American Diabetes Associat ion (ADA) .Classificatio n and Diagnosis of Diabetes: Standards of Medical Care 
in Diabetes – 2021b . Diabetes Care .2021b ;44(Suppl . 1):S1 52S33.https://doi.org/10.2337/dc21 -S002
American Diabetes Associat ion(ADA) .6.Glycemic targets: Standards of Medical Care in Diabetes – 2021. 
Diabetes Care .2021c ;44(Suppl . 1):S 73-S84.http://doi .org/10.2337/dc21 -S006
American Diabetes Associat ion(ADA) . 
Com prehensive medical evaluat ion and assessment of comorbidi ties: 
standards of medical care in di abetes —2019. Diabetes Care. 2019;42(suppl 1):S34 -S45.http://doi.org/
10.2337/dc19 -S004
Aroda VR, Ratner R. The safet y and tol erabilit y of GLP -1 receptor agonists in the treatment of ty pe 2 diabetes: 
a review. Diabetes Metab Res Rev . 2011;27(6):528 -542. https://doi.org/10.1002/dmrr.1202
Badaru A, Klingensmit h GJ, Dabelea D, et al. Correl ates of treatm ent patterns am ong y outh wi th type 2 
diabetes. Diabetes Care . 2014;37(1):64 -72. https://doi.org/10.2337%2Fdc13-1124
Banks PA, Freeman ML; Practice Parameters Committee of the American Co llege of Gastroenterology. 
Practi ce gui delines in acute pancreat itis. Am J Gastroenterol . 2006;101(10):2379 -2400.
Ludvi k B, Gi orgino F, Jódar E, et al. Once -weekly ti rzepat ide versus once -daily insulin degludec as add -on to 
metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS -3): a randomised, 
open -label, parallel -group, phase 3 trial. Lancet . 2021;398(10300):583 -598. https://doi.org/ 10.1016/S0140 -
6736(21)01443-4
BYDUREON BCISE P rescribing Information. AstraZeneca Pharmaceuticals LP. Published July 23, 2021. 
Accessed 30 July 30, 2021. h ttps://www.accessdata.fda.gov/drugsatfda_docs/label/ 2021/209210s017lbl.pdf
Capri o S, Tamborl ane WV. Effect of puberty  on insulin act ion and secretion. Semin Reprod Endocrinol . 
1994;12:90 -96.
[CDC] Centers for Disease Control and Prevent ion. Nati onal Diabetes Stati stics Report. 20 20.Atlanta, GA: 
Centers for Disease Control and Prevent ion, U.S. Dept of Health and Human Services; 2020. Available at: 
https://www.cdc.gov/diabetes/pdfs/data/statist ics/national -diabetes -statistics-report.pdf. Accessed June 11, 
2021.
Constant inoM,Molyneau xL,Limacher -Gisler F,etal.Long -term complicat ionsandmortalit yinyoung-onset
diabetes :type 2 diabetes ismorehazardous andlethal thantype 1 diabetes Care . 2013 ;36(12): 3863-3869.
Dabelea D, May er-Davis EJ, Say dah S, et al.Prevalence of ty pe 1 and ty pe 2 di abetes am ong children and 
adolescents from  2001 to 2009. JAMA . 2014;311(17):1778
-1786. https://doi.org/ 10.1001/jama.2014.3201
D’Adamo E, Caprio S. Ty pe 2 di abetes in y outh: epi demi ology and pathophysio logy. Diabetes Care .
2011;34(suppl 2):S161 -S165.
Dahl D, Onishi Y, Norwood P, et al. Tirzepat ide, a dual GIP/GLP -1 receptor agonist, is effect ive and safe 
when added to basal insulin for treatment of y pe 2 di abetes (SURPASS -5) [abstract]. American Diabetes 
Associ ation 81st Sc ientific Sessio ns. June 25 -29, 2021. Virtual.
EuroQol  Research Foundat ion. EQ -5D- Y User Guide, Versi on 2.0, September 2020. Available fro m: 
https://euroqol.org/publicat ions/user -guides.Accessed May  4, 2021
CONFIDENTIAL Protocol  I8F-MC-GPGV
117Frías JP, Davies MJ, Rosenstock J, et al. Tirzepa tide versus semagluti de once weekly in patients with Type 2 
diabetes. N Engl J Med . 2021; 385(6):503 -515. https://doi.org/ 10.1056/NEJMoa2107519
International Diabetes Foundat ion(IDF). The IDF Gui deline : Pocketbook for m anagement of di abetes in 
childhood and adolescence in under -resourced countries, 2nd edit ion, updated 21/08/2018 .Available at: 
https://www.i df.org/e -library/guidelines/89 -pocketbook -for-management -of-diabetes -in-childhood -and-
adolescence -in-under -resourced -countries-2nd- edition.html. Acces sed June 18, 202 1.
Koizumi M, Takada T, Kawarada Y, et al.JPN guidelines for the management of acute pancreat itis: diagnostic 
criteria for acute pancreatit is. JHepatobiliary Pancreat Surg . 2006;13(1):25 -
32.
Lawrence JM, Divers J, Isom S, et al. Trends in prevalence of Ty pe 1 and Ty pe 2 diabetes in children and 
adolescents in the US, 2001 -2017. JAMA . 2021;326(8):717 -727. https://doi.org/ 10.1001/jama.2021.11165
Marshall WA, Tanner JM. Variat ions in the pattern of pubertal changes in bo ys. Arch Dis Child . 
1970;45(239):13 -23.
Marshall WA, Tanner JM. Variat ions in pattern of pubertal changes in girls. Arch. Dis Child . 
1969;44(235):291 -303.
Nauck M. Incretin therapies: highlight ing commo n features and differences in the modes of act ion of glucagon -
like peptide -1 receptor agonists and dipept idyl peptidase -4 inhibitors. Diabetes Obes Metab . 2016;18(3):203 -
216.
Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safet yof a novel  dual GIP and GLP -1 receptor agoni st 
tirzepat ide in pat ients with type 2 di abetes (SURPASS -1): a doubl e-blind, randomised, phase 3 trial. Lancet . 
2021; 398(10295):143-155. https://doi.org/ 10.1016/S0140 -6736(21)01324 -6
Rubin DB. Mult iple Imputati on for Nonresponse in Surveys. John Wiley  & Sons, Inc.; 1987.
Steinberg WM, Buse JB, Ghorbani MLM, et al. Amylase, lipase, and acute pancreat itis in people wit h type 2 
diabetes treated wi th liraglutide: Results fro m the LEADER rando mized trial. Diabetes Care . 2017a;40(7):966 -
972. [Erratum  in:Diabetes Care . 2018 Jul;41(7):1538.]
Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of liraglut ide on amylase, lipase, and acute 
pancreat itis in part icipants wi th overwei ght/obesi ty and norm oglycemia, pre diabetes, or ty pe 2 di abetes: 
Secondary  analyses of pooled data from the SCALE clinical development program. Diabetes Care . 
2017b;40(7):830 -
848.
Tamborl ane WV, Barri entos -Perez M, Fainberg U, et al. Liraglut ide in children and Ado lescents wi th Ty pe 2 
Diabetes. N En gl J Med. 2019; 38(7):637 -649.
Tamborl ane WV, Klingensmith G. Crisis in care: limited treatment options for ty pe 2 di abetes in adolescents 
and y outh. Diabetes Care . 2013;36(6):1777-1778.
Tamb orlaneWV, Bishai, R, Geller D , et al . 91-LB: once- w eekly  exenat ide in youth wi th Type 2 diabetes: a
pivotal Phase III randomized study. Diabetes . 2021;70 (1). https://doi.org/10.2337/db21 -91-LB
TODAY Study  Group. A clinical trial to maintain glycemic control in y outh wi th type 2 di abetes. N Engl J 
Med. 2012;366(24):2247 -
2256.
TODAY Study  Group, Bj ornstad P, Drews KL, et al. Long -term complicati ons in youth-onset Ty pe 2 Diabetes. 
N Engl J Med . 2021;385(5):416 -426. https://doi.org/ 10.1056/NEJMoa2100165
CONFIDENTIAL Protocol  I8F-MC-GPGV
118Varni JW, Delamater AM, Hood KK, et al. Pediatric Qualit y of Life Inventory  3.2 Di abetes Module Testing 
Study  Consorti um. Pedi atric Quali ty of Life Inventory  (PedsQL) 3.2 Diabetes Module for y outh with Type 2 
diabetes: reliabilit y and validi ty. Diabet Med . 2019;36(4):465 -472. http://doi.org/10.1111/dme.13841.
Victoza [summary  of product characteri stics]. Bagsværd, Denmark: Novo Nordisk A/S.
Victoza prescribing information. Novo Nordisk. Accessed J une 01, 2021. https://www.novo -
pi.com /victoza.pdf.
World Heal th Organizat ion. The WHO STEPWise approach to noncommunicable disease risk factor 
surveillance. WHO STEPS Surveillance Manual. Updated January 26, 2017. Accessed March 13, 2020. 
https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf
L e o  D o c u m e n t  I D  =  0 d d a c 8 4 7 - e e 9 3 - 4 e 4 5 - 9 2 c b - 4 9 3 9 6 b 2 3 c d 7 c 
A p p r o v e r :   ( A M \ C 2 9 5 7 6 2 ) 
A p p r o v a l  D a t e  &  T i m e :  1 4 - D e c - 2 0 2 1  2 0 : 0 6 : 1 0  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :   ( A M \ C 2 2 9 8 3 4 ) 
A p p r o v a l  D a t e  &  T i m e :  1 4 - D e c - 2 0 2 1  2 1 : 1 8 : 2 6  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 